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ABSTRACT 
As baby boomers age, estimated to reach 78.8 million Americans over the age of 65 by 2050, 
their health care costs are skyrocketing. Increased costs in coronary artery bypass surgery have 
been linked to length of stay (LOS), the inflammatory response, and blood loss related to 
conventional coronary artery bypass (C-CAB). 
Off-pump coronary artery bypass (OPCAB) has become a popular alternative to C-CAB. 
Utilizing proximal connector devices has truly made this option "clampless." If 
detrimental outcomes can be linked to cross clamping, the use of cardiopulmonary bypass 
(CPB) may diminish. When the use of CPB is necessary, there are a number of circuit 
coatings available, along with drugs like Aprotinin, to decrease the inflammatory 
response, and Amicar, to decrease the amount of blood loss, all due to the exposure of the 
body to CPB. This study compares the cost and LOS involved with OPCAB vs. C-CAB, 
including a comparison of the inflammatory response and blood loss with each drug 
regime and circuit coating used. 
Analysis of the data revealed no significant difference in several cost areas. The total 
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operating room (O.R.) costs showed that the C-CAB with Aprotinin group's mean cost 
was $8559.13 (statistical difference [SD] of $1056.61; 95% confidence interval[CI] was 
reported as $8164.58 for lower bound and $8953.67 for the upper bound). The C-CAB 
with Amicar group's mean cost was $9096.40 (SD of $1859.16; 95% CI was reported as 
$8402.17 for lower bound and $9790.62 for upper bound). The OPCAB group's mean 
cost was reported as $8442.86 (SD of $1482.63; 95% CI was reported as $7621.81 for 
lower bound and $9263.92 for upper bound). 
The O.R. supply costs showed that the C-CAB with Aprotinin group's mean cost was 
$3889.66 (SD of$685.91; 95% Cl was reported as $3633.54 for the lower bound and 
$4145.79 for the upper bound). The C-CAB with Amicar group's mean cost was 
$3934.30 (SD of $1198.46; 95% CI was reported as $3486. 78 for the lower bound and 
$4381.81 for the upper bound). The OPCAB group's mean cost was $4014.13 (SD of 
$1084. 77; 95% CI was reported as $3413.40 for the lower bound and $4614.86 for the 
upper bound). 
The pharmacy costs showed that the C-CAB with Aprotinin group's mean cost was 
$2553.76 (SD of $1305.61; 95% CI was reported as $2066.24 for the lower bound and 
$3041.29 for the upper bound). The C-CAB with Amicar group's mean cost was 
$2654.33 (SD of $3502.66; 95% CI was reported as $1346.41 for the lower bound and 
$3962.25 for the upper bound). The OPCAB group's cost was reported as a mean of 
$1710.93 (SD of$1147.01; 95% CI was reported as $1075.73 for the lower bound and 
$2346.13 for the upper bound). 
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CHAPTER 1 
INTRODUCTION 
Every year millions of people in the United States are diagnosed with some 
form of coronary artery disease, one of the top five leading causes of death. Of these 
millions, approximately 516,000 required surgical intervention in 2001 (American Heart 
Association, 2001 ). Open-heart surgery is regarded as one of the most significant medical 
advances in the 20th century (Lillehei, 1993). During the past 10 years, dramatic changes 
have occurred in the management of cardiac surgery patients (Dzavik et al., 2001 ). With 
the introduction of decreased reimbursement to providers by insurance carriers, rapid 
recovery programs introduced the concept that "less might be better" (Ley, 2001). Shorter 
intubation times and lengths of stay (LOS) have been associated with improved outcomes 
(Ott, Gutfinger, Steedman, Tanner, & Hlapchich, 1999), including decreased respiratory, 
neurological complications and blood usage (Ascione et al., 1999). 
Attention shifted to lesser incisions via minimally invasive cardiac surgery 
through multiple thoracotomy incisions, and thus port access cardiac surgery began. The 
knowledge of adverse inflammatory and neurological effects of CPB (Ascione et al., 
2000; Edmunds, 1998), along with the possibility ofreducing costs and LOS (Lancey, 
Soller & Vander Salm, 2000), led to the pursuit of using a" pump-less" technique thus 
making OPCAB procedures the current trend in cardiac surgical care. The ability of 
operating on a "beating" heart has been accomplished through the use of special 
stabilization devices, such as the Medtronic Octopus® retractor (Jansen et al., 1998). 
The introduction of the St. Jude (St. Paul, MN) Symmetry® Bypass System 
Aortic Connector (Eckstein et al., 2001) has led to clamp-free revascularization. The 
body's response to the bypass circuit has been addressed by the use of coating these 
circuits (Ranucci et al., 1999; Schiel et al., 2001; Wendel, Philipp, Weber, Birnbaum, & 
Ziemer, 2001 ). In addition, the use of drugs to reduce bleeding has improved clinical 
outcomes of C-CAB (Lemmer, et al., J 996; Harmon, 1996). 
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The healthcare costs associated with the upcoming care of the "baby-boomers" 
are staggering and need to be addressed (Lee, Abdelhady, & Capdeville, 2000). If using 
the OPCAB technique, while maintaining acceptable patient outcomes, significantly 
reduces costs, then this arena of care needs continued investigation. As expected, newly 
available advanced technologies usually come with a staggering price tag. This factor 
may eventually render the OPCAB to be more expensive with no discernable difference 
in clinical outcomes, and therefore offers no advantage. By utilizing circuit coatings and 
differing drug regimes, in the presence of C-CAB, the possibility of maintaining effective 
cost and outcomes may be a possibility. Evidence is now needed in guiding the medical 
and healthcare community in making informed decisions based on the multiple variables 
involved with these new options for the care of the cardiac surgical patient. 
Statement of Problem 
Recent emphasis on cost containment in healthcare has focused attention on the 
economics of all medical procedures. Selections for the appropriate treatment of coronary 
artery disease are of increasing concern (Ryan, Carrier, Nugent, Mora Mangano & 
Magovern, 2000). Cost reduction with improved patient outcomes for C-CAB is 
reported to be possible through several strategies. Collaboration between healthcare 
providers involved in cardiac care and improved case management strategies, early 
extubation, reduced intensive care unit (ICU) LOS and attempting OPCAB techniques 
may reduce the overall costs. 
Ethically, cost containment should not be the only consideration (Bull et al., 
2001). With over 1414 open-heart surgeries performed every day (American Heart 
Association, 2001), outcomes including morbidity, mortality, and quality must not be 
forgotten. Patients are the payers and deserve the satisfaction knowing that the quality of 
their care, rather than the cost, is the driving force (Arom et al., 2000). However, the 
major determinant of costs in C-CAB still remain the variable and fixed direct costs of 
disposable supplies, drugs and care, especially in the presence of post-operative 
complications (Bowles, 2001). Utilizing the technique of OPCAB could influence the 
factors ofreducing blood loss (Mahomed & Vijay, 2000) and decreasing the 
inflammatory response (Joffs et al., 2001). Therefore, a further cost savings might be 
realized by using this surgical technique to decrease the fixed direct cost while 
maintaining clinical quality of care (Ascione, et al., 1999). 
The length of stay and cost of nursing care required for coronary artery bypass 
patients are of special concern for the nurse administrator. By reducing these parameters, 
the amount of nursing care hours and thus costs (especially in the post-operative phase), 
can effectively be reduced. Expediting patients' return to the stage of self-care and 
greater independence will also decrease the number of nursing care hours required. This 
is especially significant in the face of the national shortage of nurses currently being felt 
and on the expected future shortfall (Loquist, 2002). 
3 
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Statement of Purpose 
The purpose of this study is to compare the cost of OPCAB with C-CAB. 
Comparison will be made of the cost of two different circuit coatings, with two different 
drug regimes, and their impact on the inflammatory response along with blood loss. This 
study is designed to specifically measure the differences of (a) total intraoperative cost, 
(b) length of stay, including post-ICU hospitalization, (c) inflammatory response, (d) 
post-operative blood loss for each protocol, and (e) differences in post-operative nursing 
care hours as required for OPCAB and C-CAB. 
There is no knowledge by the researcher of a previous study of this magnitude 
covering and comparing the stated parameters. Results of this study will add new 
information to the body of nursing, medical and perfusion knowledge. 
Research Hypothesis 
Hypotheses: 
Hl. The intra-operative cost of OPCAB is significantly greater than the intra-
operative costs of C-CPB patients. 
H2. There is no significant difference in the ICU and post ICU hospital LOS 
between the OPCAB and C-CPB patients. 
H3. There is a significant decrease in the measured inflammatory response in the 
OPCAB vs. the C-CAB patients. 
H4. There is no significant difference between the measured inflammatory 
response between the x-coated and y-coated circuits for C-CAB patients. 
HS. There is a significant difference in measured compliment mediators between 
the pharmacological regimes, Aprotinin and Amicar. 
H6. There is no significant difference in blood loss between OPCAB and C-CAB 
patients. 
H7. There is a significant decrease in patient care hours with decreased 
complement mediator activation. 
Framework 
The framework for this study is Dorothea E. Orem's Model of Self-Care. "Orem 
labels her self-care deficit theory of nursing, a general theory composed of three related 
theories: (1) the theory of self-care (describes why and how people care for themselves), 
(2) the theory of self-care deficit (describes and explains why people can be helped 
through nursing), and (3) the theory of nursing systems (describes and explains 
relationships that must be brought about and maintained for nursing to be produced"; 
Taylor et al., 1998, p.176). Each is discussed briefly in the following text. 
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The theory of self-care is a human regulatory function that individuals must, with 
deliberation, perform for them or have performed for them to maintain life, health, 
development, and well-being. This research study is appropriately supported by this 
theory. A patient undergoing open-heart surgery does not have the ability to perform self-
care. The care required is beyond what the average family can provide, thus the patient 
requires the expert care by nurses to achieve a satisfactory outcome. The elaboration of 
the concepts of self-care, self-care demand, and self-care agency provide the foundation 
for understanding the action requirements and action limitations of persons who may 
benefit from nursing care (Orem, 1991). 
This model focuses on what nurses actually do when they practice nursing. Orem 
proposed that individuals generally know how to take care of themselves (self-care). If 
6 
they become dependent in some way such as when they need post-operative care 
following a coronary artery bypass (CABG) surgery, family members must take on the 
responsibility (dependent care; Orem, 1991 ). If individuals are ill or have some self-care 
deficit (i.e. immediate post-op care including major intravenous monitoring lines and 
mechanical support as is common after open-heart surgery), these individuals require 
special care (therapeutic care). An individual's capacity to provide self-care is referred to 
as self-care agency. A self-care deficit occurs when self-care demand exceeds self-care 
agency (Taylor et DO1998). 
"Nursing care is provided only when there is a deficit in the self-care or 
dependant care that the individual and his family can provide (self-care deficit). In this 
case, the nurse or nurses develop a nursing system to provide the needed care" (Bums & 
Grove, 1997, pp.146-147). This system involves prescribing (monitoring vital signs, 
dynamic pressures, equipment and medications necessary to maintain homeostasis), 
designing (setting parameters for individualized care), and providing the described 
needed care. "The goal of nursing care is to facilitate resumption of self-care by the 
person and/or family. There are three types of nursing systems: wholly compensatory, 
partly compensatory, and supportive-educative" (Bums & Grove, 1997, pp.147). As the 
patient progresses through the different stages of'post-op recovery and their self-care 
activities increase, they progress and return to independent self-care within the 
supportive-educative nursing system. 
Taylor, et al., (1998) in the book Nursing Theorists and Their Work, notes, 
The Theory of Nursing Systems proposes that nursing is human action; nursing 
systems are action systems formed (designed and produced) by nurses through the 
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exercise of their nursing agency for persons with health-derived or health 
associated limitations in self-care or dependent care. Nursing agency includes 
concepts of deliberate action, including intentionality and operations of diagnosis, 
prescription and regulation. Nursing systems may be produced for individuals, for 
persons who constitute a dependent-care unit, for groups whose members have 
therapeutic self-care demands with similar components or who have similar 
limitations for engagement in self-care or dependent-care. 
The central ideas of the Theory of Self-Care Deficit, are that the requirements of 
persons for nursing care are associated with the subjectivity of mature persons to health-
related or health-care-related action limitations. This renders them completely or partially 
unable to know existence and emerging requisites for regulatory care for themselves and 
to engage in the continuing performance of care measures to control or in some way 
manage factors that are regulatory of their own functioning. "Self-care deficit is a term 
that expresses the relationship between the action capabilities of individuals and their 
demands for self-care. Self-care deficit is an abstract concept that, when expressed in 
terms of action limitations, provide guides for selection of methods of helping and 
understanding patient's roles in self-care" (Taylor, et al., 1998, pp.180-181). 
Orem's theory addresses the nursing care philosophy, management, and financial 
concerns regarding the techniques of the two cardiac surgical procedures, and patient 
outcomes of this study. By implementing the patient self-care portions of Orem's theory 
and the ability of the nurse to recognize the stages of self-care, the nurse can further 
·utilize the ability of patients to perform more of their own care, thus decreasing the need 
for additional nursing-care hours. Regarding the financial aspect, the more quickly the 
i 
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patient can provide self-care, the shorter the LOS in the hospital setting, thus reducing 
costs. The concept, of decreased LOS and early discharge (Ott et al., 1997; Ott et 'al., 
1999), propelled the idea of converting C-CAB into OPCAB. By eliminating the heart-
lung machine and decreasing the inflammatory response, ventilator time, ICU time and 
blood usage (Fransen, Maessen, Dentener, Senden, & Buurman, 1999), the patient should 
recover more rapidly. A faster return to self-care will progressively decrease reliance on 
nursing care agency. In summary, Orem's Model of Self-Care guides this study's 
purpose to examine the differences in costs and its related factors, including 
inflammatory response, use of pharmacological agents, and blood loss during OPCAB 
and C-CAB. 
Definitions 
· 1. OPCAB 
Conceptual: Coronary artery bypass procedure performed on a slowed beating 
heart without the use of cardiopulmonary bypass, utilizing specialized retraction 
systems and proximal connector devices. 
2. C-CAB 
Conceptual: Coronary artery bypass procedure performed on a still, motionless 
heart with the use of the cardiopulmonary bypass machine, providing a 
bloodless field. 
3. Costs 
Conceptual: Amount of hospital revenue required to provide the necessary 
equipment, personnel, and disposable materials needed for OP ACAB and C-
CAB techniques and surgeon protocols, during the peri-operative period. 
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Operational: Actual cost, in dollars, of the operating room charges. These will 
include the cost of cardiac surgery overhead (room costs, staff: assistants, 
circulating nurses, scrub technicians, and perfusionist), equipment and disposable 
material charges as measured from the patient's record after discharge from the 
hospital. 
4. Hospital LOS 
Conceptual: Number of days spent in the hospital from the time of discharge 
from the ICU to the time of discharge from the institution. 
Operational: Number of days as recorded in the patient record from the time of 
discharge from the ICU to the time of discharge from the institution. 
5. ICU LOS 
Conceptual: Number of days spent in the ICU from the time of admission until 
time of discharge to the floor. 
Operational: Number of days recorded in the patient record from admission to 
discharge from the ICU. 
6. Inflammatory Response 
Conceptual: Measurement of increased activity of the immune system can be 
performed at predetermined intervals. 
Operational: Levels of inflammatory mediators, including a combination of 
available cytokine (IL-6, IL-10) and matrix metalloproteinases (MMP- 2, MMP-
9), will be collected, tested, and recorded at specific times: pre-stemotomy, peri-
and post-operatively. 
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7. Bypass Circuits 
Conceptual: Type of coating used on the different cardiopulmonary bypass 
circuits. Circuits may be coated with either covalent or hydrophilic/hydrophobic 
heparin on the internal surface of the bypass circuit. 
Operational: Exposure of the subjects according to the measurement of the 
actual inflammatory mediators previously explained at the appropriate time 
intervals. 
8. Nursing Care Hours 
Conceptual: The number of nursing care hours required to effectively provide 
the necessary care of the patient within the three stages of Orem's Model of Self 
Care. 
Operational: Actual number of hours calculated by the nursing managers, on 
the postoperative step down unit, for the amount of nursing care required for 
each of the protocols used. 
9. Blood Usage 
Conceptual: The use of blood or blood products in the care of the patient 
undergoing coronary artery bypass surgery. 
Operational: Measurement and documentation of the amount of blood or blood 
products required during the operative and post-operative periods in the 
OPCAB and C-CAB groups being studied. 
10. Drug Regimes 
Conceptual: The are two different drug regimes which are as follows: Amicar 
5-5-5 indicates, that 5 grams of Amicar will be administered after the loading 
dose of Heparin, 5 grams in the cardiopulmonary bypass circuit prime, and 5 
grams will be administered after Protamine administration; Aprotinirl Yi dose 
indicates that 1 million units administered prior to the median sternotomy, 1 
million units in the cardiopulmonary bypass circuit prime, and an infusion rate 
administered at 250,000 units/hour during the entire operative period. 
Operational: The inflammatory mediators, IL-6, IL-10, MMP-2, MMP-9, will 
be collected and documented at the specified time intervals during the drug 
regimes. 
Major Assumptions 
1. Patients are more self-sufficient and require fewer nursing care hours when 
there is a decrease in the measured inflammatory response. 
2. Patients desire to be discharged from the hospital as soon as they are self-
sufficient in their care. 
3. Less invasive procedures cause fewer complications and thus lead to a 
quicker recovery. 
Major Limitations 
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1. The patient population examined (primary C-CAB) is non-randomized due to 
the need to have the cardiopulmonary bypass system SUHSDUHGprior to the 
patients' arrival to the operating room. 
2. The convenience of not having two circuits (x-bonded and y-bonded) in use 
at the same time limits the randomization process. 
3. Physician protocols of drugs use, due to cost factors and possible side effects, 
limit the researchers ability for randomization. 
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4. Physician caseload may affect the frequency of preferred treatment modalities 
and thus the type of patient population studied. 
5. Patient selection is limited to a single healthcare facility, thus the anticipated 
type of patient enrollment might lead to limitation of generalization to other 
health care facilities. 
6. Various certified clinical perfusion techniques might influence the results of 
the research. 
7. Sample may be biased toward the male gender therefore may be less 
generalizable to the female population. 
8. Physician selection criteria for techniques used may be biased toward ability 
to complete total revascularization. 
9. Increasing public awareness of differing operative techniques currently in use 
has the potential to effect randomization. 
Significance of Proposed Study 
The significance of the study is its unique focus on the different aspects of major 
changes in the treatment of the cardiac surgery patient. Although the advances in surgical 
techniques are at first promising, all aspects of the final outcomes must be reviewed. Cost 
cannot be ignored, but also cannot be the sole determinant for change. Short term positive 
results are promising, but the long term results can and will be the finalizing factor 
(Puskas et al., 1999). As research focuses on determining whether on pump or off-pump 
is initially more cost effective (Ascione et al., 1999), the LOS and need for nursing care-
hours must also be noted. If patients in the OPCAB group actually prove to be more 
independent and discharged earlier at a reduced cost with acceptable long-term results 
(Puskas et al. 1999), then there truly is a place for the OPCAB surgical procedures. 
Summary 
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As more and more "baby boomers" reach the age when they require additional 
intense medical treatment, the costs of such treatment will increase dramatically. In 
response to this situation, medicine and health-care providers are searching for ways to 
stretch the health-care dollar. One method currently being explored to expand the 
financial revenues available for coronary artery bypass surgery is to perform OPCAB. 
Benefits found with this technique are the hypothesized decrease in several treatment 
modalities: (a) less ventilator and ICU times, (b) decreased inflammatory response due to 
lack of exposure to the large surface area of the cardiopulmonary bypass machine (CPB), 
( c) decreased use of blood and blood products. It is proposed that these benefits will lead 
to faster recovery to self-care, and thus earlier discharge. Therefore, there will be 
reduced costs and more effective use of the health-care dollar. Negative aspects may 
include: (a) the inability to perform as many bypass grafts and thus result in incomplete 
revascularization, (b) no actual cost saving due to the cost of specialized equipment 
necessary for the techniques, and ( c) longer operating room times and thus higher costs 
will produce poorer patient outcomes. 
Nursing care is threatened by the expected national shortage of nurses. If patients 
are able to become independent sooner (decreased acuity) and thus require less nursing 
care hours, then the benefits would be enormous. By more quickly returning to 
independent self-care, patients will have improved self-worth resulting in improved 
quality oflife. Orem's Self-Care Model can guide the nurse as he or she identifies the 
patient's progression through the stages of self-care and thus more independence. 
Knowing whether OPCAB or C-CAB is the most cost effective technique is essential · · 
information for administration when planning overall health-care costs. 
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CHAPTER2 
REVIEW OF LITERATURE 
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The review of the literature (ROL) reflected an increasing interest in the ability 
to safely perform coronary artery bypass surgery in the absence of the heart-lung machine 
while maintaining acceptable results. ROL included research studies and articles in 
research, medical and perfusion literature, nursing journals, and nursing texts. Only 
relevant articles dealing with the direct parameters of the study were reviewed. The 
purpose of the review, delimitations, resources, and keywords used, along with a 
combination of theoretical and research literature, are discussed in this chapter. 
Purpose of Review 
The purpose of this ROL was to gain an appreciation for the body of 
knowledge regarding C-CAB and OPCAB that exists today. The issues involving LOS 
(Rosen, Humphries &, Muhlbaier, 1999), length of nursing care hours and the projected 
nursing shortage (Loquist, 2002; Milstead, 2002), inflammatory response of the human 
body (Joffs et al., 2001), and costs (Lee, Abdelhady, & Capdeville, 2000) are all 
concerns and interests that guided this review. Also of interest are the different 
operative techniques currently used and the advantages of each (Magovern, Benckart, 
Landreneau, Sakert, & Magovern, 1998). Many 'studies involving the use of CPB and 
its detrimental effects have been published (Bull et al., 2001; Kirk et al., 2001; Lancey 
et al., 2000) but the question still remains, is it the pump or the surgical techniques that 
cause detrimental side effects? (Taggart, Browne, Halligan, & Wade, 1999) Are the 
long-term results of OPCAB better for patients than having them subjected to C-CAB? 
(Arom et al., 2000; Bowles, 200 I; Puskas et al., 1999) 
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With the estimated clientele of 516,000 patients per year (American Heart 
Association, 2001) expected to increase with the addition of the "baby boomers" reaching 
their 50s and 60s (Beller, 2001), the process of providing the most cost-effective and safe 
method of revasculization of the heart needs to be addressed. Extensive review of the 
literature has failed to find a previous study that compares OPCAB with C-CAB 
including the variables that have been identified for this study, which indicates the need 
for a study of this magnitude. There are numerous previous studies which have focused 
on a few of the variables proposed, but to date none have been found that address the 
relationships of this study's variables. The variables involved are numerous and will 
provide a broad scope for this study. Wholly available and commonly used surgical 
techniques, drug and perfusion practices will be studied and thus will provide results and 
information that can and will assist health care providers with informed and responsible 
decisions. 
Delimitations 
The extent of the ROL was limited to periodicals from the years 1992 to the 
present and books spanning seventeen years, 1986 to the present, since these authors are 
considered to be experts in the early years of cardiovascular surgery. 
Keywords and Resources 
The keywords for searching electronic databases were: (a) Aprotinin; (b) Blood; 
(c) Bonded Circuits; (d) Compliment Activation; (e) Cardiopulmonary Bypass (CPB); (f) 
Complications; (g) Off-Pump Coronary Artery Bypass (OPCAB); (h) Cardiopulmonary 
Bypass Grafts (CABG); (i) Cost; G) Fast Tracking; (k) Length of Stay (LOS); (I) 
Proximal Connector; (m) Proximal Connector; and (n) Stabilization Devices. 
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The databases utilized were: (a) the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), (b) Medline (Medical Literature Analysis and Retrieval 
System Online), (c) Medscape, and (d) AMSECT Digital Interactive Library. Other 
resources used were the (a) McKee Library at Southern Adventist University, (b) 
Erlanger Medical Center Library, and (c) Memorial Hospital Medical Library. Other 
resources, including abstracts and numerous medical, perfusion, and nursing journals, 
along with texts, were referenced. 
Description of Literature 
In the world of ever changing medical treatments and techniques, those who are 
dormant will find themselves in the dust of the progressive ones. Within this context fall 
the present and ambitious changes in cardiovascular surgery. Whether driven by changes 
in reimbursement, a need to improve outcomes, or a combination of both, health care 
providers are once again involved in the search for better techniques. This has led to the 
resurgence of OPCAB. A resurgence of interest in CABG without CPB began when it 
was first performed by Kolessov in the former Soviet Union and by Favaloro and Garret 
and associates in the United States (Buffolo et al., 1996). Researchers in the United States 
and Canada later reported on the technique but abandoned it as the use of CPB, along 
with cardioplegic cardiac arrest, became routine. 
A major advantage in using CPB during C-CAB is the ability to operate on a still 
heart with a relatively bloodless field. This also enables the exposure of all distal 
coronary arteries (Ardehali, Kessler, Formosan, & Lakes, 1999). Manipulation of the 
heart can allow for more accurate, secure grafts and allow for the reinstitution of blood 
flow to the myocardium. Numerous complications have been linked to the use of CPB. 
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Included in these complications are coagulopathy, inflammatory responses, edema, renal 
dysfunction, and neurological deficits (Kirk, et al., 2001). Kirklin (1986) stated, "the 
most obvious mechanisms for damage during CPB are exposure of blood to an abnormal 
environment, and altered arteriatblood flow patterns". It is with these changes in mind 
that the analysis of current techniques and trends are reviewed. 
Off-Pump Coronary Artery Bypass 
It has been shown that CPB initiates a cascade of inflammatory processes that 
may result in many complications (Lee, Abdelhady, & Capdeville, 2000). Avoidance of 
CPB during OPCAB has gained increased popularity in modern cardiac surgery. With the 
development of new mechanical stabilization devices (Jansen et al., 1998), the 
revascularization of the posterior wall of the heart and the distal right coronary 
circulation has become feasible. High-risk patients, with multiple risk factors for open-
heart surgery, will especially profit from this approach due to avoidance of the negative 
effects associated with CPB (Tugtekin et al., 1999). 
Advances in technology and commercial availability of mechanical stabilization 
systems have permitted wider application of OPCAB surgery. These systems strive to 
provide a well-exposed, immobilized target site for performance of precise vascular 
anastomosis. The early clinical outcome and angiographic follow-up in patients who have 
undergone left internal mammary artery (LIMA) anastomosis to the left anterior 
descending (LAD) coronary artery with the available mechanical stabilization systems 
have been encouraging (Puskas et al., 1999). 
Since minimally invasive techniques have become increasingly common in 
CABG, there has been renewed interest in facilitating mechanical anastomotic devices 
i ' 
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that may have the potential of replacing the standard suturing techniques in vascular 
anastomoses. Recently, the Symmetry Aortic Connector®, which attaches the proximal 
vein graft to the aorta without the use of a side-clamp, provided this option. This 
technology is attractive for all CABG procedures because aortic manipulation is reduced 
with resultant reduction of possible particulate emboli (Eckstein et al., 2001 ). 
Indications are that arterial conduits, such as the LIMA, can easily be used, and 
most coronary arteries can be bypassed. The mortality rates continue to show promise 
with low rates, and the incidence of serious complications such as arrthymias, pulmonary, 
and neurological sequelae are lower than with C-CAB. The patency rate for the bypass 
grafts is similar to the C-CAB patients. 
These concerns and observations have been studied by numerous researchers and 
have been reported with differing results. One such study was conducted at a large 
teaching institute in the southern United States (Kirk et al., 2001). This study 
retrospectively compared the performance of OPCAB versus C-CAB patients over a 
period of six months. Data was collected and compared from the National Cardiac 
Database of the Society of Thoracic Surgeons (STS). Variables studied included age, 
gender, left ventricular ejection fraction (LVEDF), previous myocardial infarction (MI), 
disease severity, number of grafts, complications, blo'od usage, ventilator times, operating 
room (OR) times, and LOS. 
There was no significant difference, as measured by the Student's !-test, between 
the patient groups with regard to age, gender, L VEDF, previous MI, and LOS. A p-value 
of< 0.05 was considered significant. Data was presented as mean± standard deviation. 
The C-CPB patients had significantly (p < 0.05) more diseased vessels (2.9 vs. 2.6) and 
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distal grafts (4.1vs.2.7), as compared to the OPCAB group. The OPCAB group had a 
significantly lower (p < 0.05) mean OR time (365 min. vs. 406 min) and reduced niean 
ventilator times (3.4 vs. 8.3 hours) as compared to the C-CPB group. There were 
significantly fewer blood transfusions (p <0.05) in the OPCAB group (1.1 vs. 2.4 units), 
and the patients transfused were significantly lower (34.9% vs. 57.3%). 
The study group size was adequate (n = 212 patients) and the demographic data 
were similar. The significant differences have been given. Several studies have reported 
the cost savings of OPCAB over C-CAB surgeries (Ascione et al., 1999; Lee et al., 2000; 
Smith, Smith, & Muhlbaier, 1997) and long-term patency rates of OPCAB bypass grafts 
as acceptable (Puskas et al., 1999). Some concerns that are evident and deserve 
justification are the significantly lower number of OPCAB bypass grafts (2.7 vs. 4.1) and 
the possibility of incomplete revascularization (Hart, Spooner, Edgerton, & Milsteen, 
1999). 
Limitations of this study include: that the study was non-randomized, 
retrospective, and may not be applicable to prospective groups. No post-operational 
procedures were done to verify the anastomotic patency or bypass graft patency, and 
there was no long-term follow-up to verify the benefits of OPCAB. Overall, the study 
was thorough and gave good statistical support to verify the hypothesis. 
A comparative study of a consecutive series of 8, 7 51 patients (Buffolo, Silva de 
Andrade, et al.), reported that from 1981 to 1994, patients (1, 274) received CABG 
operations without the use of CPB. Results indicated that the operation can be performed 
with an acceptable mortality rate (2.5%), and that all types of arterial conduits can be 
used. Most commonly the LAD and right coronary arteries (RCA) were bypassed. The 
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incidence of pulmonary and neurological complications was significantly lower in this 
group of patients compared with patients receiving CABG with CPB. Most importantly, 
there was a decreased cost (approximately $3000.00) when the procedure was used, 
because no extracorporeal circulation, cardioplegia sets, or cannulas were used. 
Methods used were within the parameters of the other previous study, although 
the sample size was significantly larger. Demographics were also consistent with other 
study including age, sex, pre-operative status, the severity of coronary artery disease, 
previous myocardial infarction(s), and arteries receiving bypass grafts. Number of grafts 
patients received in the study (OPCAB) group was 1.7, which was not compared to the 
control group. It is of interest that statistics, though no analysis, were given for the 
patency rates of the internal mammary artery before hospital discharge. Both the control 
and study groups had a 93.4% patency rate. 
The advantages for OPCAB were as follows: (a) less mortality/morbidity, (b) 
lower use of homologous blood, (c) lower cost, and (d) decreased length of stay. The 
disadvantages given were: (a) technically more demanding, (b) possible in only 20% of 
cases, and ( c) lower reproducible results. 
In summary, this study was able to provide indications for OPCABs in ' 
'i 
approximately 20% of their population, with acceptable results and low complication 
rates. Though no analysis was given, the raw numbers would indicate comparable results, ' 
therefore the authors felt that further use of the procedures were justified. 
OPCAB may seem like the trend of the future, due to elimination of problems 
already mentioned, but it is not without possible complications. A couple of these 
complications have been identified in current literature. These include, but are not limited 
' 
I 
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to, an increase in the incidence of acute aortic dissection due to manipulation of the heart 
during retraction (Chavanon et al., 2001), and a concern that a hypercoagulable status 
may occur after OPCAB that can potentially endanger the patency of the anastomosis 
(Kim et al., 2001 ). 
Conventional Coronary Artery Bypass 
The advantage of using CPB during C-CAB is the ability to operate on a still 
heart with a relatively bloodless field, while enabling exposure of all distal coronary 
anatomy. The surgeon can manipulate the heart, make accurate and secure grafts, that 
then allow the re-establishment of blood flow to the distal coronary circulation. 
Cardiopulmonary bypass is a nonphysiological process. Deleterious effects 
attributed to its use include coagulopathy, inflammatory responses, edema, renal 
dysfunction and neurological deficits (Lillehei, 1993). Kirklin (1986) states, "the most 
obvious mechanisms for damage during CPB are exposure of blood to an abnormal 
environment, and the altered arterial blood flow patterns" which may lead to increased 
operative mortality and morbidity and thus effect length of stay and hospital costs (p.53-
54). 
Edmunds ( 1998) noted that a large number of vasoreactive substances are 
produced during CPB and open-heart surgery which cause edema, decreased myocardial 
function, and changes in the vascular bed resistance. Reduction in mortality associated 
with adverse effects is the goal of numerous researchers today. 
CPB is known to activate five plasma protein systems: contact, intrinsic 
coagulation, extrinsic coagulation, compliment and fibrinolytic. The purpose of this 
sectio.n of the review was to explore studies regarding prevention of the activation of 
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these systems. Activation of the plasma protein systems mediates some of the 
complications of CPB: bleeding, fluid retention (edema), and temporary organ 
dysfunctfon. The use of the drug Amicar addresses the fibrinolytic problem, sometimes 
associated with bleeding. Aprotinin has been shown to decrease the detrimental effects on 
the platelets and to decrease the inflammatory response (Mojcik & Levy, 2001). Heparin 
is used to prevent coagulation, but is not the ideal anti-coagulant because it inhibits 
coagulation at the end of the coagulation cascade rather than at the beginning. Thus many 
powerful proteases are produced before heparin inhibits clot formation. 
Many non-blood variables affect the magnitude of the inflammatory response, 
including biomaterials in contact with blood, surface coatings, activation of some 
proteins by the operation itself, temperature, aortic cross-clamping, myocardial 
reperfusion, steroids, antitoxins, and the various protease inhibitors that may attenuate the 
response (McCann & Gatto, 1999). 
Costs 
Some institutions are reporting a cost savings with OPCAB of $3000/case due to 
decreased use of disposable equipment such as oxygenators, cardioplegic sets, and 
cannulas (Buffalo et al., 1996). Lee et al., (2000), reported a reduction in variable direct 
. 
costs per case of29%, as attributed to lack of complications such as stroke, renal failure, 
or sternal infections for the OPCAB group in their study. 
Fast track methods have been reported (Ott et al., 1997; Ott et al., 1999) for 
patients utilizing both C-CAB and OPCAB techniques. The LOS varied from 5.2 days 
with C-CAB to 3.9 days OPCAB. It was interesting to note finding that the number of 
bypass grafts was considerably lower in the OPCAB group (2.9 versus 3.6) than for the 
C-CAB group. 
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Ascione, et al. (1999) noted that the emphasis on cost containment in coronary 
artery bypass surgery is becoming increasingly important in modem hospital 
management. The sample included 200 patients undergoing primary CABG surgery, 
which were randomized to either the C-CAB group or OPCAB group. Variable and fixed 
costs were obtained for each group during the operative and postoperative periods. The 
data were presented as mean ± standard error of the mean (SEM). Comparison of the 
groups was performed using the unpaired/- test and Fisher's exact test where appropriate, 
assuming equal variance. Two-tailed tests were used and differences were considered 
significant where p < 0.05. 
The researchers found there was no statistical difference between the groups with 
respect to pre- and intra-operative patient variables. OPCAB surgery was significantly 
less costly with respect to operating materials, bed occupancy, and transfusion 
requirements (total mean cost per patient: C-CAB = $3731.6 +/- $1169.7 vs. OPCAB 
$2615.13 +/- $953.6;p <0.001). Morbidity was significantly higher in the on-pump 
group as reflected in an increased cost (Ascione et al., 1999). 
The conclusion reached was that OPCAB revascularization offers a safe, cost-
effective alternative to C-CAB surgery. The samples were of adequate size, the statistical 
analysis was very good, and the variables were well covered in comparison to the 
previous studies. Demographics, including age, sex, diabetes, ejection fraction, CPB 
times, OR times, number of grafts (including patency rates) were analyzed and statistical 
significances were given. Variables for cost were identified and well described. Clinical 
postoperative data included mortality, morbidity, myocardial infarctions, blood usage, 
intubation times, and ICU and hospital LOS. Furthermore, these cost reductions are· 
distributed from the operative theater to post-operative management. 
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Lancey, Soller & V antler Salm (2000) reviewed the comparison of OPCAB and 
the trends demonstrated towards fewer complications, faster recoveries and lower costs 
compared with C-CAB surgery. All patients entered into the study were case-matched by 
age, sex, and risk scores according to the Society of Thoracic Surgeons. Equal numbers 
of participates were entered into the two groups and surgery was performed by the same 
surgeon. 
Data were collected prospectively on all patients. Data were continuously 
analyzed using a paired t-test, while categorical values were analyzed using a McNemar 
chi-square test. Both tests were effective for patients that were matched prior to statistical 
analysis and had significance indicated by p values< 0.05. Cost differences, as well as 
relationships between ages, preoperative risk score and costs were examined using a t-
test. 
Results of specific interest to this research included the difference in the average 
number of distal anastomoses, OPCAB: 2.8; C-CAB: 3.7; p = 0.00001. Although, 
operating room times averaged 25 minutes less for the OPCAB group, this was not 
statistically significant and may reflect the fewer number of distal anastomosis 
performed. Average time on the ventilator was significantly lower for the OPCAB group, 
mean (in days) of 0.26 vs. 0.77,p = 0.007. The mean ICU LOS was shorter for the 
OPCAB group (in days), 1.80 vs. 2.41 for the C-CAB group, p = 0.144; and mean 
hospital LOS was also shorter for OPCAB (in days) with 5.17 vs. 6.24,p = 0.112. Both 
LOS means fell short of being of statistical significance. 
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The average number of packed red blood cells transfused was significantly 
lower on the first postoperative day for the OPCAB group, 0.25 vs. 0.88, p = 0.00001; 
this trend continued which showed statistical significance on postoperative day two with 
transfusions reported to be 0.05 (OPCAB) vs. 0.18 (C-CAB), p = 0.040. No statistical 
differences were reported for complications, including atrial fibrillation, stroke, 
perioperative myocardial infarction, re-operation for bleeding and mortality. 
Total costs revealed a savings for OPCAB ($15041.68) vs. C-CAB ($18943.73), 
but was not statistically different (p> 0.05). The costs savings for OPCAB were reported 
in the following areas: (a) blood transfusions, 87.4%; (b) mechanical ventilation, 67.7%; 
(c) OR equipment (including CPB), 67.3%; (d) ICU, 44.2%; and (e) pharmacy, 64.2%. 
The authors concluded that by reducing the need for mechanical ventilation, 
transfusions, ICU and hospital LOS via "fast-track" protocols, OPCAB surgery decreased 
the use of limited and costly resources without producing an increase in morbidity or 
mortality. 
Length of Stay 
There was also a decreased LOS in the intensive care unit and in the hospital, 
mean LOS of 5.2 days for OPCAB versus 9.6 days for C-CAB (Buffolo et al., 1996). Lee 
et al. (2000) reported the OPCAB group in their study reflected a shorter LOS (6.1 versus 
7 .1 days) than the C-CAB group. The management of these patients in reference to fluids, 
electrolyte and respiratory care is simpler. Undoubtedly, the OPCAB technique is more 
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demanding, and there is a learning curve, however the surgeon had the option of placing 
the patient on CPB, if the need arises. 
Ott et al. (1999) retrospectively reviewed a series of patients undergoing C-CAB, 
using a fast-track recovery method and compared this with OPCAB. Using the fast-track 
method, all patients were placed on a protocol emphasizing a short CPB time, early 
extubation, and atrial fibrillation prevention. All patients were targeted for transfer from 
the ICU on the first post-operative day, aggressive ambulation on the second post-
operative day, and all were allowed to shower on the third post-operative day. Discharge 
was accomplished when there was absence of weeping wounds, dysrhythrnia and fever. 
Follow-up appointments were arranged within 72-96 hours after discharge. 
The data were presented as a mean ± SEM. Comparison of the groups was 
performed using the t- test, whereas categorical variables were compared using the chi-
squared test. Two-tailed tests were used and differences were considered significant 
where p < 0.05 or p < 0.01, as indicated. 
The group size for C-CAB was adequate (n = 104) but the OPCAB group was 
small (n = 25). Demographic data correlated well between the groups. However, the 
OPCAB group was found to be at a higher-risk with increased incidence ofleft-
ventricular dysfunction (29% vs. 6%,p < 0.01),·congestive heart failure (48% vs. 15%,p 
< 0.01) and symptomatic peripheral vascular disease (29% vs. 8%,p < 0.05). Number of 
bypass grafts performed was 3.6 ±1.O for C-CAB and 2.9 ± 1.0 for OPCAB,p < 0.01. 
OR times showed no significant difference with the C-CAB at 151 ± 31 minutes and the 
OPCAB group at 146 ± 35 minutes. 
Mortality, post-operative complications, and LOS had no statistical difference 
between the groups. Data included: C-CAB vs. OPCAB: mortality, 1.9% vs. 0%; LOS 
(days), 4.8 ± 2.4 vs. 5.2 ± 2.3; and bleeding, 4.9% vs. 0.0% (Ott et al., 1999). 
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Ott and others concluded that eliminating CPB is not as important as minimizing 
operative risks. OPCAB is best suited for high-risk patients requiring 3 or fewer grafts. 
With aggressive fast-track recovery methods, patients requiring three or more bypass 
grafts should undergo C-CAB with the same cost and LOS results. 
Inflammatory Response 
The pro-inflammatory cascade of the immune system plays an important role in 
patients who undergo cardiopulmonary bypass (Edmunds, 1998). These patients 
displayed a "primed" system, which opens a window of susceptibility during which any 
physiologic stressor can unleash a generalized auto-destructive inflammatory cascade that 
if unchecked, can lead to several syndromes including Adult Respiratory Distress 
Syndrome (ARDS), Multi-Organ Dysfunction Syndrome (MODS) and death (Goris, te 
Boekhorst, Nuytinck, & Gimbrere, 1985; Terregino, Lopez, Karras, Killian, & Arnold, 
2000). In association with CPB, a condition called post-pump syndrome (PPS), has been 
well characterized in humans and animal models (McCann & Gatto, 1999). 
Ischemia-reperfusion 
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Figure 2.1 
Tissue Injury - Multiple Organ Dysfuction 
(Wan, LeClerc &, Vincent, 1997, p.677) 
The CPB circuit has been shown to activate the pro-inflammatory arm of the 
immune system, as well as the coagulation cascade (McCann & Gatto, 1999), and is 
commonly referred to as systemic inflammatory response syndrome (SIRS). Normally, 
. 
patients recover without undue sequellae of this event. In some patients, the pro-
inflammatory response becomes over activated, resulting in the previously mentioned 
phenomena, MODS (Baue, 1992). 
Measurement of the degree of immune system activation can be performed by a 
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combination of available cytokine and matrix metalloproteinases (MMP) assays (Dollery, 
McEwan &, Henney, 1995; Parsons, Watson, Brown, Collins, & Steele, 1996) as well as 
clinical outcome measurements (Boyle, Pohlman, Johnson, & Verrier, 1997; Meduri et 
al., 1995; Pinsky et al., 1993). Measurements of these mediators in plasma can provide 
insight into the level of their production during and after procedures involving CABG. 
Important clinical endpoints include indices of specific organ failure, most importantly 
the lungs, which through ARDS, demonstrates early and frequently irreversible 
consequences in MODS, contributing to increased ICU stays, hospital LOS, and other 
complications including mortality (Boyle, Pohlman, Johnson &, Verrier, 1997). 
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Assays of cytokines and mediators throughout the pre-, peri-, and post-operative 
periods allow for the measurement of the levels during various times, differing 
techniques, and protocols utilized. Assessment of the clinical outcome data including 
assays, along with the differing protocols used, will allow for analysis and determination 
of statistically significant differences between the techniques, drugs and circuit bondings 
being studied. These intermediate and clinical analyses have not been previously 
characterized in a prospective fashion involving this researcher's numerous identified 
variables in patients undergoing CABG. 
The cytokines selected for measurement include IL-6 and IL-10. IL-6, a pro-
inflammatory mediator, selected as a candidate variable as it has been previously well 
characterized as correlated with poor outcomes such as MODS, and can be reliably 
measured (Kishimoto, Akira, Narazaki, & Taga, 1995). IL-10 was selected as a variable 
as it has been previously well characterized as an anti-inflammatory mediator and has 
been studied during MODS, and the ratio ofIL-6 to IL-10 correlates with SIRS severity 
and outcomes (Taniguchi et al., 1999). 
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The MMPs are a group of at least 28 enzymes that effect tissue remodeling in 
both normal and pathological states. In pathological states, these enzymes can exert their 
effects either in a chronic or acute fashion. The MMPs have been shown to act in the 
acute phase following cardiac stress, leading to both ventricular remodeling and multiple 
organ failure (Camey et al., 1999). MMP-2 and MMP-9 have also been shown to rise in a 
predictable fashion in association with CPB (Joffs et al., 2001). 
Joffs, et al. (2001), researched the question of whether a recently discovered 
family of enzymes, the MMPs can degrade the extracellular matrix as expressed after 
cardiopulmonary bypass. As previously stated, the MMPs are a large family of 
proteolytic enzymes responsible for extracellular matrix degradation that may account for 
many of the complications noted after cardiopulmonary bypass involving the pulmonary, 
neurological, and renal systems. 
Patients (n = 28; 18 men and 10 women) with an average age of 63 ± 1 year, 
undergoing elective CABG were entered into the study. Blood samples were drawn after 
the induction of anesthesia, just prior to initiation of CPB, and again just after termination 
of CPB. Additional samples were obtained at 30 min., six and 24 h\ours after CPB. 
All data analysis was completed using analysis of variance for repeated measures, 
followed by a Boferroni corrected t-test. Values were expressed as mean± SEM. No 
level of statistical significance was given. 
The researchers reported findings that would indicate that there is an increased 
release of several classes of MMPs in the period after CPB. Also, one class of MMPs 
(MMP-13) increased immediately after the release of the cross-clamp and transiently 
after separation from CPB. Thirdly, some of these enzymes may be related to the 
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ischemic myocardium during revascularization. Some of these MMPs (MMP-2, MMP-9) 
have been demonstrated in several cardiac states including atheromatous plaques, 
aneurysms, and after MI's. This would lead one to believe that the release of certain 
MMPs is from the manipulation of the myocardium and not CPB. 
Results included: MMP-8 levels rapidly increased at separation from CPB (p < 
0.001) and returned to normal levels within 30 minutes after termination of CPB; pro-
MMP-13 levels increased from baseline after cross-clamp removal (p < 0.002) and 
remained elevated after removal from CPB, then returned to normal levels within 6 hours 
post CPB; pro-MMP-9 levels increase significantly from baseline values at cross-clamp 
release (p < 0.001) and remained elevated until 30 minutes after CPB. 
The researchers concluded that numerous MMPs are released during and after 
CPB. Because MMPs can degrade extracellular proteins essential for cellular 
maintenance, enhanced MMPs release and activation may contribute to alterations in 
tissue homeostasis in the early postoperative period. 
The following diagram co.rrelates several strategies reviewed in the subsequent 
text that have been shown to affect the inflammatory response to CPB: 
Preconditioning < 
Drugs 
Steroids 
Pretreatment Intraoperative 
CPB Circuits < 
Coatings 
Ultrafiltration 
Reduced 
Inflammatory 
Response 
Leukocyte 
Depletion 
Some therapeutic strategies to reduce the inflammatory response to CPB 
(Wan, LeCleric, & Vincent, 1997, p. 685) 
Figure 2.2 
Circuits 
Advances in cardiopulmonary bypass circuits in recent years have addressed the 
subject of the inflammatory response. The contact between formed and unformed blood 
elements and the non-endothelialized surfaces of the cardiopulmonary bypass circuits 
result in an intense inflammatory reaction, thought to be responsible for much of the 
morbidity following artificial circulation. Advances in biomaterial-surface interactions 
attempt to limit such damage. 
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The use of heparin-bonded circuits (HBC) has been demonstrated to attenuate the 
activation of neutrophils, platelets, complement and release of cytokines during CPB by 
altering the blood-surface interface (Aldea & Shemin, 1998). A new polypeptide and 
active heparin coating has been developed that simulates a natural endothelium, thus 
decreasing the inflammatory response. These polypeptides can be absorbed on the surface 
of the bypass circuits, thus serving as a link system for the heparin molecules. Through 
both covalent bounding and ionic interaction, the heparin molecules form a stable bond 
with the polypeptide surface. 
8 
0 Immobilized Polypeptides 
Schematic illustration of heparin molecules to the immobilized polypeptides 
(Bader, 2001, p. 25) 
Figure 2.3 
Wendel et al. (2001) reviewed currently available circuit coatings and whether the 
inflammatory response is altered between the type· of coating and application techniques 
involved, thus decreasing the depositing of fibrin and platelets. One coating is currently 
in use at the participating facility (Duraflo II ®) and the second coating is the study 
coating, Bioline®. 
An established CPB model was used to simulate an extra-corporeal circuit. Using 
fresh human, heparinized blood, n = 7 oxygenators from each of the four groups was run 
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at 3 L/min. flows with a mean arterial pressure of 60 mmHg for 120 minutes. At specified 
times, laboratory analysis of platelets, white blood cells, and B- thromboglobulin (B-TG) 
were analyzed and documented. 
The results were expressed as mean ± SEM. Statistical analysis was performed 
by the statistics software SPSS. Differences between the groups were calculated by 
univariate analysis of variance. Level of significance was set at 0.05. 
Reported results for uncoated circuits versus Bioline® coated circuits are as 
follows (no data given for Duraflo II ®). The number of diminished platelets was not 
significant in the experimental group (Bioline®) during the first 60 minutes of 
recirculation, 211.33 ± 7.65 X 103 to 183.00 ± 7.28 X 103 I ul. After 120 minutes of 
recirculating, a greater reduction was observed, 127.83 ± 4.46 103 I ul. An immediate and 
highly significant (p<0.001) reduction of platelets was measured in the non-coated 
control group. After 1 minute ofrecirculation, the platelets fell from 213.00 ± 9.29 X 103 
I ul to 32.67 ± 13.97 X 1Q3/ ul (p<0.001). During 5- 30 minutes ofrecirculation, the 
platelets stayed at a constant low level of 4.33 ± 1.91 X 103 I ul to 11.83 ± 2.22 X 103 I ul 
and increased to values of 82.50 ± 14.15 X 103 I ul at the end of circulation. 
The release of the platelets activation marker B- thromboglobulin developed 
inversely proportional to the loss of the platelets. The values of B-TG increased only at 
the end of recirculation in the experimental group, Bioline®. Plasma concentrations of 
1257.17 ± 171.89 IU/ ml were measured after 120 minutes of circulation. The non-coated 
circuit control group showed a highly significant (p<0.001) increase of B-TG up to 
5927.32 ± 171.89 IU/ ml after 120 minutes. 
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There were similar changes in the white blood cell counts in comparison to the 
platelets. The experimental group showed only a small reduction in the first 60 minutes 
ofrecirculation, 5.47 ± 0.35 X 1000/ul. A greater reduction of white blood cells was 
found after 120 minutes ofrecirculation, 3.52 ± 0.35 X 1000/ul. However, the white 
blood cell counts showed a continuous decrease during the whole recirculation in the 
control group (from 4.85 ± 0.40 X 1000/ul to 2.02 ± 0.20 X 1000/ul). This reduction is 
highly significant with the results of the coated circuit (p<0.001). 
The researchers concluded that the advantage of coated circuit is to be seen in 
selective adsorption of plasma proteins and will be achieved by biopassivation and 
bioactivation as well. With the discovery of new circuit coatings, a pathological deposit 
of fibrin, platelets and other blood cells on the circuit, will be reduced and thus decrease 
the inflammatory response. 
Another new polymer-coated circuit in which the surface has been coated with 
poly 2-methoxyethylacrylate (PEMA) has been developed and studied to assess the 
inflammatory responses during CPB and indicate if there were any significant differences 
with the HBC (Saito, Motoyama & Sawamoto, 2000). 
Saito et al. (2000) reviewed known factors that induce the inflammatory response 
during cardiopulmonary bypass. This inflammatory response may contribute to the 
development of post-operative complications such as respiratory failure, renal 
dysfunction, bleeding disorders, and multiple organ failure (Baue, 1992; Goris et al., 
1985). In particular, pulmonary-edema-associated lung injury is a problem of 
considerable clinical significance (Meduri et al., 1995). HBC have been demonstrated to 
reducing the inflammatory response, which is known to have detrimental effects on 
numerous body systems. The researcher was interested in the newer polymer bonded 
circuit in which the blood-contacting circuits were coated with PEMA. 
Using an animal model (swine), randomly selected groups were subjected to 
bypass. Four groups were identified: 1) control (n = 3), 2) heparin-coated (n = 3), 
uncoated (n = 5), or PEMA coated (n = 5). All CPB circuits consisted of the identical 
components. CPB was conducted for a period of 4 hours without additional procedures 
such as aortic cross-clamping, hypothermia, and heparin neutralization. Blood samples 
were taken at intervals of 5, 15, 30, 60, 120, and 240 minutes after initiation of bypass. 
Appropriate inflammatory mediators were tested. 
Data was recorded and reported as mean ± SEM. One-way analysis of variance 
(ANOV A) followed by the Tukey test was used for comparing variables among 
experimental groups. Statistical significance was assumed for values of p < 0.05. 
Reported results between the four groups indicated that the uncoated groups 
inflammatory mediators increased continuously throughout CPB. On the other-hand, the 
percentages in the PEMA coated group decreased gradually 30 to 240 min after start of 
CPB, and then the values increased slightly 15 minutes after CPB was terminated. No 
mention was made of the heparin-coated circuit group. There were no actual values 
reported to identify statistical differences. All reported results were comparing the 
PEMA-coated circuits with the uncoated circuits, and no results were given comparing 
the HBC and the PEMA-coated circuits. The conclusion made was that PEMA-coated 
circuits should result in the reduction of inflammatory responses, including pulmonary 
edema after CPB, compared to subjects being tested with uncoated circuits. 
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Decreasing the activation of surface contact between blood and the circuit surface 
has long been sought. HBC has been researched as a means of decreasing the risks 
associated with a non-coated circuit. te Velthuis, et al. ( 1997) compared the benefits of 
utilizing a HBC on compliment activation as opposed to the untreated circuit. 
The sample includ
ed 30 patients, who were undergoing elective CAB surgery, 
randomized to two groups, one group (n = 15) allocated to utilize an HBC, and the other 
group (n = 15) to utilize a non-treated circuit. Blood samples were obtained from the 
radial arterial line before induction of anesthesia, ten minutes after induction of CPB, and 
within minutes of cessation of CPB. Data were statistically analyzed using the paired t-test and between groups using 
regression. The adjusted R2 for regression analysis was given and the coefficients were 
expressed within a 95% confidence level. Dichotomous variable analyses were performed 
utilizing Fischer's exact test. In all reported data, a two-sided probability of< 0.05 was 
considered to be significant. Data were presented as means ± 95% confidence interval. 
Findings of the researchers included a 62% (p = 0.06) in the measured 
inflammatory mediators after the onset of CPB and by 43% (p = 0.026) after the cessation 
of CPB in the coated circuit group as compared to the uncoated circuit group. The results 
of the statistical analysis indicated that the use of coated circuits was felt to significantly 
reduce the presence of inflammatory mediators that were measured. 
Pharmacology 
Another advancement in the use of CPB is the addition of drugs to help alleviate 
complications associated with the inflammatory responses. Before the discovery of its 
hemostatic properties, Aprotinin was thought to be a potential anti-inflammatory agent. 
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Since its clinical introduction in 1987 to prevent blood loss during cardiac surgery, its 
anti-inflammatory benefits have been largely overlooked in favor of a vigorous debate 
centering on whether Aprotinin may be pro-thrombotic. Aprotinin has been shown to 
exhibit an anti-inflammatory effect by suppressing leukocyte activation and therefore can 
be expected to provide a significant clinical benefit. This expectation has been borne out 
in clinical practice, particularly in the case of high-risk patients, in which the LOS 
following CPB surgery was significantly reduced by Aprotinin compared to other anti-
inflammatory strategies, thereby offsetting the initial cost of the drug during surgery 
(Harmon, 1996; Landis et. al, 2000). 
Cicek, Demirkilic, Kuralay, Ozal, & Tatar (1996) studied the relevancy of using 
Aprotinin to reduce post-operative blood loss and the need for blood transfusions. Three 
groups were assigned, n = 25 per group, comparable in all demographic and operative 
variables and for treatment with high-dose Aprotinin, intra-operatively (group 1 ), 
postoperative Aprotinin (group 2) and a non-medicated control (group 3). 
Post-operative chest tube drainage was significantly decreased in both aprotinin 
groups compared with those in the control group (295 mL in group 1 and 325 mL in 
group 2 versus 411 mL in group 3;p< 0.05). No significant difference was seen between 
the two Aprotinin groups. The use of homologous blood products was significantly less 
in group 1 and group 2 than in group 3 (1.15± 1.13 units and 1.35 ± 1.30 units versus 
2.55 ± 1.09 units; p< 0.05). 
All results were expressed as the mean and standard deviation. Results were 
compared by ANOVA with subsequent pairwise comparisons according to Duncan's 
multiple range test. A p value ofless than 0.05 was considered statistically significant. 
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The conclusion reached by the researchers was, despite the small patient sample, 
that Aprotinin was effective in reducing blood loss, even when administered after' the 
activation of the hemostatic system. However, the results cannot be applied universally 
since the population studied would be considered to be low risk for post-operative 
bleeding. Higher-risk patients need to be investigated regarding the comparative efficacy 
of post-operative Aprotinin administration. 
Zabeeda et al., (2002) studied the effect of low-dose trasexamic acid (TA) on 
post-operative bleeding and coagulation variables after CABG. Fifty patients undergoing 
primary CABG were assigned to receive either a placebo (0.9% NaCl; n = 25) or a 10 
mg/kg TA loading dose followed by an infusion of TA at 1 mg/kg per hour during the 
operation (n= 25). Numerous coagulation measurements were taken during and following 
the operation. Results were as follows: the TA group weighed less and post-operative 
bleeding was less (194 ± 135 mL versus 488 ± 238 mL,p. <001), whereas blood 
requirements were higher in the control group (1.68 ±1 versus 0.52 ± 0.9 U of packed 
cells per patient,p< 0.001). 
Normally distributed continuous variables were expressed as± SEM. Abnormally 
distributed variables are expressed as medians. For statistical analysis, the two-tailed t-
test was used for normally distributed variables and the Mann-Whitney U test for 
abnormal distributed variables. Non-continuous variables were compared by Fisher's 
exact test as appropriate. Differences were considered significant with a p less than 0.05. 
This study concluded that the use of low-dose TA during CABG significantly 
reduced the coagulopathy-induced post-operative bleeding and requirements of blood 
products. TA had no effect on platelet function during CPB. 
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Blood Loss 
Nader, Reich, Bacon, Salemo, & Panos (1999), examined intra- and post-
operative bleeding and the use of blood products during CABG using either on-pump or 
off-pump techniques. The charts from 126 patients undergoing CABG, 66 patients 
revascularized off-pump and 60 patients with CPB were reviewed. 
There were no differences in preoperative platelet counts or hemoglobin 
concentrations between groups. More patients received preoperative heparin in the off-
pump group, resulting in increased partial thromboplastin times (40.4 ± 2.9 versus 34.7 ± 
3.6 seconds) and activated clotting time (150.1±13.3 versus 130.5 ± 10.5 seconds) in 
this group as compared to the on-pump group (p < 0.05). Intra-operative blood loss was 
calculated by the amount of cell-saver volume returned and was found to be lower in the 
OPCAB patients compared with the C-CAB group (508 ± 64 versus 715 ± 50 mL). 
OPCAB patients had lower post-operative chest tube drainage in the first 24-hour period 
compared with the C-CAB patients (771 ± 66 versus 1084 ± 82 ml, p < 0.05). Finally, the 
OPCAB group required an average of2.25 less units of packed red blood cells, 1.75 less 
units of fresh frozen plasma and 3.75 less units of platelet-rich plasma (p < 0.05). Results 
were express as the mean and standard deviation. All data was analyzed using unpaired t-
test, x2, and Fischer's exact test as appropriate. 
The conclusion reached by the researchers was that even though the OPCAB 
started with higher partial thromboplastin times and activated clotting times, they 
received less blood products and had lower post-operative blood loss. The OPCAB 
procedure has recently become more standardized, simplified, and refined, leading to 
encouraging results. With the decrease in blood product use, OPCAB surgery may 
provide a means for decreasing the risk of transmitting blood-borne pathogens, blood 
transfusion reactions, and the associated risks of nonautologous transfusions. 
Summary of Description of Literature 
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CABG without CPB is once again gaining popularity as an alternative technique 
of myocardial revascularization. Although the method was described many years ago, it 
was abandoned with the advancements in CPB with cardioplegic arrest. With the 
resurgence of the need to be more cognizant of patient outcomes and the constraints of 
the financial aspects, major manufacturers have developed specialized retraction and 
anastomotic devices to assist the surgeon in these techniques. 
Fast-tracking the CAB patient, whether using CPB or not, has shown a reduction 
in costs by decreasing LOS. The shorter amount of time spent by the patient in the 
hospital reduces the number of nursing hours required, which in fact, will decrease the 
work load on nurses and their staff. 
If the surgeon chooses to utilize the CPB machine, numerous coatings and drugs 
are available to decrease the inflammatory response and the potential side effects. 
Inflammatory responses, when held in check, may decrease the side effects and thus lead 
to early discharge, presumably at a cost savings. Possible detrimental effects associated 
with CPB, has led the medical community the re-evaluate patient selection parameters for 
the use of CPB. 
The studies that were reviewed reflect the interests of both the medical and 
general population. These studies highlighted better utilization of resources that are 
currently available to provide care for the ever-increasing number of patients with 
coronary artery disease (CAD) that are requiring CABG procedures. Cost containment 
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should not be the only consideration when choosing the type of procedure; patient 
outcomes and satisfaction are also of concern. In the never-ending search for acceptable 
outcomes, the medical community has devised ways using stabilization devices to 
produce acceptable cost reductions with amiable outcomes. Yet to be studied are the 
long-term patency rates of the grafts, which will be the determining factors for the 
success of the OPCAB procedure. 
This review of literature was conducted to generate a picture of what is known 
and not known concerning multiple outcomes of CAB surgery with and without CPB. 
Relevant literature was reviewed to provide an in-depth knowledge concerning both 
techniques. Included in the review was the economic factor as well as outcome analysis. 
A broad background and understanding of the benefits versus the potential drawbacks of 
each method was reviewed. The sources were selected for quality and relationship to the 
problem statement. 
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CHAPTER3 
METHODS AND PROCEDURES 
A quasi-experimental comparative research design was used for the study. 
Differences between OPCAB and C-CAB were examined. The variables measured were: 
(a) total intraoperative cost, (b) length of stay, including post-ICU hospitalization, (c) 
inflammatory response, (d) post-operative blood loss for each protocol, and (e) difference 
in post-operative nursing care hours as required for OPCAB and C-CAB.. 
Studies have been previously performed pursuing information related to but not 
as thoroughly covered as this study (Bull et al., 2001; Kirk et al., 2001 ); therefore this is a 
partial replication study with the addition of several variables, i.e. addition of Amicar and 
Aprotinin and the circuit coatings of Heparin and Bioline®. 
The following figures depict the research design (3.1) and major variables (3.2) 
involved within the proposed study: 
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This study's design did not change any current treatment modalities that patients 
would normally receive. The circuit coatings are not optional to the patient. Surgeons and 
perfusionist determine the selection of circuit coatings depending on what is available in 
the market place and what best fits the needs of the patient. All patients receiving 
treatment involving the cardiopulmonary circuit utilize circuits that all have the same 
coating, therefore interaction of selection and treatment is not a viable validity concern. 
The number of patients who decline to participate was reported in order to address 
concerns regarding external validity. Interaction of setting and treatment was addressed 
by the fact that the participating institution and physicians are all concerned with 
providing the best alternatives to their clients while maintaining the most cost effective 
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environment. Ability to identify best possible care and cost effective variables lead to the 
decision to conduct the research (Denton, Luevanos, & Matloff, 1998). 
Population and Sample 
There were five groups to be studied: control (utilizing y-bonded circuits) with 
Amicar (n = 30) and Aprotinin (n= 30); experimental (utilizing x-bonded circuits) with 
Amicar (n= 30) and Aprotinin (n= 30); and finally the OPCAB group (n= 30). A minimal 
sample of 30 for each group was used to ensure adequate sample size for statistical 
analysis. Power analysis indicated a minimum sample size of27 per group. Utilization of 
statistical techniques addressed the question involving possible error rate problems. 
The sampling criteria for the target population of this study were all elective, 
primary, CAB candidates, of both genders, over the age of 18, who had not received any 
thrombolytic intervention (whether in the cardiac catheterization lab or anti-platelet 
therapy pre-operatively). Each group analyzed was compared as to type of data 
distribution and the subject of randomization was clearly explained. All participants gave 
informed written consent. Exclusion criteria included the ability to give informed written 
consent, anyone under the age of 18, emergent procedures, multiple procedures (i.e. CAB 
with valve replacement), exposure to thrombolytic agents, or desire to withdraw from 
study. Multiple or emergent procedures, along with exposure to thrombolytic agents can 
have adverse effects on variables being measured (amount of chest tube drainage, platelet 
counts, number of units of blood and blood products used) therefore the presence of these 
factors precluded inclusion of these subjects. 
Standardization of the five groups was controlled starting with the planning phase 
and continuing through the implementation phase by providing exact instructions for type 
47 
and kind of testing done and what parameters are being studied (type of case, time 
factors, costs, LOS). Irrelevancies of surgeon preferences and techniques was . 
acknowledged. This was necessary so that individual surgeons continued to use the best 
course of treatment for their patients. The patient convenience samples were divided 
according to the surgical technique used (Amicar or Aprotinin) and which circuits (x-
coated or y-coated) was in use at the time of testing. OPCAB data was collected as the 
patients are scheduled for this procedure according to the surgeon's preference. 
Compensatory equalization of treatments, compensatory rivalry by respondents, along 
with resentful demoralization of respondents can be avoided due to the fact that the 
selection of therapy or treatment is solely based upon the surgeon's preference so will not 
bias this research. 
Selection of the sample has been addressed and its group dependency has been 
shown. Ambiguity on the causality is prevented due to the number of samples per group. 
Only using one bypass circuit at a time and maintaining the current protocols for each 
individual surgeon SaHYHQWHGimitation of treatments. 
Heterogeneity is addressed because surgeon preference, of either Amicar or 
Aprotinin, but not the circuit, is involved. When OPCAB candidates are enrolled, care 
will be taken to provide equivalent demographic'populations and overall pre-operative 
cardiac status. All groups were examined for equivalency before investigating and 
analyzing data variables. 
Representativeness deals with the fact that the sample must be as much like the 
population as is possible (Bums & Grove, 1997). A limitation for generalization of the 
results may be a fact that this sample being studied is taken from a private, mid-sized, 
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urban institution that targets the mid-to-upper socioeconomic population. The care of the 
individuals in different socioeconomic status may differ from the sample population. 
"Studies conducted in private hospitals often exclude the poor" (Burns & Grove, p. 295). 
"Of major importance is whether the samples used to establish parameters were 
representative of the target population in terms of characteristics such as age, gender, 
ethnicity, educational level and socioeconomic status" (Burns & Grove, p. 296). 
Educational and socioeconomic levels will not be factored into this study so that sample 
subjects will not find these questions offensive and choose not to participate in this study. 
A sampling error of systematic variation is possible in this study, since the 
sampling process is non-random. A bias may occur since the sample may differ from the 
general population. Convenience sampling will choose the subjects in this study, simply 
by the fact they are eligible for inclusion based solely on the scheduling of the surgery. 
Strengths of the sample include but are not limited to the following: (a) all 
candidates will have the same surgical procedure; (b) will be totally voluntary; ( c) will be 
from the same geographical area; ( d) will have the same surgical group as the primary 
care providers; (e) will have the same protocols as those not in the study; (f) will have the 
same post-operative care; and finally, (g) will receive excellent care from a recognized 
medical facility. 
Setting 
The setting for this study is a private, mid-sized, urban medical center located in 
the southeastern United States where approximately 5.3% of the nearly 1000 open-heart 
procedures performed annually are OPCAB. Understanding the possible validity 
problems as previously stated, proper precautions were taken to ensure applicability to 
r' 
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the general population by identifying and stratifying the sample population and providing 
all details of said sample. A possible strength of this study will be that an equal number 
and type of subjects available with the minimal number of participants needed. 
Ethical Considerations 
The principal researcher successfully completed the Human Participants 
Protection Education for Research Teams online course sponsored by the National 
Institutes of Health (NIH) and Human Research Training. This course reviewed the 
ethical principles and federal guidelines that should be followed, gave definitions and 
components necessary for informed and valid consent, and a description of the details of 
the Internal Review Board (IRB) in the research process when human subjects are 
involved. In addition, training was completed for the shipping of infectious substances 
(see Appendix C). 
Prior to data collection, permission was first obtained from the School of Nursing 
at Southern Adventist University (SAU). Permission was then obtained from the Human 
Participants Subcommittee at SAU and the IRB at the participating medical center. In 
addition, written permission was obtained from all cardiac surgeons to include their 
patients in the study. 
Excluding the surgical procedure itself, the actual study represented minimal risk 
to the study participants. The researcher approached each possible participant so that all 
questions may be answered. Inclusion in the study was completely voluntary and pressure 
to be included in the study was not applied. Once agreement to participate was reached, a 
written, informed consent was obtained. Ability to withdraw from the study was 
reinforced numerous times throughout the consent period, and a pager number was 
attached to the patients chart so communication with the principal investigator could be 
maintained at all times. The informed consent precluded any chance for covert data 
collection, as the participants had full knowledge of the study. 
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"Privacy is the right an individual has to determine the time, extent, and general 
circumstances under which private information will be shared with or withheld from 
others" (Bums & Grove, 1997, p. 203). Since informed consent is required, privacy is 
upheld, and any identifying factors will be removed from the data collection sheets. 
Identification was kept confidential by the use of a coding system, known only to the 
principal researcher and only aggregate data was reported. Participants gave consent for 
presentation and possible publication of findings. 
In this type of study anonymity is not guaranteed. The participants can remain 
anonymous only if no written consent is required. Also, during the review of records, 
personal information cannot be avoided. The researcher did provide complete 
confidentiality by the measures previously stated, and by following the guidelines 
outlined by the NIH. Any data that is entered into databases will be password protected 
and the original copies of the instrument will be under lock and key. Names were 
removed when the coding was completed. 
Fair treatment is the right of any individual based on the ethical principal of 
justice. Since this study cannot have complete randomization, any patient that met the 
criteria was approached about possibility becoming a participant. This helped preclude 
any possible bias by the researcher having to do with patient selection. Surgeon protocols 
partially dictated the selection process of participates to the study. 
This study, utilized current FDA approved techniques, equipment and 
pharmacological regimes, thus providing the bases for protecting the participants from 
undue harm and discomfort. There are no investigational products or techniques used. 
The researcher was simply interested in response of the participants in the areas 
previously noted as they are affected by different techniques and protocols in use by the 
surgeons. 
Instrumentation 
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The data collection instrument developed by the researcher is located in Appendix 
A. Each group of participants was identified on the data collection instrument. Numerous 
laboratory data, inflammatory mediator measures, clinical data, intra-operative costs, and 
LOS was recorded. Currently, a data sheet is being used at the medical center. To avoid 
duplication of recording data, the principal investigator gleaned and transcribed it onto 
the research data collection tool. This information was basically demographic in nature. 
Data Collection 
Once subjects met inclusion criteria and written consent was obtained, data 
collection began in the preoperative area using the data tool developed by the researcher. 
Ensuring the following measures diminished the possibility of a threat to internal validity, 
any event that occurred while a patient is enrolled in the study that was not planned, 
automatically removed the subject from the study. In that event, no further data collection 
was continued and all previously gathered data was "purged" from the study. All data 
was collected at the same intervals as previously outlined to ensure equality and validity 
and prevent maturation as a threat to internal validity. 
Treatments being studied were of the nature currently available to the general 
public, were all FDA approved, and were considered the "gold standard" for most · 
patients undergoing coronary artery revascularization (Aldea & Shemin, 1998) which 
precluded the interaction of history and treatment for this study. 
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During the consent process, the ability to withdraw from the study was noted, as 
was a means of contacting the investigator. After informed consent was obtained, pre-
operative information was documented on the data collection instrument. Routine pre-
stemotomy laboratory blood specimens were drawn, appropriate laboratory values 
documented, and another 8-milliliter specimen of whole blood, properly labeled (date, 
time and base excess (B.E.)), was obtained in a serum separator tube and stored in a 
blood cooler. After completion of the procedure, the second specimen was drawn, 
properly labeled and stored in a blood cooler, as was the final specimen at the six-hour 
post-operative time period. All specimens were obtained from the radial arterial line. 
The blood cooler containing the three specimens was then transported by the 
researcher to an on site laboratory and all specimens were centrifuged at 6500 x g for 15 
minutes, and 1 milliliter of the supernatant decanted into cryogenic tubes, labeled with 
patient sample sequential number corresponding to their study identification number and 
stored at -72 degrees centigrade. Once collection of all study specimens was completed, 
the frozen specimens were transported via a Saf-T-Pak® container to the Erlanger 
Research Cytokine Laboratory. 
Upon arrival at the Erlanger Research Cytokine Laboratory, the specimens were 
thawed and enzyme-linked immunosorbent assays (ELISA's) for IL-6 and IL-10 was 
performed using Pelikine® Tool Kit, Pelikine® compact Human IL-6 ELISA Kit, and 
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Pelikine® compact Human IL-10 ELISA Kit (Research Diagnostics, Inc., Flanders, NJ). 
Assay protocols were followed according to the manufacturer's instructions. Abs6rbances 
were measured using a VersaMax® Microplate Reader (Molecular Devices Corporation 
Sunnyvale, CA) at a wavelength of 450nm with a reference wavelength of 405nm. MMP 
specimens were transported at-72 degrees centigrade to the Medical University of South 
Carolina (MUSC) where assays were performed and reported. 
Once at MUSC, quantification of MMP species were performed with enzyme-
linked immunoassay systems (Amersham Pharmacia Biotech, Bukinghamshire, United 
Kingdom) using two-site 'sandwich' format. For MMP-2 (RPN 2617) the antiserum used 
reacts against the proform of MMP-2 (proMMP-2, 72kDa) and does not react against the 
active form. For MMP-9 (RPN 2614), the antiserum used detects the proform of the 
enzyme (proMMP-9, 92kDa). The coefficient of variation for these assays systems was 
4% to 6%; these systems did not cross-react with other proteases, and the sensitivity was 
at least 0.6ng/mL. 
Absolute values for MMP-2 and MMP-9 were examined using a 2-way analysis 
of variance in which the treatments were Amicar, Aprotinin, and OP-CAB stratified by 
time. Pair-wise comparisons were performed using post hoc Bonferroni adjusted t-tests. 
In order to more carefully examine individual response to CPB and OP-CAB with respect 
to MMP profiles, computations were performed as a function of baseline values. The 
comparisons were made using unpaired t-tests in which the mean values will be tested 
against the null hypothesis of a mean value set to 0. Individual comparisons between 
treatments were compared utilizing an unpaired t-test. All values were considered 
significant when a p value of 0.05 or less was detected. 
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All collectors in the operative suite were perfusionist, properly trained by the 
principal researcher so that strict data collection protocol was maintained. Data cdllection 
continued until all groups involved have the minimal number of participants enrolled to 
successfully complete the statistical analysis. The follow-up data collection (post-
operative data) was completed by the principal researcher, either by direct chart access or 
by accessing the Chart Max® system at the medical center. Again, all data was separated 
from patient identification factors and assigned study numbers so that individual patients 
could not be linked to the data. Codes were accessed by the principal researcher and 
secured under lock and key. Once the data had been entered into a database, the database 
had a security code only known to the principal researcher. Data will be stored for a 
minimal period of three years in a locked safe, and then will be destroyed by shredding. 
Data Analysis 
Sample Variables 
Demographic data was analyzed to assure that groups are matched and 
representative of the target population. Groups are considered to be ordinal level data, x-
bonded versus y-bonded, Amicar versus Aprotinin, OPCAB versus C-CAB. The design 
of this study allowed for identification of each group and thus the investigator has the 
ability to apply statistics to numerous variations of the groups for comparative analysis. 
Statistical analyses proposed in this study are the t- test, ANOVA, ANCOVA, 
Chi-square, and descriptive statistics. The t- test was used to determine if a statistical 
difference exists between two groups means. ANOVA measures the difference between 
three or more means by comparing the variances both within and across groups. If the 
ANO VA shows significant results, a post hoc comparison of means will be performed to 
determine the location of differences. ANCOV A measures differences among means 
while controlling the effects of covariate within groups. Application of the ANCOV A 
and Tukey's HSD test will be applied depending upon the results of the t- test and 
ANOV A. Chi-square will determine how closely observed frequencies or probabilities 
match expected frequencies or probabilities. Descriptive statistics will allow the 
researcher to organize and describe the sample and other data. 
The t-test was used to determine if there is a statistical difference between the 
interval level data: age (years), left ventricular ejection fraction (LVEF); number of 
bypass grafts, operative time (min.), cross-clamp time (min.), conduit type and 
destination, hemoglobin, hematacrit, and platelet count pre- & post-procedure and at 6 
hours, use of blood and blood products, intubation times (min.), blood salvaged and 
returned, height, weight, body surface area (BSA), number of diseased vessels, and the 
specified inflammatory response for each of the five groups that are to be studied. 
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Chi-square was used to determine differences between nominal level data: gender, 
operative technique, circuits, and drug regimes. The ANOV A was used to determine 
differences among three or more means by comparing the variances both within and 
across groups, control group (Amicar and Aprotinin), study group (Amicar and 
Aprotinin) and the OPCAB group. Ifthere was significant, observed differences, a post 
hoc comparison of means, such as the Tukey HSD test was applied. If it was determined 
that a demographic variable, such as age or gender, was unequal between groups, the 
ANCOVA was used to control for the effects of that variable. 
Research Variables 
The following hypotheses were analyzed with the t-test and ANOV A: 
Hl. The intra-operative cost of OPCAB is significantly greater than the intra-
operative costs of C-CPB patients. 
H2. There is no significant difference in the intensive care unit and post ICU 
hospital length of stay between the OPCAB and C-CPB patients. 
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H3. There is a significant decrease in the measured inflammatory response in the 
OPCAB patients from the C-CAB patients. 
H4. There is no significant difference between the measured inflammatory 
response between the x-coated and y-coated circuits for either C-CAB patients. 
HS. There is a significant difference in measured compliment mediators between 
the pharmacological regimes, Aprotinin and Amicar. 
H6. There is no significant difference in blood loss between OPCAB and C-CAB 
patients. 
H7. There is a significant decrease in patient care hours with decreased 
complement mediator activation. 
Depending upon the results of the t- test and ANOVA, it proved relevant to 
ascertain ANCOVA and Tukey's HSD test for further statistical analysis. 
Communication 
Once completed, this study provided direction for further research involving the 
techniques and protocols involved. The communication of the findings was a benefit to 
the nursing, medical, and health communities as well as health care consumers. 
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The nursing community is strategically involved due to the anticipated shortage of 
nurses in the near future. Presentation of the collected data, through nursing seminars 
and educational meetings provides an excellent way to propagate the information. 
Excellent methods to present and possibly publish the research findings are in 
conjunction with the Nursing Honor Society, Sigma Theta Tau International, American 
Society ofExtracorporeal Technology, and The Society of Cardiovascular Surgeons. 
Collaborative groups, nurses, surgeons and hospital administers are other avenues for 
informing the medical community about the possible improvements shown to be 
available through the utilization of the findings. 
Community informational sessions, once approved by the medical community, 
can encourage the general population to become more informed and better consumers of 
their health care dollars, since they are the consumers and will, in the end, be the 
recipients of improved care at a more efficient rate. Also, the overall health and well 
being of the general public can be affected by the methods and procedures used to treat 
their medical conditions. 
Addendum 
As unforeseen changes can happen during the course of research, this was the ill-
timed dilemma that occurred during this study. In a news release, dated June 3, 2003, 
Jostra Corporation, the provider of the control group (y-coating) circuit, unexpectedly 
disclosed the intent that, "We ... do not believe that the current Bentley line which 
consumes a significant amount of our financial and human resource, is our future. We 
have not been successful in expanding that line and the margins on that business do not 
allow us to focus on bringing new and better products to the market to improve patient 
outcomes. As a result of our focused efforts on the future of perfusion, we have decided 
to stop manufacturing custom tubing packs and will be closing our Anasco, Puerto· Rico 
facility" (See Appendix D). 
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With the discontinuance of the y-coating product, further comparison of the 
products involved in the study proposal was no longer valid. It was felt by the 
investigators, that with the uncertainty of product availability due to corporate changes, 
that it was in the best interest of the study, to terminate data collection after enrollment of 
enough subjects to validate a portion of the research. Therefore, it was decided to 
terminate the study after 30 enrollees were obtained in each of the C-CAB groups and 15 
enrollees in the OPCAB group. 
CHAPTER4 
RESULTS 
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The estimated number of individuals accessing the health care system in the 
United States is expected to more than double within the next few decades (Beller, 2001). 
Cost containment while providing excellent patient outcomes, will become a major issue. 
It was with this issue in mind that provides the overall basis of this study. 
The first purpose of this study was to determine if the intra-operative costs 
involved with the OPCAB technique were significantly lower than the costs involved 
with the C-CAB technique. The second purpose was to determine if there was a 
significant difference between the ICU LOS and the post-ICU LOS between the groups. 
The third, to determine if there was a significant difference in the measured inflammatory 
response between the OPCAB and C-CAB groups. The fourth purpose was to identify if 
there was a significant difference in the measured inflammatory responses between the 
drug regimes of the C-CAB groups. The fifth purpose was to identify if there was a 
significant difference in blood loss between the three groups. The last purpose was to 
identify if there was a difference in patient care hours between the groups due to a 
difference in the inflammatory response. It should be noted that one of the original 
purposes of this study was eliminated due to the lo'ss of the comparative portion of the 
different circuit coatings. 
The significant statistical results are revealed in this chapter. The level of 
significance was set at p < 0.05. A 95% Confidence Interval (CI) was determined for 
each of the research hypothesis. 
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IRB approval from the university and cooperating hospital was completed in the 
fall of 2002. Data collection began in the spring of 2003 and was completed in the fall of 
2003. The researcher approached a total of 116 eligible patients, successfully enrolling 
111 (4% decline rate). Of the 111 enrollees, 75 (35% attrition rate) completed the study 
without incidence. Of the 36 enrollees dropped, 22 (61 %) were due to surgeon requesting 
full dose Aprotinin, seven (20%) were originally designated as OPCAB but were 
converted to C-CAB by the surgeon, four (11 % ) had one or more lab samples with 
hemolysis, and finally, three (8%) did not have lab specimens drawn by the staff. Data 
was recorded on the form developed by the researcher. 
Sample Demographics 
The sample demographics comparing the three groups are displayed in Table 1: 
Table 1. Patient Demographics. 
Aprotinin Ami car OPCAB 
Variable ( n = 30) ( n = 30) ( n = 15) 
Age (years) 62.2 ± 11.0 59.9 ± 8.4 60.2 ± 11.3 
Gender (Male) 83.3% 63.3% 53.3% 
BSA (m2) 2.02 2.02 1.88 
LVEF% 49.33 51.00 55.33 
Hypertensive % 46.66 66.66* 33.33 
Diabetic% 33.33** 60.00** 33.33 
Smoker% 33.33 26.66 20.00 
*p < .05 
** p < . 05 between the C-CAB groups 
Description of Findings 
Research Hypotheses One 
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The first research hypothesis stated that the intra-operative cost of OPCAB is 
significantly greater than the intra-operative cost of C-CPB patients. Variables taken into 
consideration that can influence intra-operative costs were O.R. time (minutes), overall 
O.R. costs (room, equipment, personnel), O.R. supplies (disposables), number of bypass 
grafts performed (distal anastomosis) and number of LIMA conducted. The original 
intent of the study was to compare the intra-operative pharmacy costs, but the accounting 
system to charge for pharmacy, at the participating institution, would not permit the 
breakout of costs to delineate pharmacy costs specific only to the O.R. Therefore, the 
pharmacy costs reported reflect costs incurred during the entire hospital stay. 
Comparisons of the ratio level data were performed between the aforementioned 
groups. The means and standard deviations were compared between the groups and 
significance was determined by performing an ANOV A, in combination with post hoc 
Bonferroni's adjustment, allowing for the pairwise comparison between the groups. 
O.R. Times 
The C-CAB with Aprotinin group's mean O.R. time was 267.66 minutes (SD of 
50.45; 95% CI was reported as 248.82 for lower bound and 286.50 for upper bound). The 
C-CAB with Amicar group's mean time was the highest at 277.70 minutes (SD of 59.23; 
95% CI was reported as 255.58 for lower bound and 299.81 for upper bound). The 
OPCAB group's mean time was lowest at 214.00 minutes (SD of39.76; 95% CI was 
reported as 191.97 for the lower bound and 236.02 for the upper bound). 
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There was no significant statistical difference between the C-CAB groups. 
However, there was a significant statistical difference in mean time between the C-CAB 
with Aprotinin and the OPCAB group (p < .005). There was a significant statistical 
difference between the C-CAB with Amicar group and the OPCAB group (p < .001). 
O.R. Costs 
The C-CAB with Aprotinin group's mean total O.R. cost was $8559.13 (SD of 
$1056.61; 95% CI was reported as $8164.58 for lower bound and $8953.67 for the upper 
bound). The C-CAB with Amicar group's mean total O.R. cost was $9096.40 (SD of 
$1859 .16; 95% CI was reported as $8402.17 for lower bound and $9790.62 for upper 
bound). The OPCAB group's mean total O.R. cost was reported as $8442.86 (SD of 
$1482.63; 95% CI was reported as $7621.81 for lower bound and $9263.92 for upper 
bound). There was no significant statistical difference among any of the groups. 
The C-CAB with Aprotinin group's mean O.R. supply cost was $3889.66 (SD 
of $685.91; 95% CI was reported as $3633.54 for the lower bound and $4145.79 for the 
upper bound). The C-CAB with Amicar group's mean O.R. supply cost was $3934.30 
(SD of $1198.46; 95% CI was reported as $3486.78 for the lower bound and $4381.81 
for the upper bound). The OPCAB group's mean 0.R. cost was $4014.13 (SD of 
$1084.77; 95% CI was reported as $3413.40 for tlte lower bound and $4614.86 for the 
upper bound). There was no significance statistical difference in supply costs among any 
of the groups. 
Pharmacy Costs 
The C-CAB with Aprotinin group's mean cost was $2553.76 (SD of$1305.61; 
95% CI was reported as $2066.24 for the lower bound and $3041.29 for the upper 
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bound). The C-CAB with Amicar group's mean cost was $2654.33 (SD of$3502.66; 
95% CI was reported as $1346.41 for the lower bound and $3962.25 for the upper 
bound). The OPCAB group's mean cost was $1710.93 (SD of$1147.01; 95% CI was 
reported as $1075.73 for the lower bound and $2346.13 for the upper bound). There was 
no significant statistical difference among the groups. 
Distal Anastomosis 
The C-CAB with Aprotinin group had the highest mean number at 4.33 (SD of 
1.21; 95% CI was reported as 3.88 for the lower bound and 4.78 as the upper bound). The 
C-CAB with Amicar group's mean number was 3.90 (SD of 1.26; 95% CI was reported 
as 3.42 for the lower bound and 4.37 as the upper bound). The OPCAB group mean 
number was lowest at 2.86 (SD of 1.12; 95% CI was reported as 2.24 for the lower bound 
and 3.48 for the upper bound). There was a significant statistical difference among the 
groups, p < .01 between the C-CAB with Aprotinin group and the OPCAB group, and 
p < .05 between the C-CAB with Amicar group and the OPCAB group. 
LIMA 
The final arm of Hypothesis One is the number of LIMA conducted. The C-CAB 
with Aprotinin group's mean was 0.96 (SD of 0.18, 95% CI was reported as 0.89 for the 
lower bound and 1.03 for the upper bound). The C-C:A.B with Amicar group's mean was 
0.93 (SD of 0.25; 95% CI was reported as 0.83 for the lower bound and 1.02 as the upper 
bound). The OPCAB group mean was reported as 0.93 (SD of 0.25; 95% CI was reported 
as 0. 79 for the lower bound and 1.07 for the upper bound). There was no significant 
statistical difference among the groups. 
Graphic representations of these findings are displayed in Table 2. 
Table 2. Intra-Operative Cost Factors. 
Variable 
O.R. Time (min.) 
Total O.R. Cost 
O.R. Supply Cost 
Pharmacy Cost # 
Distal Anastomosis 
LIMA Conducted 
*p< .05 
** p< .OJ 
Aprotinin 
( n = 30) 
267.66 ± 50.45* 
$8559.13 
$3889.66 
$2553.76 
4.33** 
0.96 
# Total Hospital Pharmacy Costs 
Ami car 
( n = 30) 
277.70 ± 59.13** 
$9096.40 
$3934.30 
$2654.33 
3.90* 
0.93 
Research Hypotheses Two 
OPCAB 
( n = 15) 
214.00 ± 39.76 
$8442.86 
$4014.13 
$1710.93 
2.86 
0.93 
The second research hypothesis stated that there was no significant difference in 
the ICU and post ICU hospital LOS between the OPCAB and C-CPB patients. There 
were again three groups involved: C-CAB with Aprotinin, C-CAB with Amicar, and 
OPCAB. Variables that were observed were: extubation from the ventilator (minutes), 
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LOS in ICU (days), LOS in the hospital (days) and total LOS (days). Comparisons of the 
ratio level data were performed among the aforementioned groups. The means and SD 
were compared between the groups and significance was determined by performing an 
ANOVA post hoc with Bonferroni's adjustment, allowing for the pairwise comparison 
among the groups. 
Extubation Times 
The C-CAB with Aprotinin group's mean extubation time was 462.43 minutes 
(SD of 188.00; 95% CI was reported as 392.23 for the lower bound and 532.63 for the 
upper bound). The C-CAB with Amicar group had a mean extubation time of 487.33 
minutes (SD of294.86; 95% CI was reported as 377.23 for the lower bound and 597.43 
for the upper bound). The OPCAB group's mean extubastion time was 377.40 minutes 
(SD of 90.69; 95% CI was reported as 327.17 for the lower bound and 427.62 for the 
upper bound). There was no significant statistical difference among the groups. 
LOS ICU 
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The C-CAB with Aprotinin group's mean ICU stay was 1.56 days (SD of 1.14; 
95% CI was reported as 1.14 for the lower bound and 1.99 for the upper bound). The C-
CAB with Amicar group had a mean ICU stay of2.77 days (SD of 5.42; 95% CI was 
reported as 0.75 for the lower bound and 4.79 for the upper bound). The OPCAB group's 
mean ICU stay was 1.13 days (SD of0.64; 95% CI was reported as 0.77 for the lower 
bound and 1.49 for the upper bound). There was no significant statistical difference 
among the groups. 
LOS Hospital 
The C-CAB with Aprotinin group's mean·hospital stay was 4.46 days (SD of 
3.05; 95% CI was reported as 3.31 for the lower bound and 5.60 for the upper bound). 
The C-CAB with Amicar group had a mean hospital stay of 5.12 days (SD of3.76; 95% 
CI was reported as 3.72 for the lower bound and 6.52 for the upper bound). The OPCAB 
group's mean hospital stay was 4.86 days (SD of 4.30; 95% CI was reported as 2.48 for 
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the lower bound and 7 .25 for the upper bound). There was no significant statistical 
difference among the groups. 
Total LOS 
The C-CAB with Aprotinin group's mean total post-operative stay was 6.02 days 
(SD of 3.23; 95% CI was reported as 4.81 for the lower bound and 7.23 for the upper 
bound). The C-CAB with Amicar group had a mean total post-operative stay of 7.89 days 
(SD of 5.74; 95% CI was reported as 5.75 for the lower bound and 10.04 for the upper 
bound). The OPCAB group's mean total post-operative stay was 6.00 days (with a SD of 
4.43; 95% CI was reported as 3.55 for the lower bound and 8.45 for the upper bound). 
There was no significant statistical difference among the groups. 
Graphic representations of these findings are displayed in Table 3. 
Table 3. Length of Stay 
Variable 
Extubation (mins.) 
LOS ICU (days)* 
LOS Hosp. (days)* 
Total LOS (days)* 
*Post-op 
Aprotinin 
( n = 30) 
462.43 ± 188.00 
1.56 ± 1.14 
4.46 ± 3.05 
6.02 ± 3.23 
Ami car 
( n = 30) 
487.33 ± 294.86 
2.77 ± 5.42 
5.12 ± 3.76 
7.89 ± 5.74 
Research Hypotheses Three 
OPCAB 
( n = 15) 
377.40 ± 90.69 
1.13 ± 0.64 
4.86 ± 4.30 
6.00 ± 4.43 
The third research hypothesis stated that there was a significant decrease in the 
measured inflammatory response in the OPCAB vs. the C-CAB patients. The groups that 
were observed remain the same as for the previous hypotheses. Variables that were 
observed were: pre-IL-6 & 10, pre-MMP-2 & 9; post-protamine IL-6 &10, post-
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protamine MMP-2 & 9; and IL-6 & 10 and MMP-2 & 9 drawn six hours post-op. These 
results are reported in picograms/milliliter (pg/ml). All C-CAB post- and six-hour results 
were corrected to account for hemodilution effects. Comparisons of the ratio level data 
were performed among the aforementioned groups. The means and SD were compared 
among the groups and significance was determined by performing an ANOV A with post 
hoc Bonferroni's adjustment, again allowing for the pairwise comparison among the 
groups. 
Pre-IL-6 
The C-CAB with Aprotinin group had a mean of7.24 (SD of9.45; 95% CI was 
reported as 3.76 for the lower bound and 10.78 for the upper bound). The C-CAB with 
Amicar group had the lowest mean of 3.11 (SD of 4.48; 95% CI was reported as 1.44 for 
the lower bound and 4.79 for the upper bound). The OPCAB group had the highest mean 
at 23.90 (SD of 43.61; 95% CI was reported as -.248 for the lower bound and 48.05 for 
the upper bound). There was significant statistical difference among the C-CAB groups 
and the OPCAB group (p < .05). 
Pre-IL-10 
The C-CAB with Aprotinin group had a mean of77.88 (SD of95.00; 95% CI was 
reported as 42.11 for the lower bound and 113.36 for the upper bound). The C-CAB 
w/Amicar group had a mean of 117.06 (SD of 381.00; 95% CI was reported as -25.21 for 
the lower bound and 259.33 for the upper bound). The OPCAB group had a mean of 
41.28 (SD of 40.25; 95% CI was reported as 18.99 for the lower bound and 63.57 for the 
upper bound). There was no significant statistical difference among the groups. 
L 
68 
Pre-MMP-2 
The C-CAB with Aprotinin group had a mean of 1190 (SD of± 71 ). The &a&$%
with Amicar group had a mean of 1315 (SD of ±75). The OPCAB group had a mean of 
1279.00 (SD of ±131 ). There was no significant statistical difference among the groups. 
Pre-MMP-9 
The results showed that the C-CAB with Aprotinin group had a mean of 60 (SD 
of ±5). The C-CAB with Amicar group had a mean of 67 (SD of ±7). The OPCAB group 
had a mean of 68 (SD of ±5). There was no significant statistical difference among the 
groups. 
Graphic representations of these findings are displayed in Table 4. 
Table 4. Baseline Inflammatory Measurements. 
Aprotinin 
Variable ( n = 30) 
7.24 ± 9.45 Pre-IL-6 
Pre-IL-10 77.88 + 95.00 
Pre-MMP-2 
Pre-MMP-9 
*p < .05 vs. C-CAB 
1190 ± 71 
60±5 
Ami car 
(n 30) 
3.11±4.48 
117.06 ± 381.00 
1315±75 
67±7 
OPCAB 
( n = 15) 
23.90 ± 43.60* 
41.28 ± 40.25 
1279 ± 131 
68±5 
Post-Protamine IL-6 
The C-CAB with Aprotinin group had a mean of 63.17 (SD of 45. 73; 95% CI was 
reported as 46.09 for the lower bound and 80.25 for the upper bound). The C-CAB with 
Amicar group had a mean of 90.19 (SD of 124.61; 95% CI was reported as 43.66 for the 
lower bound and 136.72 for the upper bound). The OPCAB group had a mean of37.45 
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(SD of 54.42; 95% CI was reported as 7.31 for the lower bound and 67.58 for the upper 
bound). There was no significant statistical difference among the groups. 
Post-Protamine IL-I 0 
The C-CAB with Aprotinin group had a mean of242.00 (SD of323.46; 95% CI 
was reported as 121.21 for the lower bound and 362.79 for the upper bound). The C-CAB 
with Amicar group had a mean of 217.32 (SD of283.48; 95% CI was reported as 111.46 
for the lower bound and 323.17 for the upper bound). The OPCAB group had a mean of 
75.69 (SD of 57.32; 95% CI was reported as 43.94 for the lower bound and 107.44 for 
the upper bound). There was no significant statistical difference among the groups. 
Post-Protamine MMP-2 
The C-CAB with Aprotinin group had a mean of 139l(SD of ±80). The C-CAB 
with Amicar group had the highest mean of 1574 (SD of ±79). The OPCAB group had 
the lowest mean of 1178 (SD of ±67). There was significant statistical difference among 
the C-CAB groups and the OPCAB group (p < .05). 
Post-Protamine MMP-9 
The C-CAB with Aprotinin group had the lowest mean of 45 (SD of ±3). The C-
CAB with Amicar group had a mean of 61 (SD of ±9). The OPCAB group had the 
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highest mean of 7 5 (SD of± 7). There were significant statistical differences between the 
C-CAB groups and the OPCAB group (p < .05). Also noted a significant statistical 
difference between the baseline C-CAB with Aprotinin and the post-Protamine level in 
this group (p < .05). 
Graphic representations of these findings are displayed in Table 5. 
Table 5. Post-Operative Inflammatory Measurement. 
Variable 
Post IL-6 
Post IL-10 
PostMMP-2 
PostMMP-9 
Aprotinin 
( n = 30) 
63.17 ± 45.73 
242.00 ± 323.46 
1391±80 
45 ±3* 
*p < . 05 vs. baseline 
**p < .05 vs. C-CAB 
Six-Hour IL-6 
Ami car 
( n= 30) 
90.19 ± 124.61 
217.32 ± 283.48 
1547 ± 79 
61±9 
OPCAB 
( n = 15) 
37.45 ± 54.42 
75.69 ± 57.32 
1178 ± 67** 
75 ± 7** 
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The C-CAB with Aprotinin group had a mean of 82.14 (SD of 48.47; 95% CI was 
reported as 64.04 for the lower bound and 100.24 for the upper bound). The C-CAB with 
Amicar group had a mean of 175.31 (SD of 241.23; 95% CI was reported as 85.23 for the 
lower bound and 265.39 for the upper bound). The OPCAB group had a mean of 103.15 
(SD of74.86; 95% CI was reported as 61.69 for the lower bound and 144.61 for the 
upper bound). There was no significant statistical difference among the groups. 
Six-Hour IL-10 
The C-CAB with Aprotinin group had a mean of 81.21 (SD of 124.84; 95% CI 
was reported as 34.72 for the lower bound and 127.69 for the upper bound). The C-CAB 
with Amicar group had a mean of 48.33 (SD of 84.38; 95% CI was reported as 16.82 for 
the lower bound and 79 .84 for the upper bound). The OP CAB group had a mean of 71.10 
(SD of91.78; 95% CI was reported as 20.27 for the lower bound and 121.93 for the 
upper bound). There was no significant statistical difference among the groups. 
71 
Six-Hour A!MP-2 
The C-CAB with Aprotinin group had the highest mean of 1247 (SD of ±44). The 
C-CAB with Amicar group had a mean of 1400 (SD of ±88). The OPCAB group had the 
lowest mean of 1013 (SD of ±68). There were significant statistical differences among 
the C-CAB group and the OPCAB group (p < .05). 
Six-Hour MMP-9 
The C-CAB with Aprotinin group had a mean of 79 (SD of ±4 ). The C-CAB with 
Amicar group had a mean of 92 (SD of 10). The OPCAB group had a mean of 99 (SD of 
±11). There were significant statistical difference among all groups and their respective 
baseline measurements (p < .05). 
Graphic representations of these findings are displayed in Table 6. 
Table 6. 6-Hour Inflammatory Measurements. 
Variable 
6 hr. IL-6 
6 hr. IL-10 
6hr. MMP-2 
6hr. MMP-9 
Aprotinin 
( n = 30) 
82.14 + 48.47 
81.21±124.84 
1247 ± 44 
79 ±4*# 
*p < . 05 vs. baseline 
**p < .05 vs. C-CAB 
#p < . 05 vs. Post 
Ami car 
( n = 30) 
175.31 ± 241.23 
48.33 ± 84.38 
1400 ± 88 
92 ± 10* 
OPCAB 
( n 15) 
103.15 ± 74.86 
71.10 + 91.78 
1013 ± 68** 
99 ± 11 * 
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Research Hypotheses Four 
The fourth research hypothesis stated there was no significant difference in the 
measured inflammatory response between the x-coated and y-coated circuits for C-CAB 
patients. As previous noted, with the discontinuance of the y-coating product, further 
comparison of the products involved in the study proposal was no longer valid. 
It was felt by the investigators, that with the uncertainty of product availability 
due to corporate changes, that it was in the best interest of the study, to terminate data 
collection after enrollment of enough subjects to validate the rest of the research. 
Therefore, the study was terminated after 30 enrollees were obtained in each of the C-
CAB groups and 15 enrollees in the OPCAB group. With this change, the fourth 
hypothesis will not be reported. 
Research Hypotheses Five 
The fifth hypothesis stated there was a significant difference in measured 
compliment mediators between the pharmacological regimes, Aprotinin and Amicar. 
Variables observed and statistical analyses remain the same as utilized for Hypothesis 
Three. 
Pre-IL-6 
The C-CAB with Aprotinin group had a mean pre-IL-6 count of 7.24 (SD of 9.45; 
a 95% CI was reported as 3.76 for the lower bound and 10.78 for the upper bound). The 
C-CAB with Amicar group had a mean of 3.11 (SD of 4.48; a 95% CI was reported as 
1.44 for the lower bound and 4.79 for the upper bound). There was no significant 
statistical difference between the groups. 
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Pre-IL-10 
. 
The C-CAB with Aprotinin group had a mean pre-IL-10 count of77.88 (SD of 
95.00; a 95% CI was reported as 42.11 for the lower bound and 113.36 for the upper 
bound). The C-CAB with Amicar group had a mean of 117.06 (SD of381.00; a 95% CI 
was reported as -25.21 for the lower bound and 259.33 for the upper bound). There was 
no significant statistical difference between the groups. 
Pre-MMP-2 
The C-CAB with Aprotinin group had a mean pre-MMP-2 count of 1190 (SD of 
±71). The C-CAB with Amicar group had a mean of 1315 (SD of ±75). There was no 
significant statistical difference between the groups. 
Pre-MMP-9 
The C-CAB with Aprotinin group had a mean pre-MMP-9 count of 60 (SD of 
±5). The C-CAB with Amicar group had a mean of 67 (SD of ±7). There was no 
significant statistical difference between the groups. 
Graphic representations of these findings are displayed in Table 7. 
Table 7. C-CAB Baseline Inflammatory Measurements 
Variable 
Pre-IL-6 
Pre-IL-10 
Pre-MMP-2 
Pre-MMP-9 
Aprotinin 
( n = 30) 
7.24 ± 9.45 
77.88 ± 95.00 
1190 ± 71 
60±5 
Ami car 
( n = 30) 
3.11 ± 4.48 
117.06±381.00 
1315±75 
67±7 
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Post-Protamine IL-6 
The C-CAB with Aprotinin group had a mean post-Protamine IL-6 count of 63.17 
(SD of 45. 73; a 95% CI was reported as 46.09 for the lower bound and 80.25 for the 
upper bound). The C-CAB with Amicar group had a mean of90.19 (SD of 124.61; a 95% 
CI was reported as 43.66 for the lower bound and 136. 72 for the upper bound). There was 
no significant statistical difference between the groups. 
Post-Protamine IL-10 
The C-CAB with Aprotinin group had a mean post-Protamine IL-I 0 count of 
242.00 (SD of 323.46; a 95% CI was reported as 121.21 for the lower bound and 362.79 
for the upper bound). The C-CAB with Amicar group had a mean of217.32 (SD of 
283.48; a 95% CI was reported as 111.46 for the lower bound and 323.17 for the upper 
bound). There was no significant statistical difference between the groups. 
Post-Protamine MMP-2 
The C-CAB with Aprotinin group had the lower mean post-Protamine MMP-2 
count of 1391 (SD of ±80). The C-CAB with Amicar group had the higher mean of 1574 
(SD of ±79). There was significant statistical difference between the groups. 
Post-Protamine MMP-9 
The C-CAB with Aprotinin group had a mean post-Protamine MMP-9 count of 45 
(SD of ±3). The C-CAB with Amicar group had a mean of 61 (SD of ±9). There was no 
statistical difference between the groups, although a statistical significant difference 
between the baseline C-CAB with Aprotinin and the post-Protamine level in this group 
(p < .05) was noted. 
Graphic representations of these findings are displayed in Table 8. 
Table 8. C-CAB Post-Inflammatory Measurements 
Variable 
Post IL-6 
Post IL-10 
PostMMP-2 
PostMMP-9 
Aprotinin 
( n = 30) 
63.17 ± 45.73 
242.00 ± 323.46 
1391±80 
45 ±3* 
*p < . 05 vs. baseline 
Six-Hour IL-6 
Ami car 
( n = 30) 
90.19 ± 124.61 
217.32 ± 283.48 
1547 ± 79 
61 ±9 
The C-CAB with Aprotinin group had a mean six-hour IL-6 count of 82.14 (SD 
of 48.4 7; a 95% CI was reported as 64.04 for the lower bound and 100.24 for the upper 
bound). The C-CAB with Amicar group had a mean of 175.31 (SD of241.23; a 95% CI 
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was reported as 85.23 for the lower bound and 265.39 for the upper bound). There was no 
significant statistical difference between the groups. 
Six-Hour IL-10 
The C-CAB with Aprotinin group had a mean six-hour IL-10 count of 81.21 (SD 
of 124.84; a 95% CI was reported as 34.72 for the l"wer bound and 127.69 for the upper 
bound). The C-CAB with Amicar group had a mean of 48.33 (SD of 84.38; a 95% CI was 
reported as 16.82 for the lower bound and 79.84 for the upper bound). There was no 
significant statistical difference between the groups. 
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Six-hour MMP-2 
The C-CAB with Aprotinin group had a mean six-hour MMP-2 count of 1247 
(SD of ±44). The C-CAB with Amicar group had a mean of 1400 (SD of ±88). There was 
no significant statistical difference between the groups. 
Six-hour MMP-9 
The C-CAB with Aprotinin group had a mean six-hour MMP-9 count of 79 (SD 
of ±4). The C-CAB with Amicar group had a mean of92 (SD of 10). There was 
significant statistical difference from each group's baseline measurements (p < .05). 
Graphic representations of these findings are displayed in Table 9. 
Table 9. C-CAB 6-Hour Post-Inflammatory Measurements 
Variable 
6 hr. IL-6 
6 hr. IL-10 
6hr.MMP-2 
6 hr. MMP-9 
*p < . 05 vs. baseline 
**p < . 05 vs. Post 
Aprotinin 
( n 30) 
82.14 ± 48.47 
81.21±124.84 
1247 ± 44 
79 ±4** 
Research Hypotheses Six 
Ami car 
( n = 30) 
175.31 ± 241.23 
48.33 ± 84.38 
1400 ± 88 
92± 10* 
The sixth research hypothesis stated there was no significant difference in blood 
loss between OPCAB and C-CAB patients. There were again three groups involved: C-
CAB with Aprotinin, C-CAB with Amicar, and OPCAB. Variables that were observed 
were pre-operative, post-protamine, and six-hour post-operative hemoglobin (Hgb.) 
mg/di, hematocrit (Hct.) mg%, and platelet count (Plat.) K/dl. White blood cell counts 
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(WBC) K./dl was only reported in the pre-operative time frame. The amount, in units, of 
packed red blood cells (PRBC), platelets (Plat.), fresh frozen plasma (FFP) and 
cryoprecipitate (Cryo.) was reported for the intra-operative period as well as total 
amounts given in the first 24 hours post-operatively. The amount of cell salvage returned 
was reported in milliliters (ml). All cell salvage volume was returned to all subjects. The 
final variable reported was the 24-hour chest tube drainage (ml). Comparisons of the 
ratio level data were performed between the aforementioned groups and significance was 
determined by performing an ANOVA in combination with post hoc Bonferroni's 
adjustment. 
Pre-Hgb. 
The C-CAB with Aprotinin group had a mean pre-Hgb. of 12.80 (SD of 1.62; a 
95% CI was reported as 12.19 for the lower bound and 13 .40 for the upper bound). The 
CAB with Amicar group had a mean of 11.96 (SD of 1.54; a 95% CI was reported as 
11.39 for the lower bound and 12.54 for the upper bound). The OPCAB group had a 
mean of 12.34 (SD of 1.94; a 95% CI was reported as 11.26 for the lower bound and 
13 .41 for the upper bound). There was no significant statistical difference among the 
groups. 
Pre-Hct. 
The C-CAB with Aprotinin group had a mean pre-Hct. of 37.03 (SD of 5.03; a 
95% CI was reported as 35.15 for the lower bound and 38.91 for the upper bound). The 
C-CAB with Amicar group had a mean of 35.03 (SD of 4. 71; a 95% CI was reported as 
33.27 for the lower bound and 36.79 for the upper bound). The OPCAB group had a 
mean of 34.74 (SD of 8.07; a 95% CI was reported as 30.27 for the lower bound and 
39.21 for the upper bound). There was no significant statistical difference among the 
groups. 
Pre-Plat. 
The C-CAB with Aprotinin group had the lowest mean count of 195. 73 (SD of 
56.7; a 95% CI was reported as 174.55 for the lower bound and 216.91 for the upper 
bound). The C-CAB with Amicar group had a mean of201.66 (SD of 58.29; a 95% CI 
was reported as 179.90 for the lower bound and 223.43 for the upper bound). The 
OPCAB group had the highest mean of248.60 (SD of76.86; a 95% CI was reported as 
206.03 for the lower bound and 291.16 for the upper bound). There were significant 
statistical differences between the OPCAB and Aprotinin groups (p < .05). 
Pre-WBC 
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The C-CAB with Aprotinin group had a mean of7.79 (SD of 1.62; a 95% CI was 
reported as 7.18 for the lower bound and 8.40 for the upper bound). The C-CAB with 
Amicar group had a mean of7.55 (SD of 1.87; a 95 % CI was reported as 6.85 for the 
lower bound and 8.25 for the upper bound). The OPCAB group had a mean of7.48 (SD 
of2.12; a 95% CI was reported as 6.31 for the lower bound and 8.66 for the upper 
bound). There was no significant statistical difference among the groups. 
Graphic representations of these findings are displayed in Table 10. 
Table 10. Baseline Laboratory Values 
Variable 
Pre-Hgb. 
Pre-Hct. 
Pre-Plat. 
Pre-WBC 
Aprotinin 
( n = 30) 
12.80 ± 1.62 
37.03 ± 5.03 
195.73 ± 56.72* 
7.79 ± 1.62 
*p< . 05 vs. OPCAB group 
Intra-Operative P RBC Usage 
Ami car 
( n = 30) 
11.96 ± 1.54 
35.03 ± 4.71 
201.66 ± 58.29 
7.55 ± 1.87 
OP CAB 
( n = 15) 
12.34 ± 1.94 
34.74 ± 8.07 
248.60 ± 76.86 
7.48 ± 2.12 
79 
The C-CAB with Aprotinin group had a mean intra-operative PRBC usage of 0.20 
(SD of 0.80; a 95% CI was reported as -0.10 for the lower bound and 0.50 for the upper 
bound). The C-CAB with Amicar group had a mean of 0.46 (SD of 1.00; a 95% CI was 
reported as -1.39 for the lower bound and 0.84 for the upper bound). The OPCAB group 
had a mean of0.13 (SD of0.51; a 95% CI was reported as-0.15 for the lower bound and 
0.41 for the upper bound). There was no significant statistical difference among the 
groups. 
Intra-Operative FFP Usage 
The C-CAB with Aprotinin and OPCAB groups had none administered. The C-
CAB with Amicar group had a mean of 0.02 (SD of 0.36; a 95% CI was reported as 
-6.96 for the lower bound and 0.20 for the upper bound). There was no significant 
statistical difference among the groups. 
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Intra-Operative Platelet Usage 
The C-CAB with Aprotinin and OPCAB groups had none given. The C-CAB · 
with Amicar group had a mean intra-operative platelet usage of 0.20 (SD of 1.09; a 95% 
CI was reported as -0.20 for the lower bound and 0.60 for the upper bound). There was 
no significant statistical difference among the groups. 
Cryoprecipitate Usage 
There was none given to any of the groups during the intra-operative or post-
operative periods. 
Post-Protamine Hgb. 
The C-CAB with Aprotinin group had a mean post-Protamine Hgb. of9.2 (SD of 
1.29; a 95% CI was reported as 8.71 for the lower bound and 9.68 for the upper bound). 
The C-CAB with Amicar group had the lowest mean of9.06 (SD of 1.20; a 95% CI was 
reported as 8.61 for the lower bound and 9.51 for the upper bound). The OPCAB group 
had the highest mean of 10.6 (SD of 1.44; a 95% CI was reported as 9.86 for the lower 
bound and 11.46 for the upper bound). There were significant statistical differences 
among the OPCAB and C-CAB groups (p < .05). 
Post-Protamine Hct. 
The C-CAB with Aprotinin group had a mean'post-Protamine Hgb. of27.0 (SD 
of 3.35; a 95% CI was reported as 25. 74 for the lower bound and 28.25 for the upper 
bound). The C-CAB with Amicar group had the lowest mean of26.46 (SD of3.08; a 
95% CI was reported as 25.31 for the lower bound and 27.61 for the upper bound). The 
OPCAB group had the highest mean of 31.26 (SD of 4.54; a 95% CI was reported as 
28.75 for the lower bound and 33.78 for the upper bound). There were significant 
statistical differences among the OPCAB and C-CAB groups (p < .01). 
Graphic representations of these findings are displayed in Table 11. 
Table 11. Intra-Operative Blood Product Usage 
Aprotinin 
Variable ( n = 30) 
Intra-OP PRBC 0.20 ± 0.80 
Intra-OP FFP 0.00 ± 0.00 
Intra-OP Plat. 0.00 ± 0.00 
Intra-OP Cryo. 0.00 ± 0.00 
Post-Prot. Hgb. 9.20 ± 1.29* 
Post-Prot. Hct. 27.00 ± 3.35** 
*p< . 05 vs. OPCAB group 
** p< .OJ vs. OPCAB group 
Six-Hour Post-Operative Hgb. 
Ami car 
( n = 30) 
0.46 ± 1.00 
0.02 ± 0.36 
0.20 ± 1.09 
0.00 ± 0.00 
9.06 ± 1.20* 
26.46 ± 3.08** 
OPCAB 
( n = 15) 
0.13 ± 0.51 
0.00 ± 0.00 
0.00 ± 0.00 
0.00 ± 0.00 
10.66 ± 1.44 
31.26 ± 4.54 
The C-CAB with Aprotinin group had a mean six-hour post-operative Hgb. of 
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11.21 (SD of 1.43; a 95% CI was reported as 10.67 for the lower bound and 11.74 for the 
upper bound). The C-CAB with Amicar group had the lowest mean of 10.4 7 (SD of 1.09; 
a 95% CI was reported as 10.06 for the lower bound and 10.88 for the upper bound). The 
OPCAB group had the highest mean of 11.46 (SD of 1.18; a 95% CI was reported as 
10.81 for the lower bound and 12.12 for the upper bound). There were significant 
statistical differences between the OPCAB and C-CAB with Amicar groups (p < .05). 
Six-Hour Post-Operative Hct. 
The C-CAB with Aprotinin group had a mean six-hour post-operative Hct. of 
32.39 (SD of 3.93; a 95% CI was reported as 30.92 for the lower bound and 33.85 for the 
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upper bound). The C-CAB with Amicar group had a mean of30.82 (SD of 3.35; a 95% 
CI was reported as 29.56 for the lower bound and 32.07 for the upper bound). The 
OPCAB group had a mean of33.57 (SD of3.45; a 95% CI was reported as 31.66 forthe 
lower bound and 35.48 for the upper bound). There was no significant statistical 
difference among the groups. 
Six-Hour Post-Operative Platelets 
The C-CAB with Aprotinin group had a mean six-hour post-operative platelet 
count of 148.23 (SD of 137.17; a 95% CI was reported as 134.35 for the lower bound and 
162.11 for the upper bound). The C-CAB with Amicar group had the lowest mean of 
140.86 (SD of 40.21; a 95% CI was reported as 125.85 for the lower bound and 155.88 
for the upper bound). The OPCAB group had the highest mean of 184.80 (SD of 41.71; a 
95% CI was reported as 161.69 for the lower bound and 207 .90 for the upper bound). 
There were significant statistical differences among the OPCAB and C-CAB with 
Aprotinin (p < .05) and C-CAB with Amicar (p < .01). 
Graphic representations of these findings are displayed in Table 12. 
Table 12. 6-Hour Laboratory Values 
Variable 
6 Hr. Hgb. 
6 Hr. Hct 
6 Hr. Plat. 
Aprotinin 
(n 30) 
11.21±1.43 
32.39 ± 3.93 
148.23 ± 37.17* 
*p< . 05 vs. OPCAB group 
** p< .OJ vs. OPCAB group 
Ami car OPCAB 
c n =Jo) (n 15) 
10.47 ± 1.09* 11.46 ± 1.18 
30.82 ±3.35 33.57 ± 3.45 
140.86 ± 40.21 ** 184.80 ± 41.71 
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Twenty-Four Hour Post-Operative PRBC Usage 
The C-CAB with Aprotinin group had a mean twenty-four hour post-operative 
PRBC usage of 0.56 (SD of 1.04; a 95% CI was reported as 0.17 for the lower bound and 
0.95 for the upper bound). The C-CAB with Amicar group had the highest mean of 1.46 
(SD of 2.14; a 95% CI was reported as 0.66 for the lower bound and 2.26 for the upper 
bound). The OPCAB group had the lowest mean of 0.26 (SD of 0. 70; a 95% CI was 
reported as 0.12 for the lower bound and 0.65 for the upper bound). There were 
significant statistical differences between the OPCAB and C-CAB w/Amicar (p < .05). 
Twenty-Four Hour Post-Operative FFP Usage 
The C-CAB with Aprotinin group had a mean twenty-four hour post-operative 
FFP usage of0.13 (SD of 0.73; a 95% CI was reported as-0.13 for the lower bound and 
0.40 for the upper bound). The C-CAB with Amicar group had a mean of 0.16 (SD of 
0.53; a 95% CI was reported as -3.14 for the lower bound and 0.36 for the upper bound). 
The OPCAB group had no usage. There was no significant statistical difference among 
the groups. 
Twenty-Four Hour Post-Operative Platelet Usage 
The C-CAB with Aprotinin group had a mean twenty-four hour post-operative 
platelet usage of 0.20 (SD of 1.09; a 95% CI was reported as -0.20 for the lower bound 
and 0.60 for the upper bound). The C-CAB with Amicar group had a mean of 0.60 (SD of 
1.83; a 95% CI was reported as -8.36 for the lower bound and 1.28 for the upper bound). 
The OPCAB group had no usage. There was no significant statistical difference among 
the groups. 
84 
Cell Salvage Return 
The C-CAB with Aprotinin group had the highest mean cell salvage return of 
861.66 (SD of 145.43; a 95% CI was reported as 807.35 for the lower bound and 915.97 
for the upper bound). The C-CAB with Amicar group had a mean of 776.66 (SD of 
148.40; a 95% CI was reported as 721.25 for the lower bound and 832.08 for the upper 
bound). The OPCAB group had the lowest mean of367.53 (SD of389.82; a 95% CI was 
reported as 151.65 for the lower bound and 583.40 for the upper bound). There were 
significant statistical differences between the OPCAB and C-CAB groups (p < .01). 
Twenty-four Hour Chest Tube Output 
The C-CAB with Aprotinin group had a mean of 422.50 (SD of248.85; a 95% CI 
was reported as 329.57 for the lower bound and 515.42 for the upper bound). The C-CAB 
with Amicar group had a mean of 596.43 (SD of 3 70.40; a 95% CI was reported as 
458.12 for the lower bound and 734.74 for the upper bound). The OPCAB group had a 
mean of 399.00 (SD of 171.11; a 95% CI was reported as 304.24 for the lower bound and 
493.76 for the upper bound). There was no significant statistical difference among the 
groups. 
Graphic representations of these findings are displayed in Table 13. 
Table 13. Twenty-Four Hour Blood Product Usage 
Variable 
24Hr.PRBC 
24 Hr. FFP 
24 Hr. Plat. 
24 Hr. Cryo. 
Aprotinin 
( n = 30) 
0.56 ± 1.04 
0.13 ± 0.73 
0.20 ± 1.09 
0.00 ± 0.00 
Ami car 
( n = 30) 
1.46 ± 2.14* 
0.16 ± 0.53 
0.60 ± 1.83 
0.00 ± 0.00 
OPCAB 
( n = 15) 
0.26 ± 0.70 
0.00 ± 0.00 
0.00 ± 0.00 
0.00 ± 0.00 
Cell Salvage Ret. 861.66 ± 145.43** 
24 Hr. Chest Tube 422.50 ± 248.58 
776.66 ± 148.40** 367.53 ± 389.92 
596.43 ± 370.40 399.00 ± 171.11 
*p< . 05 vs. OPCAB & C-CAB w/ Aprotinin 
** p< .OJ vs. OPCAB group 
Research Hypotheses Seven 
The final research hypothesis stated there was a significant decrease in patient 
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care hours with decreased complement mediator activation. The participating institution 
does not staff on patient acuity levels, therefore, results reported for Research Hypothesis 
Three reflect total LOS for the three groups. There was no significant difference noted 
among the groups. 
Summary of Findings 
The findings of this study supported the first hypothesis. There was a significant 
difference in the O.R. time between the C-CAB with Aprotinin group (267.66 minutes,p 
< .05), the C-CAB with Amicar group (277.70 minutes,p < .01) and the OPCAB group 
(214.00 minutes). There was also a significant difference in the number of distal 
anastomosis between the C-CAB with Aprotinin (4.33,p < .01), the C-CAB with Amicar 
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group (3.90,p < .05), and the OPCAB group (2.86) There was no statistical difference 
found for total O.R. costs, O.R. supply costs, pharmacy costs, or LIMA conducted.· The 
second research hypothesis was not supported. There were no significant statistical 
differences among the extubation time, LOS ICU, LOS Hosp., and total LOS among the 
groups. 
The findings of this study supported the third research hypothesis. There was a 
significant statistical difference in the OPCAB group Pre-IL-6 levels (p < .05). The post-
Protamine MMP-2 revealed a significant statistical difference among the C-CAB groups 
and the OPCAB group (p < .05). The post-protamine MMP-9 results showed a significant 
statistical difference among the C-CAB groups and the OPCAB group (p < .05). Also 
noted was a significant statistical difference between the baseline C-CAB with Aprotinin 
and the post level in this group (p < .05). The 6 hr. IL-6 levels also revealed no 
significant statistical difference between the groups. The six-hour MMP-2 results showed 
there were significant statistical difference among the C-CAB groups and the OPCAB 
group (p < .05). All three groups showed a significant statistical difference in the 6 hr. 
MMP-9 levels from their baselines. There were no other significant statistical differences 
in the other inflammatory mediators that were measured. 
The fourth research hypothesis was not tested. As previous stated, with the 
discontinuance of the y-coating product, further comparison of the products involved in 
the study proposal was no longer valid. It was felt by the investigators, that with the 
uncertainty of product availability due to corporate changes, that it was in the best 
interest of the study, to terminate data collection after enrollment of enough subjects to 
validate a portion of the research project. 
The findings of this study supported the fifth research hypothesis. There were 
significant differences in the measured inflammatory response between the C-CAB with 
Aprotinin group and the C-CAB with Amicar group. Differences occurred at the post 
MMP-9 level and baseline level for the C-CAB with Aprotinin and also for both groups 
for the six-hour MMP-9 levels versus their respective baselines. There were no other 
significant statistical differences found in any of the other measured inflammatory 
mediators. 
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The findings of this study supported the sixth research hypothesis. There was a 
significant statistical difference in the number of subjects receiving blood products 
among the C-CAB with Aprotinin group (30%, p < .05), the C-CAB with Amicar group 
(50%,p < .01), and the OPCAB group. Other differences occurred in the Pre-Plat. count 
between the C-CAB with Aprotinin group and the OPCAB group (p < .05); Post-
Protamine Hgb. among the C-CAB with Aprotinin group (p < .05), C-CAB with Amicar 
group (p < .01), and the OPCAB group; Post-Protamine Hct. among the C-CAB with 
Aprotinin group (p < .01), C-CAB with Amicar group (p < .01), and the OPCAB group; 6 
Hr. Hgb. in the C-CAB with Amicar group (p < .05) and the C-CAB with Aprotinin and 
OPCAB groups; 6 Hr. Plat. Count among the C-CAB with Aprotinin group, the C-CAB 
with Amicar group and the OPCAB group; 6 Hr. Plat. Count among the C-CAB with 
Aprotinin group (p < .05), C-CAB with Amicar group (p < .01), and the OPCAB group; 
24 Hr. PRBC usage in the C-CAB with Amicar group (p < .05) and the C-CAB with 
Aprotinin and OPCAB groups; and finally the amount of cell salvage return among the 
C-CAB groups (p < .01) and the OPCAB group. 
J 
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The study's findings did not support the seventh research hypothesis. There were 
no significant statistical differences in the LOS among the groups. 
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CHAPTERS 
DISCUSSIONS, CONCLUSIONS, AND RECOMMENDATIONS 
This chapter focuses on the meaning of the statistical findings for this study. Each 
research hypothesis is discussed separately, with the exception of Research Hypothesis 
Four. The significance of each hypothesis's findings are discussed in the anticipation that 
the results will increase nursing administration's body of knowledge by revealing the 
most cost effective treatment regime while maintaining excellent outcomes for patients 
undergoing CABG. 
Discussion of Findings 
Research Hypothesis One 
The actual O.R. times were reported in Table 2 and the significant statistical 
differences have already been discussed. This may be due to the difference in the number 
of distal anastomosis performed in each group, although there was no statistical 
significant reported. CABOCS results almost mirrored those reported by Hart, Spooner, 
Edgerton & Milsteen (1999) regarding the number of distal anastomosis found in the 
study groups. The total O.R. costs revealed no significant difference, which was not the 
case as reported by Buffolo et al. (1996) who reported a cost savings for OPCAB of 
$3000. It should be noted that Buffo lo et al. did not have the option of utilizing a 
proximal connection device, which one conclusion of this study was a lower, but not 
statistically significant total O.R. cost for the OPCAB group, therefore not rejecting the 
null hypothesis. 
Breaking out the O.R. supply costs from the overall O.R. costs revealed that the 
OPCAB group was the highest at $4014.13. It should be noted that only two out of29 
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possible applications of the St. Jude Symmetry Proximal Connectors® were elected to be 
used. Recent literature indicates concern over possible early graft closure when using . · 
these devices (Verma et al., 2003) and these concerns may have influenced the decision 
of whether to use the device or not. In the event the device was used in all possible 
applications, there would have been a further increase in the supply cost for the OPCAB 
group (averaging $810 per case). It was the intent of the researcher to include the use of 
the connector in all OPCAB cases to truly reflect the costs of "clampless" bypass surgery 
(Eckstein et al., 2001). 
The pharmacy costs are another area that can have tremendous impact on intra-
operative costs. The intent of the researcher was to compare the intra-operative pharmacy 
costs between the groups. It was found that the pharmacy costs were bundled for the 
entire hospitalization and that it was virtually impossible to breakout the intra-operative 
costs. Therefore, the reported costs are for the entire hospitalization. The cost of the 
Aprotinin regime used during this study is $450/dose, therefore reflecting an annual cost 
to the institution of approximately $750,000. 
Since the introduction of Aprotinin in 1987, Aprotinin has been shown to exhibit 
an anti-inflammatory effect by suppressing leukocyte activation and therefore can be 
expected to provide a significant clinical benefit. This expectation has been borne out in 
clinical practice in which the LOS following CPB surgery was significantly reduced by 
Aprotinin compared to other anti-inflammatory strategies, thereby offsetting the initial 
cost of the drug during surgery (Harmon, 1996; Landis et. al, 2000). 
By not rejecting the null hypothesis, these findings lead this researcher to 
conclude that even though there was a significant difference in the O.R. times, using the 
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C-CAB with Aprotinin regime allowed for more distal anastomosis with no significant 
difference in O.R. costs (total and supply) or pharmacy costs. A major concern is the 
possibility of incomplete revascularization in the OPCAB group as was noted by Hart et 
al., 1999. 
Research Hypothesis Two 
Comparing the LOS between the groups as seen on Table 3 demonstrated no 
significant statistical differences. Though the hypothesis was supported, Buffolo et al. did 
not demonstrate this in 1996. Their study demonstrated a statistical significant difference 
in the total LOS for the OPCAB group. This study's mean LOS Hosp. was noted to be 
similar to the findings of Lee et al. in 2000 where they reported a LOS of 6.1 versus 7 .1 
for OPCAB and C-CAB. The similar LOS demonstrated in this study between the C-
CAB with Aprotinin group and the OPCAB group (6.02 vs. 6.00) reinforces the possible 
positive effects of Aprotinin on the inflammatory mediators thus allowing the patient to 
progress through the stages of self-care more rapidly. 
A useful tool in assessing LOS ICU is the time it takes to wean and extubate a 
patient from the ventilator. This study demonstrated a lower time for extubation of the 
OPCAB group than the C-CAB group though this was not statistically significant. Kirk et 
al. in 200 I reported similar results though they showed a statistically significant 
difference between the OPCAB and C-CAB groups (3.4 vs. 8.3 hours). 
A difference may be that the study institution is "pseudo" fast tracking similar to 
what Ott et al. in 1999 reported. A major advancement is the use of a new drug not 
available then. All patients in the study received Precedex®, which when administered in 
the presence of certain anesthetic agents is likely to lead to an enhancement of effects, 
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giving the anesthesia personnel the ability to decrease the dose of narcotics and allowing 
for earlier weaning and extubation from the respirator. 
Research Hypothesis Three 
Tables 4, 5 & 6 report the actual results of the inflammatory mediators that were 
measured in this study and were corrected for hemodilution as indicated. This was 
important in that in the C-CAB group's hemodilution could affect the final results. One 
unique aspect of this study was the measurement of the various inflammatory mediators 
in combination of differing drug regimes in the presence of a hemoconcentrator. 
The first significant finding was that there was a significant difference in the Pre-
IL-6 levels, with the OPCAB group having the difference (p < .05). This result could be 
from numerous causes. It was not the intention of the researcher to monitor what 
occurred pre-operatively as for how long and what incidences happened to the subjects 
during this period. This may have influenced these results. 
The pro-inflammatory cascade of the immune system plays an important role in 
patients who undergo coronary artery bypass (Edmunds, 1998). These patients may 
display a "primed" system, which opens a window of susceptibility during which any 
physiologic stressor can unleash a generalized auto-destructive inflammatory cascade that 
if unchecked, can lead to several syndromes including Atiult Respiratory Distress 
Syndrome (ARDS), Multi-Organ Dysfunction Syndrome (MODS) and death (Goris, te 
Boekhorst, Nuytinck, & Gimbrere, 1985; Terregino, Lopez, Karras, Killian, & Arnold, 
2000). The population may have been representative of those seen by Ott et al. in 1999 
where they reported that the study population was found to be at a higher-risk with 
increased incidence of left-ventricular dysfunction, congestive heart failure and 
symptomatic peripheral vascular disease. This might shed light as to the lack of a 
significant difference in the total LOS between the groups. 
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The post-protamine MMP-2 revealed a statistical difference between the C-CAB 
groups and the OPCAB group (p < .05). The MMPs have been shown to act in the acute 
phase following cardiac stress (Camey et al., 1999). MMP-2 and MMP-9 have also been 
shown to rise in a predictable fashion in association with CPB (Joffs et al., 2001). These 
observations are most likely associated with the methods used to arrest the heart during 
C-CAB and the manipulation of the myocardium associated with the additional distal 
anastomosis. 
The post-protamine MMP-9 results showed a statistical significant difference 
between the C-CAB groups and the OPCAB group (p < .05). Some of these enzymes 
may be related to the ischemic myocardium during revascularization. This would lead 
one to believe that the release of certain MMP' s is from the manipulation of the 
myocardium and not CPB as Joffs, et al. noted in 2001. Also noted a statistical significant 
difference between the baseline C-CAB with Aprotinin and the post level in this group (p 
< .05). This may reflect the attenuation ofMMP-9 by Aprotinin, although this has not 
been supported in recent literature. 
All three groups showed a statistical difference in the 6 hr. MMP-9 levels from 
baseline. This is indicative of a generalized inflammatory response regardless of surgical 
modality (Spinale, 2002). It should be noted that at this time interval all salvaged blood 
had been returned to the subjects. This is important in that the two classifications of the 
MMP's are not of the molecular weight to be sieved off by the hemoconcentrator. The 
molecular weight of the inflammatory mediators measured are: IL-6 = 26 kDa; IL-10 = 
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39 kDa; MMP-2 = 72 kDa; MMP-9 = 92 kDa. The hemoconcentrator cutoff limit is 65 
kDa. This fact in itself might shed light as to why the IL' s in the C-CAB groups did · 
reflect a significant change from baseline but it does not address the significant change 
from baseline in the OPCAB group. None of these findings can be supported in the recent 
literature. Therefore the null hypothesis was not rejected; there were no statistically 
significant decrease in all measured inflammatory mediators. 
Research Hypothesis Four 
The fourth research hypothesis was not tested. As previous stated, with the 
discontinuance of the y-coating product, further comparison of the products involved in 
the study proposal was no longer valid. 
Research Hypothesis Five 
The fifth research hypothesis stated that there was a statistically significant 
difference in the measured inflammatory responses between the C-CAB groups. These 
results are found on Tables 7, 8 &9. 
Landis et al., 2000, and Harmon, 1996, each reviewed the effects of Aprotinin in 
reducing blood loss and LOS. Both of these studies used full dose, whereas this study 
used Yi dose. Neither of the aforementioned studies actually measured the inflammatory 
mediators but did make mention of possible benefits in this area. 
Englberger, Kipfer, Berdat, Nydegger &, Carrel, 2002, reported that there was no 
statistical difference in the inflammatory process when using Yi dose Aprotinin. The only 
similarity of these researchers, from an inflammatory standpoint, to this study was in the 
measurement of IL-6. Significant differences observed in this study were post-MMP-9 
and 6 hr. MMP-9 in the Aprotinin group and post-MMP-9 in the Amicar group. These 
differences were from the respective groups baseline measurements and no significant 
differences were found between groups, therefore the null hypothesis was not rejected. 
Research Hypothesis Six 
The sixth research hypothesis predicted that there was a statistically significant 
difference in blood loss and therefore the usage of blood products between the three 
groups. These findings are displayed in Tables 10, 11, 12 & 13. 
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Similar studies found in the literature revealed comparable results. Kirk et al., 
2001 demonstrated there were significantly fewer blood transfusions (p <0.05) in the 
OPCAB group (L 1 vs. 2.4 units), and the patients transfused were significantly lower 
(34.9% vs. 57.3%). The C-CAB group of patients in that study received the Amicar 
regime. In comparison, this study's OPCAB group received fewer blood transfusion of 
0.26 vs. 1.46 units and patients transfused of 13% vs. 50%. Nader, Reich, Bacon, Salemo 
&, Panos (1999), along with Lancey et al., 2000 reported similar results to this studies 
groups. 
Pre-operative lab work revealed a significant difference in the pre-Plat. level for 
the C-CAB with Aprotinin group. There is no reasonable explanation for this but it is 
interesting to note that although the counts were significantly lower, the use of blood and 
blood products along with chest tube drainage ZDanot statistically significant from the 
OPCAB group. This reinforces the research of Cicek, Demirkilic, Kuralay, Ozal, & Tatar, 
1996, when they studied the relevancy of using Aprotinin to reduce post-operative blood 
loss and the need for blood transfusions. 
There was also a significant difference in the post-protamine Hgb. and post-
protamine Hct. between the C-CAB with Aprotinin group (p < .05), the C-CAB with 
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Amicar group (p < .01) group and the OPCAB group. This can easily be attributed to the 
fact that when these levels are measured, there has been no salvaging of the patients 
blood from the CPB circuit. It is usual and routine not to salvage the blood until the 
sternal wires are placed as to allow for the patient to be hemodynamically stable. 
The 6 hr. Hgb. for the C-CAB with Amicar group showed a significant difference 
from the other two groups (p < .05). Several factors could have influenced this. First, the 
pre-Hgb. was lower than the other groups though this was not statistically significant. 
Secondly, the amount of cell salvage returned was less than the C-CAB with Aprotinin 
group. Finally, the amount of chest tube drainage was higher, though again not 
statistically significant. 
Six-hour platelet counts showed a significant difference between the C-CAB with 
Aprotinin group (p < .05), the C-CAB with Amicar group (p < .01) group and the 
OPCAB group. Interesting to note that although the C-CAB with Aprotinin began with a 
statistically significant lower count from the other two groups, the platelet count in the C-
CAB with Amicar group dropped to a lower level at the measured time period. This 
would indicate that there possible is some degree of protection of the platelets from using 
the Yz dose Aprotinin regime. Aldea & Shemin, (1998), demonstrated the effects on the 
formed elements in the blood when exposed to the HBC:: of CPB. This could also explain 
the drop in the platelet count. Finally, there is wide spread belief that the platelets tend to 
sequester in the spleen and liver during bypass and the destructive nature of the "pump" 
portion of the CPB circuit in itself can account for the decreased counts. 
Usage of PRBC's at the 24 hr. timeframe for the C-CAB with Amicar group 
showed a significant statistical difference than the other two groups. The pre-Hgb. was 
lower in this group than the other groups though this was not significant. Secondly, the 
amount of cell salvage returned was again less than the C-CAB with Aprotinin group. 
Finally, the amount of chest tube drainage was higher, though again not statistically 
significant. All of these factors combined may account for the differences found. 
Cell salvage return revealed a significant statistical difference between the C-
CAB group and the OPCAB group (p < .01). This has already been accounted for when 
addressing the post-Protamine Hgb. and Hct. results between the C-CAB and OPCAB 
groups. 
97 
Patient transfusion percentage showed a significant difference between the C-
CAB group and the OPCAB group (p < .05). These findings are similar to those found in 
the literature as was given in the beginning of this section. These results supported the 
hypothesis. 
Research Hypothesis Seven 
The seventh research hypothesis regarded the difference in patient care hours with 
a decrease in the inflammatory response. It was reported that there were no statistical 
differences found, therefore the null hypothesis could not be rejected. It should be noted 
that the C-CAB with Amicar group contained data from the only mortality observed in 
this study. This subject suffered a massive stroke requirin'g an ICU LOS of 30 days and 
this is reflected in the final data. 
Conclusions 
Historically, numerous studies have shown the possible detrimental effects that 
were associated with CPB. Techniques to attenuate these side effects have been explored 
and several methods to decrease these effects have been given, including coating the CPB 
circuit and different drug regimes. The evolvement of the specialized retractors to 
accomplish CABG without the use of the CPB has lead to numerous theories felt to 
improve patient outcomes. This study has introduced a possible alternative to 
accomplishing complete revascularization while attenuating the inflammatory response. 
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It is well documented that changing the very method of salvaging the blood in the 
CPB circuit utilizing a hemoconcentrator has been effective in eliminating certain 
inflammatory mediators. In addition to the ability to remove Il-6 & 10, adding a platelet 
protector such as Aprotinin may also decrease some of the inflammatory responses while 
providing for platelet protection. This combination of modalities is not currently seen in 
recent literature. 
Difference in the O.R. times was a direct result of the number of distal 
anastomosis performed. Addressing the concern for complete revascularization has 
previously been addressed in other research and thus was well supported by the ROL. 
The null hypothesis was not rejected due to any statistical difference in the O.R. cost 
between the groups even though the available proximal connector was only used in 6.8% 
of the possible applications. 
LOS has been shown to have extreme importance in numerous aspects of the 
hospital organization. The efficient utilization of beds, 'both in ICU and on the ward and 
the decrease in the stress on the nursing personnel by enhancing the recovery of the 
patient has significant importance for administrators. The ROL indicated that fast 
tracking could allow the patient to recover more quickly and provide for earlier discharge 
thus increasing efficiency and better utilizing personnel while providing for increased 
independence of the patient. Dorthea Orem's Model of Self-Care supports this concept. 
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There was no significance statistical difference demonstrated between the groups 
as for a reduction in LOS. This aspect may prove to be beneficial for the nursing 
administrator to realize in the staffing process. Additionally, this information has the 
potential to provide nursing administration with the best alternatives in patient care to 
pursue facing the current and future shortage of nurses. 
The differing inflammatory results, especially in the MMP groups, more than 
likely reflect the methods used to arrest the heart during C-CAB. In the presence of 
severe coronary artery disease, the ability to protect the myocardium is hampered, and 
this could be a factor involved in the results. Even with these differences, the null 
hypothesis was not rejected. 
Comparison of the C-CAB group related to drug regimes involved can influence 
the inflammatory mediators in the presence of the hemoconcentrator. The molecular 
weight of the IL's has been shown to be less than what is passed through the 
hemoconcentrator, thus potentially accounting for no significant difference in these 
results, therefore the null hypothesis was not rejected. The aGRVHAprotinin regime used 
has been supported in the ROL. 
There was a significant statistical difference in the utilization of blood products. 
The number of patients receiving transfusions was significant statistically different 
between the C-CAB groups vs. the OPCAB groups, and also between the C-CAB groups. 
Even though the pre-Plat. count was lower in the C-CAB with Aprotinin group; there was 
no significant statistical difference in the use of platelets in this group, indicating the 
protective properties of the drug that is well documented in the ROL. The decreased use 
of blood and blood products in the OPCAB group was also well supported in the ROL. 
The hypothesis dealt with blood loss and the results indicate no significant difference 
between the groups, therefore the hypothesis was accepted. 
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The final hypothesis dealt with in the presence of a reduction in the inflammatory 
mediators there should be an accelerated advancement to self-care therefore decreasing 
the need of nursing care hours. It was demonstrated that this was not the case, therefore 
the null hypothesis was not rejected. 
Recommendations 
Exploring non-conventional ideas to improve patient outcomes tends to tread into 
territory that is often tenuous. Offering new ideas that may affect standard medical 
practices often is not well received. Simply employing available technology in a different 
way may reveal interesting outcomes. This was the unexpected result that was revealed in 
this research project. 
With the recent concerns generated over the long-term patency of the proximal 
connectors, the ability to perform "clampless" CABG is in limbo. This leads this 
researcher to favor the "single-clamp" method utilizing CPB. Results given showed there 
were more distal anastomosis performed with no significant difference in costs or LOS. If 
the ability to provide for a more complete revascularization is available, there needs to be 
consideration as to the long-term benefits vs. drawbacks of the two techniques. 
Addressing the inflammatory issue, results given indicated that using the C-CAB 
with the hemoconcentrator method showed no significant differences in the measured 
inflammatory mediators as compared to the OPCAB group. This supported the idea that 
the IL's were being sieved off by the hemoconcentrator, as was demonstrated by the size 
of the molecule and what the hemoconcentrtaor would pass. A generalized inflammatory 
response was seen in all groups at the six-hour time frame, indicating that the surgical 
process itself was the most likely culprit. Therefore, it is recommended to utilize the 
hemoconcentrator in the presence of C-CAB. 
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Looking at the inflammatory issue involving the two C-CAB regimes, no 
difference was found. Interestingly enough, the pharmacy costs were also no different 
even in the presence of Aprotinin. With these factors in mind, it is recommended that the 
potential benefits of using Aprotinin for platelet protection and possible additional 
inflammatory effects, at no additional cost, in the presence of C-CAB be implemented. 
The next recommendation involves the use of blood products. It was shown there 
were significant differences noted between the C-CAB group and the OPCAB group. 30-
50% of the C-CAB group received blood or blood products as compared to 13% of the 
OPCAB group. This was well supported in the ROL. The results for the C-CAB groups 
also showed significant differences, thus reinforcing the recommendation to use 
Aprotinin for the reasons previously stated. 
The final recommendation deals with LOS. There were no differences found 
which could indicate a couple of reasons. First, the "psuedo" fast tracking needs to be 
revised and implemented as to encourage compliance from the O.R. to the ward. 
Secondly, the organization itself needs to rethink the process to discharge and implement 
ways to expedite the process and take advantage of the patient's progression through the 
stages of self-care. 
Additional research should be conducted that would include exploring means to 
sieve additional inflammatory mediators that could be removed via differing pore size 
hemoconcentraors. Also, refining the current study to actually measure the amount of 
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mediators removed could prove to be beneficial. Finally, adding another "arm" to include 
a C-CAB group that utilized the standard practice of blood salvage using the cell-saver, 
could enter an aspect to compare this studies population against that seen nationally. 
Summary 
This chapter reviewed the reported results and what possible implications may be 
available to the study population. Findings indicated the importance to explore existing 
and new technologies that may have an influence on patient outcomes. This might well 
prove to be extremely important considering the potential number of individuals that will 
require CABG surgery in the future. Combined with the continuing and expected nursing 
shortage, nursing administrators may well benefit from the expanded knowledge of this 
study. 
A through review of the statistical findings was done and recommendations were 
made. Encompassing all aspects of this study, interpreting the results, and delineating out 
possible positive changes to provide the best outcomes, was the main purpose of this 
chapter. 
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APPENDIX A 
CABOCS Instrument 
Memorial Hospital Data Collection Sheet 
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Study ID Number 
Instrument 
*All participants are Primary Coronary Artery Bypass Patients* 
*All participants will utilize Endoscopic Vein Harvesting* 
Demographics: 
Pre-Operative Data: 
- Age (years): - Gender: Male 
-LVEF%: Female 
-OP-CAB: 
-CPB: 
- Coating: D: B: 
Aprotinin: __ Ami car: 
Baseline Laboratory Data: 
- Hbg. (mg./ di): _ - Hct. (mg.%): __ 
-Plat. Count (K/dl): __ 
-Inflammatory Mediator Labs Drawn (YIN): _ 
(must be pre-sternotomy, placed in proper tube & labeled with date, time, and Base 
Deficit) 
-IL-6: __ _ IL-10: MMP-2: __ MMP-9: __ _ 
Blood/ Blood Product Usage (lntraoperative): 
(Total amount given- anesthesia & perfusion- whether OP-CAB or CPB) 
- PRBC's (units): __ - FFP (units): __ 
- Plat. (units): __ - Cryo (units): __ 
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Post-Procedure Laboratory Data: 
- Hbg. (mg/di): _ - Hct. (mg%): __ 
- Inflammatory Mediator Labs Drawn (YIN): __ 
(must be placed in proper tube and labeled with date, time and Base deficit) 
-IL-6: __ IL-10: MMP-2: MMP-9: 
- Blood Salvaged Hemoconcentrate (ml.): __ 
Post-Operative Data: 
Laboratory Data: 
(6 hours post-op) 
- Hbg. (mg/di): _ 
- Plat. Count (Kid!): __ 
- Inflammatory Mediator Labs: 
- Hct. (mg%): __ 
- Salvaged Blood Returned (YIN): __ 
(must be placed in proper tube and labeled with date, time and Base deficit) 
-IL-6: __ 
Blood/ Blood Product Usage: 
(24 hour total amounts given) 
IL-10: 
- PRBC's (units): __ 
- Plats. (units): __ 
Chest Tube Drainage: 
(till removed or 1st 24 hours) 
- Amount (cc's): __ 
Time to Extubation: 
- Time (ruins.): __ 
Miscellaneous Data: 
MMP-2: MMP-9: 
- FFP (units): __ 
- Cryo (units): __ 
Operating Room: 
Length of Stay: 
STS Data: 
- Time (min.): __ 
- Cost($): (OP-CAB will include stabilizer and proximal 
connector(s)). 
- ICU (hours): __ 
- Hospital (hours): __ 
(measurement begins at time of operation) 
- Height (cm.): __ - Weight (kg.): _ 
-BSA (M2): 
- Pump (min.): __ -Clamp (min.): __ 
Coronary Cath Data (% of disease): 
-RCA: -PDA: 
-LM: -LAD: 
-Diag: __ -RMI: 
-OMI: -OM2: 
-Cx: -Other: 
-Number of distal anastomosis performed: 
-Number ofIMA's performed: __ _ 
-Was a radial artery used?: OYes D No 
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0(aW5,$/
HOSPITAL 
Surgery Date I SS# 
Surgeon: Assist: 
Anes: CRNA: 
Cardiologist: Group: 
Perfusionisl: OR Room#: 
Weight: __ kg Height: __ cm BSA __ M2 
Cardiopulmonary Bypass and Support Data 
CPS from the Cath lab · D Yes D No 
lnotropes (ARRIVING OR) 0 Yes 0 No 
Antiarrhythmics (ARRIVING OR) 0 Yes 0 No 
Cardiopleaia: D Yes D No 
tJ Blood 
IABP: 
VAD: 
D Crystalloid 
0 Oxygenated Crystallaid 
Infusion I.lode: D Antegrade 
D Retrograde 
Infusion Dose: D Intermittent 
D Continuous 
Cardiopegia Temp: D Warm 
0 Cold 
Hot Shat Used? D Yes D No 
D Yes D No 
D Preop D lntraop D Postop 
Indication: 
0 Low CO 
D Unstable Angina 
D Shack 
D Yes D No 
0 LVAD 
0 SVAD 
0 PTCA Support 
0 CPS Wean 
D Prophylactic 
0 RVAD 
DTAH 
Cardioversion: 0 Yes D No 
D Yes D No Defibrillatian 
Last SV02 on CPS> 65% 0 Yes 0 No 
Lowest Hct. On CPS> 19% · D Yes D No · 
Hemoconcentrator D Yes D No 
Cellsaver D Yes D No 
Amount of Autologous Blood Recovered ml. 
Weaned without homologous blood D Yes D No 
Number of 
PRSC's used on CPS? --· 
CPS Time: min Cross Clamp Time: __ min 
Lowest Core Temperature: ___ (C") 
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l'h:ase place p;11ic111 ID l.:ibd here 
Status: 
D Elective 
D Emergenl 
D Urgent 
D EmergenVSalv;ige 
Operative Data ., · · 
Operative Category: 
1111111 trpe of ptocedure rs I/le SaWLFQWVFaaGXOHGto unde<9o' niis :hoL11:J no: reflect 
;m1• 1mmtended procedures 01 procedures mat were pertormed as a resu= of 
LQaUDRSHUDaLYHcomp!tcations. 
0 CAB+ Othei 0 CAB 
D Valve 
0 CAB+ Valve 
D Other 
D CAB + Valve +Other 
D Valve + O:her 
Operative Procedure: 
OaWt)r.e of aRFH-ZHdid t!le pa:ient '"1:!e1go' 
0 CAB 
0 Valve: (check all that apply6 
D Replace:D A 1,1 D T DP 
' 0 Repair: 0 A 0 M 0 T 0 P 
Cardiopulmonary Bypass Used D Yes 
Cannulation Methods 
D Femoral Mery 
D Femoral Vein/Jugular Vein 
D Aorta 
D Atrial Cava! 
· D Other. Specify ________ _ 
Vent D Yes D No 
D Aorta · D Left Heart 
D Other. Specify ________ _ 
Aortic Occlusion D Yes D No 
·. D Cross Clamp D Balloon Occlusion 
DNo Coronary Occlusion D Yes 
Total Occlusion Time -----minutes 
lntraoperative Pharmacologic Agents 
D Bela Blocker (e.g. esmolol) 
D Calciu!TI Channel Slacker (e,g. aLOLD]DP
0 Adenosine D Trasylol 
D Amicar 
D Other. Specify ________ _ 
Suture Technique 
D Running D Interrupted 
0 Stapler 
D Other, Specify;_· --------
PLEASE RETURN THIS FORM TO ,THE PERFUSION OFFICE 
a11 IS\l>A l'A\l ISERS\071•1 C>\.'iTS 11:11:1,hcct.ik•c 
'"''' "rintcd lll/ICll'Jll l :1'1 l'M 
Operative Data (Continued) 
Vessel Stabilization D Yes D No 
D Suture Snare D Suction Device 
D Stabilization/Restraining Device 
D Other, Specify _______ _ 
D Other Cardiac Procedures: ^FKHFaall that apply) 
D LVA 0 VSD 
D ASD D Batista (ventricular reduction) 
D Congenital D Transmyocardial Laser 
D. Cardiac TraumaD Cardiac Transplant 
D Pacemaker D AJCD 
D Other. Specify _______ _ 
D Other Non-Cardiac: (check all that apply) 
D Aortic Aneurysm 
D Ase D Arch D Desc 
D Thoraco/Abd D Abd 
D Carotid Endarterectomy 
D Other.Vascular D Other Thoracic 
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Diabetic Management For Patients 
Undergoing Cardiac Procedures 
I . Docs the p;tticnt ha\'c n history of: 
D NIDDM D IDDM 0 NONE 
I'' l\:ri-opcratin: Gluc<lsc = ----- mg/DI 
3. Did !!lm:osc durin!! CPB exceed '.?00 nl!!/dl'? 
DYES D NO - -
If so. wlwt mrs the highest glucose on CPB'! __ 
I. If the glucose exceeded ::WO mg/di on CPB. which 
treatment \\11S instituted to correct l!lucosc'! 
D aHVWKHVLDnotified, No treatment instituted 
D Insulin drip instituted by anesthesia 
D Insulin bolus administered 
Coronary Bypass Data 
Left Main disease >50% D Yes D No 
Endarterectomy Performed D Yes D No 
a26WFQRVLV7 J1e aRVLVshouf;i bo defined for Ille vessel branch iri L'.ll•c/J t11c s:enosis is Jo:a:ed. This mat be 
GaHUHQtha•1 t!1e L1fC!.1ch aāOOFLOis r;rat.ed. 
H!iA Used 
Left: 
Right 
D Yes D No 
D Yes D No 
D Yes D No 
:; of Distal Anast __ # of Prox Anast __ 
#of !MA Grafts __ #of !MA Distals __ 
:; of GEPA grafts __ #of GEPA Distals __ 
a.. Sh:no.,.is 

a
51·70"'A. 
)s āaāa
4='!1-'l'l% 
;\= II`a
aWāaāfur ·rahlC' 
('cmd11i1 Tl'dmi\tlli: 
a l=Jlin:cl 
 a$ 1=1ndin:ct 
8a,$
4•Frw IM:\ 
:'=-CiEPA ll=Fn .. -..:<iU)A 
7=Rmli;ll .\rlCI")' . N=Olh<r 
Valve Surgery Data 
Procedure Prosthesis 
Aortic: Implant .. _._·__ . Size:_ 
Explant __ Size: 
Mitra!: Implant__ Size: 
Explant: __ Size: 
Tricuspid: __ Implant:__ Size: 
Explant: __ Size: 
Pulmonic: __ Implant:_. _ Size: 
Mec:hanical 
aGLHV
7=St. Jude Mech. 
Explant: __ Size: 
a

14•StJude·Stentless 
20=CE.Pericardial 
21=CE.Poitine 
22=Cryotife 
LM 
RM 
LAD 
01 
02 
Int Med 
Cx 
OM1 
OM2 
OM3 
PDA 
LVB 
AM 
Type:_ 
Type:_ 
Type:_ 
Type:_ 
Type:_ 
Type:_ 
Type:_ 
Type:_ 
Bi!m 
23=CE·Rirg 
aStenosis Conduit Conduit Har1·est 
Technique 
t-ncstomotic 
Te:hnique 
Key for Valve Surgery Data Table 
a
1=Replacement 
2•Annutoplasty- Ring 
3=Annuloplasty - No Ring 
4=ComrtUssurotomy- Ring 
S=Commissurotorny- No Ring 
6=Chordal Rupture Repair 
 3DSaDU\Muscle 5HSDa
a
Valve Size in mm 
a
M=Mechanical 
B•Bioprosthesis 
H=Homogralt 
S=Aortic Root ReconstrudiOn 
9=Leallettepair--------- ·------ .. 
IO=Resuspension Aortic Valve 
11=Resection of Sub-Aortic Stenosis 
12=Valvectomy 
IJ=RossSwitch 
14=0ther Complex Repair 
A 1 •Autogralt wilh Aortic Homograft 
A2=Autogralt wilh Pulmonary Homogtaft. 
A3=Autogralt ZaKStentless Porcine 
R•Ring 
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SAU Approval Form A 
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Memorial Hospital IRB Approval Letter 
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Directions: Please complete this form and submit with the following documents if used: (1) 
Informed Consent Form, (2) Data Collection Instrument (e.g., questionnaire) or Protocol. 
Level I review: Obtain approval and signature from the course professor/student club or 
association sponsor. Submit Form A with signature to course professor and keep copy for self. 
Level II review: Obtain approval and signature(s) from Chair/Dean. Submit copies of Form A 
with signatures to course professor, Chair/Dean(s), and self. 
1. Identification of Project 
Principal Investigators: 
James Zellner, M.D., Assistant Professor, 
University of Tennessee College of Medicine, Chattanooga Unit; 
Alliance of Cardiac, Thoracic and Vascular Surgeons 
Chattanooga, Tennessee 37404 
( 423) 624-5200 
Michael M. Wyckoff, R.N., C.C.P. 
Candidate MBA I MSN, Southern Adventist University 
Department of Perfusion 
Memorial Hospital 
2525 DeSales A venue 
Chattanooga, Tennessee 37404 
( 423) 495-7850 
Pager: (423) 655-4622 
E-mail: Michael Wyckoff@Memorial.org 
Title: Comparative Analysis of Coronary Artery Bypass: Costs of Off-
Pump vs. Conventional Techniques with Variably Bonded Circuits and 
Drug Strategies. (CABOCS) . 
Department: School ofNursing 
Faculty Supervisor: David Gerstle, PhD, RN 
Starting Date: Fall, 2002 
Completion Date: Summer, 2003 
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II. Purpose of Study 
The purpose of this study is to examine and compare costs of differing treatment 
modalities for coronary artery bypass surgery, including off-pump coronary artery bypass 
(OPCAB) and conventional coronary artery bypass (C-CAB). When the use of C-CAB is 
indicated, there are numerous circuit coatings available, along with drugs like Aprotinin, 
to decrease the inflammatory response associated with the exposure of the body to the 
bypass circuit. Exposure of the body to the cardiopulmonary bypass circuit has been 
shown to activate the pro-inflammatory arm of the immune system, as well as the 
coagulation cascade, and this is referred to as the systemic inflammatory response 
system. In some patients, the pro-inflammatory response may become over activated and 
several squeal can occur, including adult respiratory distress syndrome (ARDS), multi-
organ dysfunction (MODS), and possibly death. New innovations have led to the 
development of methods to perform coronary artery bypass without the use of the 
cardiopulmonary bypass machine, commonly referred to as OPCAB, and thus the side 
effects of the bypass circuit can be avoided. Several drug regimes are available to inhibit 
the inflammatory response and these will also be investigated. If the inflammatory 
response is inhibited or is not activated, it is theorized that the patient will recover 
quicker and thus require less nursing care hours and be discharged earlier. Therefore, 
costs of both surgical techniques, inflammatory responses, along with length of stay 
(LOS), will be the emphasis of this study. 
III. Description and Source of Research Subjects (e.g., human, animals, plants documents) 
The sampling criteria for the target population of this study is all elective, 
primary, coronary artery bypass candidates, of both genders, over the age of 18, who 
have not received any thrombolytic intervention (whether in the cardiac catheterization 
lab or anti-platelet therapy pre-operatively) currently admitted to Memorial Hospital, 
Chattanooga, Tennessee by local cardiac surgeons for C-CAB or OPCAB procedures. A 
convenience sample of the target population will be performed, as the choice of the 
procedure is dependant upon the surgeon's preference. All participants will have the 
ability to give written, informed consent. Exclusion criteria will include inability to give 
written, informed consent, anyone under the age of 18 years old, emergent procedures, 
multiple procedures (i.e. coronary artery bypass with valve replacement), exposure to 
thrombolytic agents, or desire to withdraw from study. Multiple or emergent procedures, 
along with exposure to thrombolytic agents can have adverse effects on variables being 
measured (amount of chest tube drainage, platelet counts, number of units of blood and 
blood products used) therefore the presence of these factors must preclude utilization of 
these participates. 
If human subjects are involved, please check any of the following that apply: 
Minors 
Prison inmates 
Mentally impaired 
Physically disabled 
X Institutionalized residents (Hospitalized patients) 
Vulnerable or at-risk groups, e.g., minority, poverty, pregnant women (or fetal 
tissue), substance abuse populations 
__ Anyone unable to make informed decisions about participation 
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If any of t/1e above is clzecked, proposal requires Level Ill review. Form B must be 
completed in addition to Form A. 
IV. Materials, Equipment, or Instruments 
All equipment and supplies used are those currently in use in the investigational 
institution. All methods and techniques are FDA approved. The inflammatory indicator 
samples are to be obtained from the laboratory or directly from the operating room as 
soon as possible after collection. These samples, IL-6, IL-10, will be taken to the 
Erlanger Research Cytokine Laboratory, where they will be centrifuged at 3000 xg for 
thirty minutes. The specimens will be stored at -20 degrees C until analysis. Two levels, 
MMP-2, MMP-9, will be transported to The Medical University of South Carolina for 
analysis (unable to be performed locally) at-70 degrees C. All samples will have 
identifying numbers only, as to protect the identity of the patients. 
V. Methods and Procedure 
The design chosen by this researcher is a quasi-experimental, comparative 
research design. The differing treatments, OPCAB, C-CAB, drug regimes, coatings of 
circuits, inflammatory response of each and finally operative costs are examined. 
There are five groups to be studied: control (utilizing y-bonded circuits) with 
Amicar (n = 30) and Aprotinin (n= 30); experimental (utilizing x-bonded circuits) with 
Amicar (n= 30) and Aprotinin (n= 30); and finally the OPCAB group (n= 30). A 
minimal sample of 30 for each group will be used to ensure adequate sample size for 
statistical analysis. Power analysis indicated appropriate minimal sample size per group. 
Utilization of statistical techniques will address the question involving possible error rate 
problems. 
Selection of the sample has been addressed and its group dependency has been 
shown. Ambiguity on the causality is prevented due to the number of laboratory samples 
per participant. Imitation of treatments is prevented by only using one circuit at a time 
and maintaining the protocols for each individual surgeon, as is currently being the in the 
research institute. 
The basic design of this study will not change any current treatment modalities 
that the patients would normally receive. The circuit coatings are not optional to the 
patient. All patients receiving treatment involving the cardiopulmonary circuit utilizes 
circuits that have the same coating, therefore interaction of selection and treatment is not 
a viable validity concern. 
VI. Sensitivity: Psychological discomfort or harm experienced by human participants 
because of topic under investigation, data collection, or data dissemination. 
On a scale of 0 (not sensitive) to 5 (extremely sensitive), rate the degree of sensitivity of 
the behavior being observed or information sought: 
_I_ Sensitivity of behavior to be observed or information sought. 
If greater titan "1 "proposal requires Level Ill review. Form B must be completed in 
addition to Form A. 
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VII. Invasiveness: Extent to which data collected is in public domain or intrusive of privacy 
of human participants within context of the study and the culture. 
On a scale of 0 (not sensitive) to 5 (extremely sensitive), rate the degree of invasiveness 
of the behavior being observed or information sought. 
_l_ Sensitivity of behavior to be observed or information sought. 
If greater than "1 "proposal requires Level Ill review. Form B must be completed in 
addition to Form A. 
VIII. Risk: Any potential damage or adverse consequences to researcher, participants, or 
environment. Includes physical, psychological, mental, social, or spiritual. May be part 
of protocol or may be a remote possibility. 
On scale of 0 (no risk) to 5 (extreme risk), rate the following by filling each blank. 
Extent of Risk To Self To Subjects To Environment 
Physical harm 
Psychological harm 
Mental harm 
Social harm 
0 ---
Spiritual harm _O_ 
1 0 -- --
0 --
0 --
0 
If any blank is greater tlza11 "1, "proposal requires level III review. 
completed in addition to Form A. 
IX. Benefit-Risk Ratio (Benefits vs. Risks of this Study) 
Form B must be 
The benefit of the study is that it will provide information of costs differences 
between OPCAB and C-CAB, and the related factors of circuit and pharmacological 
agents on inflammation and blood usage. As medical therapies advance and progress, it 
behooves us as medical professionals to continually evaluate the current advances in 
therapies available. Risks involved are minimal, since the therapies are all FDA 
approved and the surgeon's preferences will not be altered. 
X. Confidentiality/Security Measures 
Since informed consent is required, privacy is upheld, and any identifying factors 
will be removed from the data collection sheets. Identification will be kept confidential 
by the use of a coding system, known only to the principal investigators and supervisory 
faculty. All information will be publishable and the participants will acknowledge this in 
the informed consent. 
With the need to review records, personal information cannot be avoided. The 
researcher will provide complete confidentiality by the measures previously stated and by 
following the guidelines outlined by the National Institutes of Health (NIH). 
Only aggregate data will be reported and all data that is entered in to databases 
will be password protected, the original copies of the instrument will be under lock and 
key, and the names will be removed after the coding is completed. All data will be 
separated from the identifying factors and assigned codes so that the patient cannot be 
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linked to the data. Codes will be accessed only by the principal investigator(s) and 
secured under lock and key. Once the data has been entered into a database, the database 
will have a security code only known to the principal investigator(s). Data will be stored 
for a minimal period of three years in a locked safe, and then will be shredded and 
destroyed. 
XI. Informed Consent Process 
All participates will have the ability to give written, informed consent. Prior to 
data collection, permission will first be obtained from this researcher's thesis committee 
of the School of Nursing at Southern Adventist University (SAU). Permission will then 
be obtained from the Institutional Review Board at the participating institution. In 
addition, permission from the cardiac surgery group involved will be obtained, to include 
their patients in the study. 
__ Potential for coercion, which is considered any pressure placed upon another to 
comply with demand, especially when the individual is in a superior position. Pressure 
may take the form of either positive or negative sanctions as perceived by the participants 
within the context and culture of the study. 
__ Coercion or Deception involved. If so, explain. 
If either checked, proposal requires Level IV Full Review. 
XII. Debriefing Process 
Not applicable for this study. 
XIII. Dissemination of Findings 
_X_ Potential for presentation or publication outside of University. 
If so, proposal requires Level II Review. 
XIV. Compensation to Participants 
No compensation is awarded to either the participants or researchers involved in 
this study. 
Southern Adventist University 
Signature Page 
Form A 
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By compliance with the policies established by the Institutional Review Board of Southern Adventist 
University, the principal investigator(s) subscribe to the principles and standards of professional ethics in 
all research and related activities. The principal investigator(s) agree to the following provisions: 
• Prior to instituting any changes in this research project, a written description of the changes will 
be submitted to the appropriate Level of Review for approval. 
• Development of any unexpected risks will be immediately reported to the Institutional Review 
Board. 
• Copies of approval for off-campus sites of data collection will be obtained from the site and 
submitted in triplicate to the appropriate Level of Review prior to data collection. 
• Close collaboration with and supervision by faculty will be maintained by SAU student 
investigator. 
Principal Investigator Signature ____________________ Date __ _ 
Co-Principal Investigator(s) Signature __________________ Date __ _ 
* * * * * 
As the supervising faculty, I have personally discussed the proposed study with the 
investigator(s), and I approve the study and will provide close supervision of the project. 
Supervising Faculty/Sponsor Signature _______ a_________ Date __ _ 
(Required by all SAU student investigators) 
* * * * * 
As Dean/Chair, I have read the proposed study and hereby give my approval. 
Chair(s)/Dean(s) Signature ____________________ Date __ _ 
Date -------------------------------- ---(If Level II approval required) 
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Southern Adventist University 
RESEARCH APPROVAL FORM 
FormB 
This form is required in addition to Form A because of involvement of one or more of thefollowingfactors: 
1. At-risk participant populations 
2. Sensitivity 
3. Invasiveness 
4. Risk 
5. Deception 
Please answer the following question(s) as appropriate to the proposed research and submit 6 copies of 
Form A and Form B to Subcommittee Chair. If coercion or deception is involved, submission must be 
made to !RB for full review. · 
1. Describe the at-risk participant population. 
The sampling criteria for the target population of this study is all elective, 
primary, coronary artery bypass candidates, of both genders, over the age of 18, who 
have not received any thrombolytic intervention (whether in the cardiac catheterization 
lab or anti-platelet therapy pre-operatively). All participants will be in-patients at the 
participating hospital. 
Measures to be used to protect the participants from harm. 
All subjects will be protected from physical harm in that the specimens will be 
obtained from existing arterial ports and samples that are stored in the laboratory. No 
additional access or laboratory samples will be required from the participants. 
The very bases of this study, utilizing what is already FDA approved and 
currently in use, along with the institutions and surgeons' desires to provide the best 
possible care at the most economically feasible price provides the bases for protecting the 
participants from harm and discomfort. There are no investigational products in use. The 
researcher is simply interested in response of the participates in the areas previously 
noted as they are affected by the different techniques and protocols of the surgeons. 
None of the five categories identified by Reynolds in 1972, fit the nature of this study. 
2. Describe the sensitive nature of the topic under investigation, data collection, or data 
dissemination. 
The need to review records and personal information cannot be avoided since the 
records contain the research information (i.e. surgical technique, circuit used, drug 
regime, blood usage, etc.). 
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Safeguards that will minimize the sensitivity. 
The researcher can and will provide complete confidentiality by the measures 
previously stated, and by following the guidelines outlined by the National Institutes of 
Health (NIH). Any data that is entered in to databases will be password protected, the 
original copies of the instrument will be under lock and key, names will be removed 
when the coding is complete. 
3. Describe the degree of invasiveness. 
The only invasive procedure, other than the actual surgical procedure, is the 
collection of blood samples from an existing arterial port. No invasive procedures will be 
incurred that are not usual for normal C-CAB or OPCAB. 
4. Describe the degree of risk. 
There is no risk involved to the subjects other than is customary for patients 
undergoing C-CAB or OPCAB surgeries. Standardization of the five groups as for equal 
treatment will be controlled during the planning phase all the way through the 
implementation phase by providing exact instructions as for when testing is done and 
what parameters are being studied (type of case, time factors, costs, length of stay). 
Precautions that will minimize harm. 
All supplies and medication utilized are FDA approved and are in use at 
participating institution, with the exception of the different bypass circuit, currently under 
evaluation. 
5. Describe the use of coercion and/or deception. 
NIA 
Justify its use in this project. 
NIA 
Safeguards that will minimize harm. 
See Precautions Section. 
Signature Page 
FormB 
127 
By compliance with the policies established by the Institutional Review Board of Southern Adventist 
University, the principal investigator(s) subscribe to the principles and standards of professional ethics in 
all research and related activities. The principal investigator(s) agree to the following provisions: 
• Prior to instituting any changes in this research project, a written description of the changes will 
be submitted with 6 copies to the appropriate Level of Review for approval. 
• Development of any unexpected risks will be immediately reported to the Institutional Review 
Board. 
• Copies of approval for off-campus sites of data collection will be obtained from the site and 
submitted in triplicate to the appropriate Level of Review prior to data collection. 
• Close collaboration and supervision by faculty will be maintained. 
Principal Investigator 
Co-Principal Investigator(s) Signature ________________ Date __ _ 
* * * * * 
The IRB Subcommittee has reviewed the proposal and hereby grants approval to the project. 
Name of IRB Subcommittee -------------------------
Subcommittee Chair Signature ___________________ Date. __ _ 
(If Level III approval required) 
* * * * * 
The IRB has reviewed the proposal and hereby grants approval to the project. 
IRB Chair Signature ________________________ Date. __ _ 
(If Level IV approval required) 
January 27, 2003 
Mr. Michael M. Wyckoff, R.N., C.C.P. 
Department of Perfusion 
Memorial Hospital 
2525 DeSales A venue 
Chattanooga, TN 37404 
Dear Michael: 
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SOUTHERN 
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P.O. Bnx 370 
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Tenne>><:e '7.l 15 
423.2lfl.21 ll 
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The Human Participants in Research Subcommittee has approved your research application 
"Comparative Analysis a/Coronary Artery Bypass: Costs o/Off Pu11f{J vs. Conventional Techniques with 
Variab{v Bonded Circuits and Drog Strategies". Investigating the modes of treatment for post coronary 
bypass surgery will benefit future patients and improve recovery after surgery. 
The research project is well designed and ensures confidentiality of the individuals involved in your 
study, and I am delighted to approve your project. 
Linda Ann Foster, Ph.D., Chair, Human Participants in Research Subcommittee 
Associate Professor, Biology Department 
Southern Adventist University 
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Title: Comparative Analysis of Coronary Artery Bypass: Costs of Off-Pump vs. 
Conventional Techniques with Variably Bonded Circuits and Drug Strategies. 
(CABOCS) 
I. Identification of Project: 
Principal Investigators: 
James Zellner, M.D., Assistant Professor, 
University of Tennessee College of Medicine, Chattanooga Unit; 
Alliance of Cardiac, Thoracic and Vascular Surgeons 
Chattanooga, Tennessee 37404 
(423) 624-5200 
Michael M. Wyckoff, R.N., C.C.P. 
Candidate MBA I MSN, Southern Adventist University 
Pager: ( 423) 655-4622 
E-mail: Michael Wyckoff@Memorial.org 
Department: School of Nursing 
Faculty Supervisor: David Gerstle, PhD, RN 
Starting Date: Fall, 2002 
Completion Date: Fall, 2003 
II. Purpose of Study 
The purpose of this study is to examine and compare costs of differing 
treatment modalities for coronary artery bypass surgery, including off-pump 
coronary artery bypass (OPCAB) and conventional coronary artery bypass (C-
CAB). When the use of C-CAB is indicated, there are numerous circuit coatings 
available, along with drugs like Aprotinin, to decrease the inflammatory response 
associated with the exposure of the body to the bypass circuit. Exposure of the 
body to the cardiopulmonary bypass circuit has been shown to activate the pro-
130 
inflammatory arm of the immune system, as well as the coagulation cascade, and 
this is referred to as the systemic inflammatory response system. In some 
patients, the pro-inflammatory response may become over activated and several· 
sequellae can occur, including adult respiratory distress syndrome (ARDS), multi-
organ dysfunction (MODS), and possibly death. New innovations have led to the 
development of methods to perform coronary artery bypass without the use of the 
cardiopulmonary bypass machine, commonly referred to as OPCAB, and thus the 
side effects of the bypass circuit can be avoided. Several drug regimes are 
available to inhibit the inflammatory response and these will also be investigated. 
If the inflammatory response is inhibited or is not activated, it is theorized that the 
patient will recover more quickly and thus require less nursing care hours and be 
discharged earlier. Therefore, costs of both surgical techniques, inflammatory 
responses, along with length of stay (LOS), will be the emphasis of this study. 
In the current realm of reimbursement, cost issues lead a predominant role 
in patient care. The supplies used influence the costs incurred for surgical 
procedures. OPCAB has been widely embraced due to the "lower" costs by 
eliminating the cardiopulmonary bypass ( apiece of the puzzle. The actual 
hospital costs to perform the off-pump procedure may not show the actual savings 
once thought. The "specialized" retractor system ( aand the necessary 
connector systems (requiring 2-4@ aeach) to make the procedure truly 
"clampless", may in reality incur more costs than they conserve. 
Finally, by documenting the inflammatory response for each category of 
procedure, including drug therapies, it may reveal the inflammatory response to 
the actual surgical procedure, and not just exposure to the bypass circuit, as the 
leading culprit in initiating this response. 
III. Description and Source of Research Subjects (e.g. humans, animals, plants, and 
documents) 
The sampling criteria for the target population of this study is all elective, 
primary, coronary artery bypass candidates, of both genders, over the age of 18, 
who have not received any thrombolytic intervention (whether in the cardiac 
catheterization lab or anti-platelet therapy pre-operatively) currently admitted to 
Memorial Hospital, Chattanooga, Tennessee by'local cardiac surgeons for C-CAB 
or OPCAB procedures. A convenience sample of the target population will be 
performed, as the choice of the procedure is dependant upon the surgeon's 
preference. All participants will have the ability to give written, informed 
consent. Exclusion criteria will include inability to give written, informed 
consent, anyone under the age of 18 years old, emergent procedures, multiple 
procedures (i.e. coronary artery bypass with valve replacement), exposure to 
thrombolytic agents, or desire to withdraw from study. Multiple or emergent 
procedures, along with exposure to thrombolytic agents can have adverse effects 
on variables being measured (amount of chest tube drainage, platelet counts, 
number of units of blood and blood products used) therefore the presence of these 
factors must preclude utilization of these participates. 
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IV. Materials, Equipment, or Instruments 
All equipment and supplies used are those currently in use in the 
investigational institution. All methods and techniques are FDA approved. The 
inflammatory indicator samples are to be obtained from the laboratory or directly 
from the operating room as soon as possible after collection. These samples, IL-
6, IL-10, will be taken to the Erlanger Research Cytokine Laboratory, where they 
will be centrifuged at 3000 xg for thirty minutes. The specimens will be stored at 
-20 degrees C until analysis. Two levels, MMP-2, MMP-9, will be transported to 
The Medical University of South Carolina for analysis (unable to be performed 
locally) at-70 degrees C. All samples will have identifying numbers only, as to 
protect the identity of the patients and will be transported to the specific 
institutions via Saf-T-Pak® containers utilizing the Comprehensive Guide to 
Shipping Infectious Substances guidelines. 
The costs incurred from the laboratory testing will be minimal as the 
researcher will be assisting the director of the Cytokine Laboratory and all testing 
in South Carolina has been volunteered without cost except shipping. 
V. Methods and Procedures 
The design chosen by this researcher is a quasi-experimental, comparative 
research design. The differing treatments, OPCAB, C-CAB, drug regimes, 
coatings of circuits, inflammatory response of each and finally operative costs are 
examined. 
There are five groups to be studied: control (n= 60) utilizing y-bonded 
circuits, 30 subjects using Amicar and 30 subjects using Aprotinin; experimental 
group (n= 60) utilizing x-bonded circuits, 30 subjects using Amicar and 30 
subjects using Aprotinin; and finally the OPCAB group (n= 30). A minimal 
sample of 30 for each group will be used to ensure adequate sample size for 
statistical analysis. Power analysis indicated appropriate minimal sample size per 
group. Utilization of statistical techniques will address the question involving 
possible error rate problems. 
Selection of the sample has been addressed and its group dependency has 
been shown. Ambiguity on the causality is prevented due to the number of 
laboratory samples per participant. Imitation of treatments is prevented by only 
using one circuit at a time and maintaining the protocols for each individual 
surgeon, as is currently being the in the research institute. A double-blinded study 
is not appropriate due the near impossibility of maintaining the appropriate bypass 
machines available at all times for emergent procedures. 
The basic design of this study will not change any current treatment 
modalities that the patients would normally receive. The circuit coatings are not 
optional to the patient. All patients receiving treatment involving the 
cardiopulmonary circuit utilizes circuits that have the same coating, therefore 
interaction of selection and treatment is not a viable validity concern. 
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VI. Sensitivity 
There is miniscule risk of harm or discomfort by human participants 
because the topic under investigation, data collection and data dissemination pose 
minimal risks. The risks involved are only those inherent to the actual surgical 
procedure. 
VII. Invasiveness 
The extent, to which the data collection is intrusive of privacy of human 
participants within the context of this study, is limited to laboratory collection 
from an existing arterial line and minimized to information accessed from the 
medical record. 
VIII. Benefit-Risk Ratio (Benefits vs. Risks of this Study) 
The benefit of the study is that it will provide information of costs 
differences between OPCAB and C-CAB, and the related factors of circuit and 
pharmacological agents on inflammation and blood usage. As medical therapies 
advance and progress, it behooves us as medical professionals to continually 
evaluate the current advances in therapies available. Risks involved are minimal 
in addition to those already associated with the surgical procedure since the 
therapies are all FDA approved and the surgeon's preferences will not be altered. 
IX. Confidentiality/Security Measures 
Since informed consent is required, privacy is upheld, and any 
identifying factors will be removed from the data collection sheets. Identification 
will be kept confidential by the use of a coding system, known only to the 
principal investigators and supervisory faculty. All information will be 
publishable and the participants will acknowledge this in the informed consent. 
With the need to review records, personal information cannot be avoided. 
The researcher will provide complete confidentiality by the measures previously 
stated and by following the guidelines outlined by the National Institutes of 
Health (NIH). 
Only aggregate data will be reported and all data that is entered in to 
databases will be password protected, the original copies of the instrument will be 
under lock and key, and the names will be removed after the coding is completed. 
All data will be separated from the identifying factors and assigned codes so that 
the patient cannot be linked to the data. Codes will be accessed only by the 
principal investigator(s) and secured under lock and key. Once the data has been 
entered into a database, the database will have a security code only known to the 
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principal investigator(s). Data will be stored for a minimal period of three years in 
a locked safe, and then will be shredded and destroyed. 
X. Informed Consent Process 
All participants will have the ability to give written, informed consent. 
Prior to data collection, permission will first be obtained from this researcher's 
thesis committee of the School of Nursing at Southern Adventist University 
(SAU). Permission will then be obtained from the Institutional Review Board at 
the participating institution. In addition, permission from the cardiac surgery 
group involved will be obtained, to include their patients in the study. 
There is no potential for coercion, which is considered any pressure placed 
upon another to comply with demand, especially when the individual is in a 
superior position. Pressure may take the form of either positive or negative 
sanctions as perceived by the participants within the context and culture of the 
study. 
XI. Debriefing Process 
Not applicable for this study. 
XII. Dissemination of Findings 
The communication of the findings of this study will provide direction for 
further research involving the techniques and protocols involved. All information 
communicated will be de-identified if published. Presentation of the collected 
data, through nursing seminars and educational meetings is an excellent method to 
propagate the information. 
XIII. Compensation to Participants 
No compensation is awarded to either tlie participants or researchers 
involved in this study. 
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James Zellner, MD 
Alliance of Cardiac, Thoracic and Vascular Surgeons 
605 Glenwood Drive, Suite 405 
Chattanooga TN 37404 
RE: Our Study # 02-11-02 
Dear Dr. Zellner: 
Protocol Title: Comparative Analysis of Coronary Artery Bypass: Costs of Off-Pump 
vs. Conventional Techniques with Variably Bonded Circuits and Drug Strategies 
{CABOCS) 
Memorial Hospital Institutional Review Board (IRS) is a duly constituted IRB in 
accordance with the requirements of the Federal Food, Drug and Cosmetic Act as 
specified in regulations 21 CFR part 56, and the requirements of the ICH Guideline for 
Good Clinical Practice. As Chairman of the Memorial Hospital IRS, I hereby certify that 
this action of the Board was taken in accordance with these regulations for the 
protection of human subjects. 
This letter is to advise you that the above referenced study was presented to the 
Memorial Hospital IRB on November 12, 2003. The Board approved this study for 
twelve months. Beverly Gordon and Margie Lawson will meet with Mr. Wycoff to help 
with standard consent language and decide on the best way to recruit participants to 
comply with HIPAA regulations. 
A request for continuation with a copy of the current informed consent must be 
submitted to the IRB for review at least one montb prior to the expiration date of 
11/11/2003. 
Please keep the Board apprised of any untoward effects associated with this study. If 
you have any questions, don't hesitate to contact me at 423-495-6375 or Margie 
Lawson, Human Protections Administrator at 423-495-6198. 
Sincerejy 
Christine W. Parker, MD 
Chairman, Institutional Review Board 
2525 de Sales Avenue Chattanooga, TN 37404· 1102 Phone 423.495.2525 
Title: 
AllIANCE OF CARDIAC 
ThoRA9C.,.C' -
VASCUl.AR aV
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Informed Consent for: 
Name 
Comparative Analysis of Coronary Artery Bypass: Costs of Off-Pump vs. 
Conventional Techniques with Variably Bonded Circuits and Drug Strategies. 
(CABOCS) 
Participants: 
Memorial Health Care Systems 
Alliance of Cardiac, Thoracic and Vascular Surgeons 
Southern Adventist University 
Principal Investigators: 
James Zellner, M.D., Assistant Professor, 
University of Tennessee College of Medicine, Chattanooga Unit; 
Alliance of Cardiac, Thoracic and Vascular Surgeons 
Chattanooga, Tennessee 37404 
( 423) 624-5200 
Michael M. Wyckoff, R.N., C.C.P. 
MBAc/MSNc 
Southern Adventist University 
Pager: ( 423) 655-4622 
E-mail: Michael Wyckoff@Memorial.org 
Introduction: 
Your surgeon is asking you to participate in a research study during your 
heart surgery hospitalization. Before agreeing to participate, it is important that 
you read and understand the information presented in this consent form. The 
consent form describes the purpose, procedures, benefits, risks, discomforts and 
precautions of this study. 
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It also describes the alternative procedures that are available to you and your right 
to withdraw from the study at any time. No guarantees or assurances can be made as 
to the results of the study. 
If you are not completely truthful with your doctor regarding your health history, 
you may harm yourself by participating in this study. 
If you have any questions after reading this form, ask a doctor or investigator 
from the study to explain. You should not sign this form until vou are sure vou 
understand all the facts. 
You may want a friend or family member to read the form and talk with the 
doctor with you. They have the right to discuss the research with the doctors or 
researchers from the study. You can also talk to your regular doctor about what you 
should do. Talking things over can help you make your decision. You will be given a 
copy of this signed and dated form. 
Background and Purpose of the Study 
You are being asked to volunteer for a research study involving different ways of 
performing open-heart surgery, including bypass machines and drug therapies currently 
used by your surgeons. Heart bypass surgery is sometimes associated with side effects, 
such as, chest pain, heart attacks, heart failure, or impairment of memory, language, and 
motor skills. The purpose of this study is to determine any differences in therapies (with 
or without the bypass machine), costs involved with these therapies, time spent in the 
hospital with each, and the possible differences between drugs chosen by your doctor. 
All therapies used, including the bypass machine, drugs and surgical techniques, are 
approved by the Food and Drug Administration. 
Approximately 150 people will participate in this study at this hospital. You may 
be able to participate if you qualify on the bases of your medical history, your surgeons' 
approval, and certain medical qualifications. 
This study consists of two phases. Phase One will involve the use of the current 
bypass machine if your doctor chooses to use it; Phase 'Fwo will involve the use of the 
FDA approved Minimized ExtraCorporeal Circulation System (MECC) with the Bioline 
Coating ®. Use of the different bypass machines is based entirely upon the phase of the 
study in which you are being asked to enroll. 
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Length of the Study 
Your surgical therapy will be based entirely upon your surgeons' protocol and 
will not be affected in any way or means by this study. Use of the different bypass 
machines is based entirely upon the time of the study in which you are being asked to 
enroll. 
The blood work will be drawn after you are asleep in surgery from an existing 
arterial access line, and 6 hours after completion of the operation. Information will be 
collected from your medical record for the duration of your time in the hospital. The 
study will be closed when 150 subjects have successfully completed the protocol. After 
leaving the hospital, there will be no further follow-up needed, thus all participants will 
have completed the study. 
Procedures 
As a participant in this study, you will have certain procedures performed. All of 
these procedures are part of the usual care patients receive who has open-heart surgery. 
During your hospital stay, some additional things will be done to help in the study. This 
includes obtaining information from your medical records and taking extra blood to be 
studied (about 10 tablespoons) throughout the course of your hospitalization. This is not 
part of the usual course of treatment during your care for your heart bypass surgery. 
After leaving the intensive care unit, there will be no further contact with the 
researcher(s). 
If your are a woman of child-bearing age, there is no additional risks involved 
with this study other than the usual risks involved with the surgical procedure as 
explained by your doctor. 
In the event that your doctor chooses to use the bypass machine, the type of 
machine used is random, according to which phase the study is in reflected upon your 
enrollment time and the duration of the study. 
Risks 
• There are no added risks beyond those normally associated with open-heart 
surgery. 
• All of the blood samples (3) will be drawn at the same time for both the study 
and your usual care. The blood samples will be taken from an existing line 
used in all open-heart procedures. 
You may want to talk about tlze risks and benefits witlt your doctor and otlter people 
you trust. If you ltave any questions, ask a doctor or researcher from tlte study. 
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Alternate Therapy 
Taking part in this study - or saying no - is up to you. If you do not participate, 
you may undergo your heart bypass surgery in the usual fashion. There are no other 
approved additional treatment therapies available at this time. 
Benefits 
who take part in studies help advance knowledge and treatment. Many 
people may be helped if the study shows benefits from the different therapies. 
You may QI may not benefit from the study related tests and procedures. 
Withdrawal From the Study 
Your participation in this study is purely voluntary. You may refuse to participate 
or withdrawal from this study at any time without the loss of any benefits to which you 
are entitled or without affecting your future medical care. There will be no change in 
your medical care or eligibility to participate in future research studies. If you withdraw 
from this study, please be aware that all information about you will be removed from the 
study. 
Responsibility for Costs 
The sponsors will pay for all the costs of the procedures that are unique to this 
study. You and I or your insurance company are responsible for the other, regular costs 
of a bypass operation and care. 
Confidentially: 
Every effort will be made to keep your personal information confidential. We 
cannot guarantee absolute confidentiality. Your personal information may be disclosed if 
required by law. 
If the study results are published, steps will be taken to make sure that no one will 
be able to tell you participated. Records of your participation in the study will be kept in 
a locked file in the principal researchers computer and possession. The confidentiality of 
the researchers computer is carefully guarded. Your research records will contain 
portions of your medical history, reports from your surgical procedure and possible 
treatments and results of your blood tests. Information collected, as part of the research 
study may also be included in your medical records 
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• Memorial Hospital Investigational Review Board (IRB), a group of people who 
review the research study to protect your rights; 
• Southern Adventist University School of Nursing Thesis Committee, a group of 
faculty who ensures the research project is conducted in and ethical and 
professional manner; 
• The blood analysis centers, Erlanger Research Cytokine Laboratory and The 
Medical University of South Carolina, centers providing laboratory services; 
• Government agencies including the Food and Drug Administration (FDA) and the 
Office of Human Research Protections (ORHP) can review the research to see 
that it is being conducted safely and correctly. 
Authorization to Share Personal Health Information in Research: 
The word "you" means both the person who takes part in the research, and the 
person who gives permission to be in the research. You are being asked to take part in 
the research described in the attached consent. To do so requires health information that 
identifies you that must be collected while you participate in this research study. 
Information from your medical record will be collected as well as results of tests as 
described above. Only information needed for the research will be collected. This 
information is described in the attached consent form. For you to be in this research, 
your permission to collect and share this information is required. 
To do the research described in the informed consent, health information about 
you will be collected and shared. By law, you must be told how information will be 
obtained and your permission is required. The following information will be collected: 
• The results of the blood work performed on you 
• The results of the clinical data collected from your medical record as required in 
the research study 
This information will be provided to CABOCS Research and The Medical 
University of South Carolina or investigators in above described places. It will only be 
given with a study number identifying you. This number will be kept confidential by the 
investigator(s) in charge of the research at this hospital. 
Your health information may be shared with people at the hospital who help with 
the research, and may be shared with researchers outside the participating institution(s). 
Some of these people are ensuring the research is conducted properly. 
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The "confidentiality" portion of this form lists these people. Some of these 
people may share your health information with someone else. If they do so, the same 
laws may not protect your health information. 
This authorization to release personal health information, and information in your 
medical records, may need to be collected or examined by: 
• Persons from the Memorial Hospital Institutional Review Board (IRB) 
which approves and monitors research 
• Persons from the Food and Drug Administration (FDA), in the event it 
decides to examine the way the research was done 
• Persons from the Office of Human Research Protections (OHRP) if they 
decide to examine the conduct of research 
• Persons from the Southern Adventist University if they decide to examine 
the conduct of research 
When these outside people decide to look at your information, they are not 
allowed to record any information in any way that will identify you. If CABOCS 
Research discloses your information, the researcher(s) are obligated to follow the same 
laws and your information must remain confidential. 
If you sign this form, your health information will be collected until the end of the 
research. Some information from your medical records may be collected after your direct 
participation in the research project ends. Some of the information will be kept for a long 
time, in case we need to look at it again. Information about you will be kept as 
confidential as possible 
Information about you will be collected until the end of the research. Information 
may also need to be collected from your medical record after the research tests are done. 
Your information may also be useful for other studies [research]. Your information can 
only be used again if a special committee in the hospital gives permission. This 
committee may require you to give your permission again before doing the research. But 
the committee may also allow the research to be done without talking to you again, if 
your health information is kept private [confidential]. . 
If you sign this form, you are giving permission to collect, use and share your 
health information. This permission to use your health information does not have an 
expiration (ending) date. You do not need to sign this form. If you decide not to sign this 
form, you cannot be in the research study. You need to sign this form and the attached 
consent form if you want to be in the research study. Research cannot be done unless 
your health information can be collected, used and shared. 
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To be in this research, you have to sign this form, giving permission to gather and 
share your information. If you change your mind later and do not want your health 
information collected or shared, you need to send a letter to the researcher at the 
following address: 
CABOCS Research 
James Zellner, M.D. 
Alliance of Cardiac, Thoracic and Vascular Surgeons 
605 Glenwood Drive 
Suite 405 
Chattanooga, Tennessee 37405 
The letter needs to say that you have changed your mind and do not want the 
researcher to collect and share your health information. You may also need to leave the 
research study if you do not want your health information collected. Health information 
collected before you withdrew may still be used. The research benefits from information 
obtained from everyone who starts a research study, not just those people who stay in it. 
If you do, you may need to leave the research study if all the necessary 
information has not been collected. We will tell you if this is the case. We may still use 
the information we have already collected. We need to know what happens to everyone 
who starts a research study, not just those people who stay in it. 
Your Name Will Not Be Made Public 
If you agree to take part, your medical records will be treated confidentially 
accept as required by law. The representatives of this study, including the institutions 
performing any laboratory studies, may look at your study related records. 
You agree to the collection, processing, transfer and storage of your personal data 
relevant to this study by the researchers and their appointed entities. Your personal data 
is information about you, but does not identify you by name. All reasonable steps will be 
taken to ensure your data is protected and that confidentially is maintained. 
You agree to authorize the Erlanger Research Cytokine Laboratory, The Medical 
University of South Carolina, and their representatives, to perform laboratory studies on 
your blood specimens as described above. Also, you agree that the principle 
researcher(s) can have access to, and obtain information from your medical records, that 
is pertinent to this study. The information obtained will be combined with other 
information collected from other patients enrolled in this study, and you will not be 
identified. Your personnel data will never be presented to anyone, either in written from 
or in a speech. 
The results of this study will be analyzed and may then be published in the 
medical literature. This may take up to 1-2 years after the study is complete. You will 
not be identified in any report or publication. 
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Emergency Contact I IRB Contact 
This study has been reviewed by and approved of by the Institutional Review 
Board (IRB) I Independent Ethics Committee (IEC) of both the participating institutions. 
During this study, if you have any additional questions about this study, please contact 
Michael M. Wyckoff, R.N., C.C.P. at (423) 655-4266. If you have any questions 
regarding your rights as a research subject, please contact Margie Lawson at ( 423) 495-
6168 with the Memorial Hospital Institutional Review Board. 
Voluntary Participation I Withdrawal 
You understand that being in this study is voluntary. If you decline to be in, or 
later withdraw from this study, your health care will not suffer in any way. 
The study researcher(s) can stop your study for any of the following reasons: 
• Your health changes in other ways 
• The researchers stop the study 
• Knowledge of unexpected or unexplained adverse events that affect patient safety 
Your doctor, the Institutional Review Board I Independent Ethics Committee, and 
the researcher(s) may remove you from the study at any time without your consent. If 
you withdraw, or are withdrawn from this study, any and all of your information will be 
removed from the data bank and destroyed. 
Patient Details 
Patient Initials: 
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Consent 
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I have been informed of the reasons for this study and: 
• Had the study requirements explained to me 
• Had all of my questions answered 
• Have carefully read this consent form, and understand that I will receive a 
signed and dated copy 
• Confirm that I give voluntary consent to participate in this study 
• Will allow direct access to my medical records, but understand these 
records will be used confidentially, except as required by law 
I understand that: 
• The study researcher(s) I participating institutions will not receive any 
reimbursement for conducting this study 
• My participating in the study is voluntary and that I can refuse to 
participate or ask to be withdrawn at any time without giving a reason, 
without my medical care or legal rights being affected. 
I want to participate in this study, and freely agree to take part. I agree that the 
researcher(s) may keep, publish, or dispose of the results of this study. 
Signature of person giving consent 
(Patient or legally authorized representative) 
Signature of Person Conducting the Consent Discussion 
Day 
Day 
Month Year Time 
Month Year Time 
a
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ADVENTISTUNIVERSITY
December 30, 2002 
The Alliance of Cardiac, Thoracic & Vascular Surgeons 
605 Glenwood Drive 
Suite405 
Chattanooga, Tennessee 37404 
Dear Sirs: 
As a candidate for a MBA I MSN, I have chosen to do my thesis on a subject involving all of my professional 
interests, perfusion, nursing, and business. The proposed research study, Comparative Analysis of Coronary 
Artery Bypass: Costs of Off-Pump vs. Conventional Techniques with Variable Bonded Circuits and Drug 
Strategies (CABOCS), will begin data collection within the next few weeks upon your approval. 
Please indicate your choice as follows to approach your patients to pa 
/ 
;:L'.I"'Cf;':nsideration. 
Michael M. Wyckoff, -a61C.C.P. 
cc: School of Nursing, SAU.; Margie Lawson, CIM, Memorial Hospital I.RB.; Jackie Jackson, R.N., 
Director Surgical Services; Joe Fischer, Administrator, Alliance of Cardiac, Thoracic & Vascular 
Surgeons. 
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Cine-Med® 
CE1l(fl!FIC5tTE 0 !F SUCCESSFULCOMPLETIONAN
APPROVEDCONTINUINGEDUCATION ACTIVITYI I 
Michael Wyckoff 
7625 Watercrest Drive 
Harrison, Tn 37341 
SUCCESSFULLYCOMPLETED
HUMANPARTICIPATION PROTECTION EDUCATION 
FOR RESEARCH TEAMS 
Code Number ND /013-624-624 
Contact Hours: 1.5 
Date of Completion: 3/ 4/02 
National Institute of Health, National Cancer Institute 
Rockville, MD. 
Authorized by: 
Brian Mozelak 4/1/02 
Director, Continuing Medical Education 
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· 127 Main Street North, Woodbury, CT 06798 Phone: (203) 263-0006 Fax: (203) 263·4839 www.cine·med.oom 
t CATHOLIC HEALTH INITIATIVES 
Memorial 
Health Care System 
Certificate of Completion 
is hereby granted to: 
Michael Wychoff 
for satisfactory completion of 
Research Training Modules 
Julv 24. 2002 
Date 
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RECORD I CERTIFICATE OF TRAINING 
( 
for the Transportation of Dangerous Goods 
Michael Wyckoff 
has completed the training and testing for the handling I offering for transport I transporting 
of dangerous goods as indicated below. 
Trained As Per 49CFR 172.700 / IATA 1.5 
J 
Part 6, Chapter 1 of ICAO Technlcal Instructions 
TDGR 9.2 Training Material Used 
Employee's Signature 
SAF·T·PAK INC. 
10807 182 Street 
Edmonton, AB T5S 1J5 
(lffJ 
; 
Saf·T-Pak's "The 2002 Comprehensive Guide 
to Shipping Infectious Substances" 
Materials Covered for Class/Div 6.2 & 9 
Classification and Identification 
Nature and Characteristics 
Packaging Requirements 
Marking and Labeling requirements 
Documentation Requirements 
Special Precaution Requirements 
Reporting Requirements 
Emergency Action Requirements 
Safety Requirements 
Date of Training Completion 
Date of a;-OLU\(IATA 1.5.0.3 expires 24 months) 
INC. 
·--- .. --------· --· ----- -·--·-·--- .. 
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OJOSCrO® 
June 3, 2003 
Dear Chief Perfusionist, 
On May 22, 2003, a press release was issued announcing Getinge AB had 
signed an agreement to acquire 100% shares of Jostra AG contingent on the 
approval of the German anti-trust authorities. The acquisition is by the Surgical 
Systems Division. · 
The Getinge group is a leading global provider of equipment and systems to 
customers within health care, extended care and pharmaceutical 
industries/laboratories. 
This acquisition does not include Jostra Corp. or Jostra Inc. It has been 
confirmed to us that the agreement includes that Jostra Corp. will continue to 
have access to all the products that it had been acquiring from Jostra AG and its 
subsidiaries. We have not been a part of Jostra AG since last year and therefore 
this acquisition has no affect on us. 
Specifically, we will continue to be able to supply you with the heart lung 
machines, oxygenators, reservoirs, cannula, filters and all other products 
acquired from Jostra AG and were not making in our Anasco, Puerto Rico, or 
Woodlands, Texas facilities. Lars Sunnanvaeder, founder and owner of Jostra 
Corp., will visit our Woodlands facility within the next couple of weeks and will 
address all issues. Of course, if there would be any change to the above, you as 
our valued customer, woul.d be immediately notified. 
Once again, we appreciate your business. If you have any questions, SKaDVHcall 
your Customer Service Representative at 1-800-854-0567. 
Sincerely, 
Michael J. Soma 
3UHaLGHQW
JP;stfa Corp. 
-RVWUDInc. 
Jostra Corp. 
2828 N. Crescent Ridge Drive• The Woodlands, TX n381 
Phone: (800) 955-4236 • Fax: (888) 570-4009 
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June 3, 2003 
Dear Chief Perfusionist: 
Jostra Corp. has made the decision to focus our development, manufacturing and 
marketing resources on minimized bypass systems, clinical data management, heart lung 
machines and other leading technologies to help you and your CV Surgical Team provide 
better patient outcomes. Due to current economic conditions of the marketplace, we are 
adapting our business to what we believe is the future of perfusion and the advancement of 
cardiac surgery. 
This month, Jostra Corp. will launch the first version of ReadySystem® MECCTM, the 
minimized bypass system. An early version of this has had tremendous success in Europe 
with currently over 4,000 successful cases. We are currently spending a great deal of our 
resources on the second and third generations of this product We hope the second 
generation will be ready for launch within the next four to six months. We strongly feel this 
will be the "Future of Perfusion." 
In addition to Jostra Carp's direct investment in the future, the following alliances have been 
formed: 
• We have recently signed distribution agreements with ARMUS to provide an 
advanced data acquisition, data management and outcomes reporting software. 
• We have also signed a distribution agreement with Surge Medical as our exclusive 
distributor of our cannula and sucker products. 
• We are in the final process of signing a licensing agreement with Surge Medical as 
an R&D arm for future innovative products in that area. As most of you may or may 
not be aware, Surge Medical is made up of the founder and key management team 
of OLP which was a major market holder of these types of products. 
• We have signed an exclusive distribution agreement with Termatrek and will by 
launching IRIS IV to the US market IRIS IV is the first intraoperative infrared 
imaging camera for CABG which will set a new standard of care for allowing the 
cardiac surgeon to noninvasively visualize flow and stenosis in coronary arteries and 
coronary grafts. 
• We are also in final negotiations and a letter of intent has been signed to work with 
Somanetics. 
Jostra Corp. has the most advanced products in the cardiopulmonary market. We continue 
to invest more resources into research and development in products such as the second and 
third versions of our minimized bypass system. In trying to bring innovative and creative 
devices to you and your CV Surgical Team, it is disappointingly clear that we cannot 
continue to support two manufacturing facilities in Anasco, Puerto Rico, and The Woodlands, 
Texas. We also do not believe that the current Bentley line which consumes a significant 
amounts of our financial and human resources, is our future. We have not been successful 
in expanding that line and the margins on that business do not allow us to focus on bringing 
new and better products to the market to improve patient outcomes. 
Jostra Corp. 
2828 N. Crescent Ridge Drive· The Woodla.nds, TX 77381 
Phone: (800) 955-4236 • Fax: (888) 5704009 
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As a result of our focused efforts on the future of perfusion, we have decided to stop 
manufacturing custom tubing packs and will be closing our Anasco, Puerto Rico facility. 
Enclosed with this letter is a listing of your current quantity of custom tubing packs that we 
are able to supply you, either RQWKHaVKHOIor work in progress, If applicable for you. You will' 
be contacted by your individual Jostra sales representative to discuss your available 
inventory. Therefore, effectively, we are no longer in the custom tubing pack business. 
By the time you receive this letter we will have notified our competitors so that we can do 
everything possible to help you in transitioning to another supplier. We will also presenting 
to our competitors options to use our Woodlands custom tubing area in case there is a need, 
due to non-availability in their current facilities, to handle additional manufacturing of these 
packs. Again, we will do everything possible to help in this transition. 
Please feel free to contact your Jostra Sales Representative or your Customer Service 
Representative at 1-800-854-0567. 
Sincerely, 
Michael J. ]
President 
Jostra Corp. 
Jostra Inc. 
Jostra Corp. 
2828 N. Crescent Ridge Drive • The Woodlands, TX 77381 
Phone: (800) 955-4236 • Fax: (888) 570-4009 
152 
153 
APPENDIXE 
American Heart Association Abstract Submission 
154 
Differential effects of serine protease inhibitors on MMP release in 
patients following cardiopulmonary bypass 
Robert E. Stroud, Arny E. Hardin, Michael M. Wyckoff, James L. Zellner, John S. 
lkonornidis, Francis G. Spinale. 
Background: Cardiopulmonary bypass (CPB) is a requirement for a number of 
cardiac procedures, but can elicit an inflammatory response and the release of 
proteolytic enzymes, such as the matrix rnetalloproteinases (MMPs). The 
release and activation of MMPs can be initiated by a number of serine proteases, 
such as plasrnin. Accordingly the present study examined the effects of the 
plasrnin fibrinolytic inhibitor, epsilon-arninocaproic acid (EACA), and the serine 
protease inhibitor, Aprotinin (APRO), on plasma MMP profiles following CPB. 
Methods: ProMMP-2 and proMMP-9 plasma levels were measured in CPB 
patients with EACA (n=30) or APRO (n=30) prior to CPB, at separation (post 
CPB) and 6 hours post CPB. All patients were equivalent with respect to cardiac 
surgery type and randomized to either treatment. All MMP levels were obtained 
through high sensitive and validated enzyme linked irnrnunosorbent assays. 
Results: Baseline proMMP-2 plasma levels (1253±52 ng/rnl) were increased 
post CPB in EACA patients (1547±79 ng/rnl, p<0.05) and returned to baseline at 
6 hours post CPB (1400±88 ng/rnl). In contrast proMMP2 levels remained 
similar to baseline in APRO patients at post CPB and 6 hours post CPB 
(1391±80, 1247±44 ng/rnl, respectively). Baseline proMMP-9 plasma levels 
(63±4 ng/rnl) remained unchanged post CPB in the EACA patients (61±9 
ng/rnl), but increased at 6 hours post CPB (92±1 O ng/rnl, p<0.05). However, 
proMMP-9 plasma levels decreased from baseline in the APRO patients at post 
CPB (45±3 ng/rnl, p<0.05), and increased at 6 hours post CPB (79±4 ng/rnl, 
p<0.05). 
Conclusion: The present study demonstrated a unique and differential effect of 
the serine protease inhibitor, Aprotinin, on MMP release and activation following 
CPB. Since interstitial MMP activity can alter structure and function, the effect of 
Aprotinin may potentially ameliorate the tissue injury sequelae of MMP activity, 
which can occur following CPB. 
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7625 Watercrest Drive Phone (423) 344-6219 
Harrison, Tennessee 37341- E-mail MGWyckoff@MSN.com 
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Michael M. Wyckoff 
Professional Vitae 
Certifications 
Honors 
Education 
Professional 
experience 
Professional 
memberships 
Certified American Board of Cardiovascular Perfusion, #920344-1253 
Licensed Clinical Perfusionist, State of Tennessee, #CP 0000000013 
Licensed Registered Nurse, State of Tennessee, #0000056858 
Graduated from Episcopal Hospital School of Perfusion Science with 
cumulative GPA of 3.89 
MSNc/MBAc 
• Southern Adventist University, Collegedale, Tennessee, 2000- present 
• Certificate in Perfusion Technology, Episcopal Hospital School of 
Perfusion Science, Philadelphia, Pennsylvania, 1991 
• Bachelors of Science in Nursing, Southern College of Seventh-day 
Adventist, Collegedale, Tennessee, 1982 
• Associate of Science in Nursing, Southern Missionary College, 
Collegedale, Tennessee, 1980 
Perfusionist 
• 1996- present Memorial Hospital Chattanooga, Tennessee 
• 1991-1996 Erlanger Medical Center Chattanooga, Tennessee 
Registered Nurse 
• 1983-1988 ICU Staff Nurse, Erlanger Medical Center, Chattanooga, 
Tennessee 
• 1988-1989 Preceptor and staff Nurse, Intensive Care, Parkridge Medical 
Center, Chattanooga 7HQQHVVaH
• 1984-1985 Clinical Instructor, School of Nursing, Southern Missionary 
College, Collegedale, Tennessee 
American Society of Extracorporeal Technologists (AMSECT) 
Sigma Theta Tau International, Honor Society of Nursing 
